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Pre-B cells in context
In this thesis I aimed to unravel the molecular mechanism involved in the origin of acute 
lymphoblastic leukemia (ALL). This malignant disease is characterized by oncogenic 
transformation of progenitors of the B cell lineage in the bone marrow. To study the 
basis of this disease I have used a mouse model: mice lacking the signaling protein 
Slp65. This is an important transducer of signals at the precursor (pre)-B cell stage, 
which reflects a crucial checkpoint for proliferation and differentiation in the bone 
marrow. Although Slp65-deficient mice do not show increased sizes of any B-lineage 
subpopulation in the bone marrow, a substantial portion of mice develop ALL. To 
understand why these Slp65-deficient cells are prone to oncogenic transformation, 
knowledge on the function of Slp65 in pre-B cells is required. In the introduction to 
my thesis, I first describe the development of B lymphocytes and in particular I focus 
on the pre-B cell stage. We are interested in the functions depending on the signaling 
protein Slp65, this involves cellular maturation and differentiation, regulation of V(D)J 
recombination and termination of proliferation. 
This introduction will help to understand the basis of the mechanisms possibly 
involved in the malignant transformation of Slp65-deficient pre-B cells (Figure 1).
Figure 1. Schematic diagram of mechanisms possibly involved in malignant transformation of 
Slp65-deficient cells.
At the pre-B cell stage, signaling via the pre-BCR and interleuking-7 receptor (IL-7R) play central roles 
in the regulation of survival, proliferation, differentiation and V(D)J recombination.
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General introduction 
The immune system is a complex of cells, tissues and organs that work together to 
protect the body against attacks by invaders, such as bacteria and viruses. Our immune 
system saves us from certain death by infection. Many of the responses of the immune 
system initiate the destruction and elimination of invading organisms and certain toxic 
molecules produced by them. The key to a healthy life is the remarkable ability of the 
immune system to distinguish foreign molecules from ‘self’ molecules. Occasionally, the 
immune system fails to make this distinction and reacts destructively against the host’s 
own molecules, leading to autoimmune disease. 
B lymphocytes contribute to the immune system by producing antibodies 
and therefore provide humoral immunity, whereas T lymphocytes are responsible 
for cell-mediated immunity. Both types of lymphocytes can generate immunological 
memory, which gives protection upon re-infection with the same pathogen. The antigen 
receptors carried by B cells (B cell receptor (BCR) or immunoglobulin (Ig) and T cells 
(T cell receptor) are highly variable in their antigen specificity, enabling an individual 
to respond to millions of different foreign antigens. The receptors provide the means 
by which lymphocytes can bind and recognize antigens (any substance capable of 
eliciting an immune response). The antigen binding sites of these receptors have a 
unique structure, so they can bind and recognize antigens. In most species Igs have 
a four chain structure and are composed of two identical heavy (H) chains and two 
identical light (L) chains (Figure 2).  The two heavy chains and the heavy and light 
chains are held together by disulfide bonds and non-covalent interactions. Both Ig H 
and L chains are composed of two regions; the variable (V) region and the constant (C) 
region, responsible for antigen recognition and determinining of the effector function, 
respectively. The V region has three specific sites that determine antigen recognition 
specificity which are called complementary determining regions (CDR) 1, 2 and 3 which 
directly interact with the antigen. Igs are subdivided into 5 different groups on the basis of 
the Ig H chain composition (IgM, IgD, IgG, IgA and IgE). This diverse repertoire of BCRs 
is generated during the development of B cells from their uncommitted precursors. The 
mechanisms which generate such diverse antibody specificity in B cells do come with a 
cost. The generation of DNA breaks and mutations during antibody diversification can 
give rise to genomic instability and potentially contribute to malignancy.
B lymphocytes develop in mammals in the adult bone marrow. Antigen 
recognition by BCRs on the surface of B cells trigger adaptive immune responses 
and control a series of antigen-independent checkpoints during B cell development. 
In addition to cellular selection, the immune system is shaped by receptor selection. 
Multiple proteins are critical for proper B cell development. Deficiency of one of these 
proteins leads to a marked reduction or absence of serum immunoglobulins, which is 
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seen in patients and mice with primary immunodeficiencies. 
 This thesis focuses on the role of the precursor pre-BCR signaling molecules 
Btk and Slp65 in early B cell development and the aberrations that lead to malignancies 
in mice lacking Btk and Slp65. The pre-B cell therefore takes a central position 
in the introduction below. In particular, the focus will be on the role of the pre-BCR 
as a checkpoint in early B cell development and the signaling pathways involved in 
proliferation, differentiation and the induction of Ig L chain recombination.   
Figure 2. Schematic drawing of an immunoglobulin molecule.
An immunoglobulin molecule is composed of two identical heavy chains and two identical light chains 
which are held together by disulfide bonds. Each chain consists of a constant region (darker part of an 
H or L chain) and a variable region (lighter part of an H or L chain). The antigen binding sites are formed 
by a complex of the variable regions of both light and heavy chains. See Appendix for full-color figure.
Control of B cell lineage commitment by transcription factors
Hematopoietic development is initiated from long-term hematopoietic stem cells (HSC) 
that are multipotent and have the potential to self-renew (1-2). One of the earliest 
differentiated precursors is the multipotential progenitor (MPP) expressing Flt3 (3) 
which can give rise to the erythroid and megakaryocytic progeny (4). Lymphoid primed 
MPP (LMPP) give rise to primarily the lymphoid lineage as well as macrophage and 
granulocytic cell lineages.  MPP can differentiate into common myeloid progenitors 
(CMP) or early lymphoid progenitors (ELP) (5). ELP start to express recombination 
activating gene 1 (Rag1) and Rag2 (6) and can further differentiate into thymic 
precursors of the T cell lineage or into common lymphoid progenitors in the bone marrow 
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(CLP) (7-8). CLP contain extensive Ig H chain DJ rearrangements (9) and their rapid 
progression to early stages of B lineage development suggests that most CLP are early 
B cell progenitors that retain residual potential for generation of alternate lineages. CLP 
are defined as Lin-Sca1+CD117+CD127+ and also represent the major intermediates 
en route to become NK cells (7, 10-11). Recently the group of Weissman (12) have 
identified Ly6d which divides CLP into two distinct populations: one that retains full in 
vivo lymphoid potential (Ly6d-) and produces more thymocytes at early timepoints than 
LMPP and another that behaves essentially as a B cell progenitor (Ly6d+). Expression 
of the B cell marker B220 by a subset of CLPs coincides with their entry into the B cell 
differentiation pathway (5). The earliest committed B cell precursors are pre-pro-B cells 
corresponding with Hardy fraction A (13) (Figure 3). These cells have Ig H chain alleles 
which are largely in germline configuration and can be distinguished from other earlier 
precursors by their ability to differentiate into B cells but not other lymphoid cells. Pre-
pro-B cells have low expression of Rag1 and Rag2 (6, 14-15).
Figure 3. Framework of B cell lineage development based on ordered changes in cell surface 
molecules.
Relative expression levels are indicated by line thickness. AA4.1 is also known as CD93 and PB493; 
CD24 as HSA (heat stable antigen); CD25 as IL-2R; MHCII, major histocompatibility complex type II; 
CD79, Igα and Igβ; SLC, surrogate light chain (λ5 and VpreB). TdT and Rag1/2 (recombination activating 
gene) expression assessed by analysis of mRNA. Figure adapted from ref. (11). See Appendix for full-
color figure.
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B cell development requires a hierarchy involving many transcription factors. In 
CLP, the helix-loop-helix protein E47, an E2A isoform, induces the expression of early B 
cell factor 1 (Ebf1) (16-18). Ebf1 in turn activates expression of the transcription factor 
Pax5 (19).  The Pax5 gene, encoding the B cell specific activator protein (BSAP) is 
expressed exclusively in B cells and activates B lineage specific genes and represses 
B lineage inappropriate genes (20). Pax5 expression is regulated by the concerted 
activities of ETS-family transcription factor PU.1 and the interferon regulatory factors 
IRF-4 and IRF-8 (19, 21). In addition to E2A, Ebf1 and Pax5, other transcriptional 
regulators that modulate the developmental progression of B lineage cells have been 
identified. Prominent among these are Ikaros, Bcl-11 and Foxo1. Ikaros-like proteins 
recognize binding sites in many lymphocyte-specific  genes including TdT, VpreB and 
λ5 (see below) whereby Ikaros proteins control the expression of λ5 in a developmental 
specific manner (22-24). B cell development in Bcl11a-deficient mice is arrested at a 
stage similar to that described for E2A- or Ebf1-deficient mice and expression of Bcl11a 
is activated by E2A proteins (25-26). Foxo1-deficient mice show a block at the pro-B cell 
stage, and Foxo1 directly activates the expression of Rag1 and Rag2 (27). Collectively, 
these factors form the transcriptional machinery that promotes commitment to the B 
cell lineage, suppresses the expression of genes associated with alternative cell fates 
and coordinates cellular population expansion with developmental progression (11, 21).
Generation of pre-B cells and Ig H chain gene recombination
Pro-B cells are distinguished from earlier precursors by a series of cell surface markers 
(11, 28). B lineage cells are identified by coexpression of B220, the high molecular 
weight isoform of Ptprc (CD45), together with leukosialin, CD43 (13).  These early 
B lineage cells are further subdivided based on expression of CD24, the heat stable 
antigen (HSA), and BP-1, a zinc-dependent cell surface metallopeptidase (Figure 3). 
Furthermore, the first step in generating the required antibody diversity is initiated in 
this stage. 
V(D)J recombination is the process which assembles previously scattered 
variable (V), diversity (D) and joining (J) encoding gene segments to assemble a (pre-) 
BCR  (Figure 4) (28-31). The reaction is initiated by the lymphoid-specific factors Rag1 
and Rag2 (14-15), which recognize recombination signal sequences (RSS) that flank 
all V, D and J gene units and introduce a DNA double strand break (DSB) at the border 
of the RSS. The resulting DNA DSB is resolved by the DNA repair machinery known as 
non-homologous end-joining (NHEJ) (32-33). If these DSB are not properly repaired, 
they may result in chromosomal translocations and lymphoid malignancies (34-36). 
V(D)J recombination is strictly regulated at many different levels. Specifically, V(D)J 
recombination is tissue-specific, lineage-specific and developmental stage-specific. 
Furthermore, V(D)J recombination is temporally ordered and cell cycle regulated, 
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whereby recombination is restricted to the G0-G1 stage of the cell cycle. In large cycling 
pre-B cells, Rag proteins are transiently downregulated to terminate further Ig H chain 
gene rearrangement. Moreover, as ongoing recombinase activity during mitosis will 
interfere with faithful transmission of the genome to daughter cells, Rag2 proteins are 
degraded during cell division, thus linking V(D)J recombination to the cell cycle (37-39). 
Figure 4. VDJ recombination.
Schematic representation of the Ig H chain locus and V(D)J recombination process. The V(D)J reaction 
can be divided into three steps. First, the Rag1/2 complex introduces a DNA DSB at the border between 
DH and JH segments and their respective recombination signal sequences (RSS), creating hairpin-
sealed coding ends and blunt signaling ends. Artemis, which is recruited and phosphorylated by the 
DNA-PKcs/Ku70/Ku80 complex, opens the hairpins through its endonuclease activity. The XRCC4/
Cernunnos/DNA-Ligase IV complex finally seals coding and signal joints. NHEJ, non-homologous end-
joining. Figure adapted from ref. (31). See Appendix for full-color figure.
The RSS that serve as recognition element for the V(D)J recombinase consist 
of a conserved heptamer, a spacer of either 12 or 23 nucleotides and a conserved 
nonamer. Only gene segments flanked by RSS with dissimilar spacer lengths can 
efficiently rearrange with one another (30, 40). The NHEJ pathway that resolves 
V(D)J recombinase-mediated DSB can be schematically divided into three steps: (1) 
the Ku70/Ku80 heterodimer is recruited to and interacts with the DNA DSB; (2) the 
DNA-dependent serine/threonine kinase DNA-PKcs and the nuclease Artemis are 
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recruited and activated to modify the DNA ends when needed; and (3) the XRCC-4/
DNA-Ligase IV complex together with Cernunnos terminates the reaction by rejoining 
the broken DNA ends (32, 41). Imprecise joining of the broken DNA ends contributes 
considerably to diversity and includes duplication of palindromic sequences (P 
nucleotides) and deletion or insertion of non templated nucleotides (N nucleotides) by 
terminal deoxynucleotidyl transferase (TdT) (42-43). In eukaryotic cells there are two 
major pathways of DSB repair, NHEJ and homologous recombination (HR) (44). HR 
repairs DSB using information on the undamaged sister chromatid. NHEJ and HR have 
overlapping roles in repairing DNA DSBs (45-47).
In the murine Ig H chain locus there are approximately 195 V genes, 13 D 
genes and 4 J genes dispersed over ~2.5 Mb of DNA on chromosome 12 (Figure 5). 
Close to half the murine VH genes belong to the J558 family. The majority of these 
are located at the 5’ end of the VH cluster, though several are also found interspersed 
amongst other gene families throughout the locus. The extreme 3’ end of the VH locus 
comprises of the 7183 family (48-49). Although not all VH genes are functional, random 
recombination of all V, D and J gene segments and random association of heavy and 
light chains still produce an enormous diverse repertoire. However, V,D and J genes are 
not used equally in the pre-immune repertoire, thus limiting the theoretical estimates of 
combinatorial diversity (50-52).
Figure 5. Organization of Ig H chain locus on chromosome 12.
Schematic map of VH gene family distribution within the mouse Ig H chain V region according to IMGT 
(www.imgt.org). The length of boxes indicates the distance spanned by members of the gene families 
and is not related to the number of genes. See Appendix for full-color figure.
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Ig gene recombination occurs in a stepwise fashion and begins with DH to 
JH junction segment rearrangement in pro-B cells (28, 53). Due to an inexact joining 
mechanism, the DH segments can be joined to the JH in any of the three reading 
frames (RF). DH segments are preferentially used in RF1, while RF2 and RF3 are 
counter selected on the basis of expression of a truncated μ chain protein and stop 
codons, respectively (54). After DHJH rearrangement, VH genes become accessible to 
the V(D)J recombinase and VH to DHJH joining takes place. VH gene accessibility is 
dependent on transcriptional regulatory elements and is associated with the onset of 
germline transcription of VH genes (55-56). Furthermore, the Ig H chain locus relocates 
from the periphery to the center of the nucleus in pro-B cells which facilitates VHDHJH 
recombination (57) and locus contraction brings the distal VH gene segments into close 
proximity with the DHJH region (57-59). Several proteins have been linked to the control 
of chromatin accessibility of the Ig H chain locus in pro-B cells or with the regulation of 
the Rag genes, including Pax5, Yy1, Ezh2, FoxP1 and IL-7R signaling via Stat5 (60-
64). Correlating with the activation of the Ig H chain locus are antisense transcripts 
originating in intergenic regions between VH gene segments. These transcripts are 
turned off when the early pro-B cells reach the late pro-B cell stage (Hardy fraction C) 
(65). However, the role of these antisense transcripts has not been elucidated yet. 
Productive in-frame V(D)J recombination in pro-B cells gives rise to the Ig μ 
chain, which is expressed by pre-B cells as part of the pre-BCR complex and marks the 
transition to the pre-B cell stage (66-68). 
Pre-B cells and the pre-BCR checkpoint 
The pre-BCR comprises of two Ig μ chains and two surrogate light chains (SLC) 
associated with the signaling subunits Igα and Igβ. The SLC substitutes the not yet 
rearranged Ig L chains and is a heterodimer composed of two germline-encoded 
invariant proteins: λ5, which resembles the constant region of conventional λ light 
chains and VpreB (Figure 6) (68-70). The pre-BCR is transiently expressed but marks 
an important checkpoint in B cell development when Ig μ H chains are tested for their 
ability to associate with the SLC. The primary functions of the pre-BCR are triggering of 
B cell differentiation, clonal expansion and H chain allelic exclusion. Pre-B cells which 
express the pre-BCR acquire the capacity to respond to low concentrations of the 
proliferation factor interleukin (IL)-7 (66-68). 
 In 1957 Burnet proposed that all B lymphocytes carry unique cell surface 
receptors for antigen (71). Each cell expresses on its surface just one kind of antibody 
and during immunization, antigen selects cells with the corresponding specificity for 
multiplication and differentiation into antibody-secreting cells. The process which 
guarantees that each B cell only produces a single antigen receptor is called allelic 
exclusion (72-73). 
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Figure 6. Structure of the pre-BCR.
The pre-BCR complex consists of the heterodimeric Igα/Igβ signal transducer and two covalently 
associated Ig H chains which are paired with the surrogate light chain, consisting of the invariant proteins 
λ5 and VpreB. The SLC contains two oppositely charged non-Ig-like tails located at the C-terminus of 
VpreB and the N-terminus of λ5. The unique tails protrude from the pre-BCR at the position where the 
CDR3 (complementarity-determining region) of a conventional L chain is located in the BCR. 
See Appendix for full-color figure.
Allelic exclusion is dependent on correct pre-BCR assembly and pre-BCR signaling 
(74-75). Large-scale contraction of the Ig H chain locus following recombination 
is instrumental in establishing allelic exclusion. The second allele is repositioned at 
centromeric heterochromatin at the pre-B cell stage while Ig L recombination takes 
place (58). Allelic exclusion of the Ig H chain is initiated in the early embryo when the 
Ig receptor loci become asynchronously replicating in a stochastic manner with one 
early and one late allele in each cell (76).  Molecular components including histone 
modification, nuclear localization and DNA demethylation leads to rearrangement on a 
single allele and a feedback mechanism that inhibits recombination on the second allele 
once recombination of the first allele has been successful (72). 
Pre-BCR signaling pathways
Currently, it still remains controversial as to how pre-BCR mediated signals are 
initiated. Pre-BCR signaling could be triggered by ligand binding or by cell autonomous 
aggregation of pre-BCR complexes on the cell surface. The non-Ig-like tail of the SLC 
component l5 induces ligand-independent pre-BCR cross-linking and as a result cell-
autonomous signaling for pre-B cell expansion (77). Recently, Jumaa and colleagues 
have shown that functional pre-BCR formation and autonomous signaling requires the 
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N-linked glycosylation site in the CH1 domain of Ig μ H chain (N46) (78). However, ligand 
mediated crosslinking seems possible since the pre-BCR shapes the VH repertoire 
at the transition from pro-B to large pre-B cells (79). Besides, several groups have 
identified interactions between the non-Ig tail of λ5 of the pre-BCR to galectin-1 (80) 
and to stromal-cell-associated heparin sulphate (81). Furthermore, the pre-BCR is a 
poly-reactive receptor and capable of recognizing multiple (self-)antigens, including 
DNA, LPS and insulin, via the non-Ig part of λ5 (Kohler 2008). Thus, pre-BCR auto-
reactivity may serve to clonally expand those cells that produce a functional μ H chain 
and ensures that this selection can occur in the absence of foreign antigens. In support 
of this idea, in SLC-deficient mice mainly autoreactive pre-B cells are selected, resulting 
in the accumulation of autoreactive antibodies (82). But also in the presence of SLC, 
more than half of the antibodies expressed in early B cell compartments of healthy 
individuals are polyreactive (83). 
Activation of pre-BCR signaling involves phosphorylation of immunoreceptor 
tyrosine based activation motifs (ITAMs) in the cytoplasmic domains of Igα and Igβ by 
the Src family kinases (Fyn, Lyn and Blk) and the cytosolic protein tyrosine kinase Syk 
(Figure 7) (67, 84). This is the first step in the formation of a lipid-raft associated calcium 
signaling module (85-86). The binding of Syk to the phosphorylated Igα and Igβ places 
the active Syk in the right position to allow further phosphorylation of neighbouring 
ITAM sequences. This results in further Syk recruitment and activation (87-88). The 
SH2 domain-containing leukocyte protein of 65 kD, Slp65 (also known as Bash or Blnk) 
is one of the most prominent targets of Syk kinase activity and is phosphorylated by Syk 
on several tyrosines. Slp65 and its close relative in T cells (Slp76) are adaptor proteins 
which lack intrinsic enzymatic function but regulate the assembly and localization of 
signaling complexes. They are able to regulate the availability of a substrate to an 
enzyme and create a scaffold for bridging signaling cascades (89). Slp65 is expressed 
in B cells and myeloid cells and has been mainly reported to function under the (pre-) 
BCR (67). 
Phosphorylated Slp65 provides docking sites for several proteins including the 
Tec family kinase Btk, Grb2, Vav, Nck, Plc-γ2 (88-90). Btk is a member of the Tec kinase 
family, which also includes Tec, Itk, Rlk and Bmx. These molecules have a structure 
containing a pleckstrin homology domain, followed by a short Tec homology domain, src 
homology domains and a kinase domain (91-92). Btk is expressed in B cells, platelets 
and myeloid cells and activated under a large variety of receptors such as BCR, Fcε, 
TLR2, TLR4, CD38, CCL5, IL-6R and IL-10R.
Activation of Plc-γ2 by Syk and Btk results in the production of inositol 
triphosphate (IP3) and diacylglycerol (DAG), both of which are second messengers 
required for cellular responses (88, 90). Models of targeted disruption of components 
of the pre-BCR or downstream signaling proteins have shown the importance of 
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these molecules in pre-BCR signaling (66, 88). Additionally, active Syk induces 
phosphorylation and activation of the lipid-modifying kinase phosphoinositide 3 kinase 
(PI3K), which regulates diverse biological processes, including cell growth, survival, 
proliferation, migration and metabolism (67, 93).
Figure 7. Signaling pathways in pre-B cells.
Pre-BCR activation results in activation of Syk which together with Src family protein kinases, such 
as Lyn, phosphorylate downstream signaling proteins resulting in pathways involved in proliferation, 
differentiation and induction of Ig L chain recombination. Activation of Slp65 recruits and activates Btk 
and Plcγ2 resulting in upregulation of Rag1/Rag2 and Irf-4, induction of Ig L chain recombination and 
induction of differentiation. An important pathway for proliferation and survival is the activation of the PI3K 
pathway. Phosphorylation of the co-receptor CD19 and the adaptor protein BCAP (B cell PI3K adaptor) 
recruit and activate PI3K resulting in the generation of the second messenger PIP3 (Phosphatidylinositol 
(3,4,5)-trisphosphate) from PIP2 (Phosphatidylinositol 4,5-bisphosphate). PIP3 recruits Akt which is 
the dominant mediator for controlling cellular proliferation. Ongoing signaling through the PI3K-Akt 
pathway induces proliferation, suppresses the Rag1/Rag2 genes and blocks Ig κ gene recombination. 
Proliferation in pre-B cells is also induced via the pathway involving Erk MAP kinase. In addition to the 
role of the pre-BCR, signaling via the interleuking-7 receptor (IL-7R) plays a central role in controlling 
the survival and proliferation of pre-B cells. See Appendix for full-color figure.
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Pre-B cell proliferation
Expansion of pre-B cells is severely impaired in mice with targeted disruption of pre-
BCR components, including μ H chain, the SLC components l5 and VpreB, Igα and 
Igβ and Syk (74, 94-98). Overexpression or constitutive activation of Syk functions as 
an oncogene by promoting growth factor independent proliferation of pre-B cells and by 
inhibiting differentiation (67). In mice deficient for components of the pre-BCR complex, 
including Igα, Igβ, SLC or Syk, Ig μ chain positive pre-B cells do not proliferate (66).
In contrast, deficiency of Slp65 or Btk shows an increased proliferative response 
to IL-7 in vitro, indicating that Slp65 and Btk are crucially involved in the termination of 
IL-7 driven proliferation (90). Slp65 inhibits IL-7R signaling through direct binding to 
Jak3 in a Btk-independent manner (99) and also by downregulating IL-17R expression 
(100). 
Downstream of the pre-BCR, Syk and the Src family protein tyrosine kinases 
induce phosphorylation of the co-receptor CD19 and/or the adaptor protein Bcap 
resulting in the recruitment and activation of PI3K (67, 93). PI3K activation results in 
phosphorylation and thereby activation of the serine/threonine kinase Akt, also known 
as protein kinase B (PKB). Akt inhibits the activities of the forkhead (Foxo) transcription 
factors (which are mediators of apoptosis and cell-cycle arrest), resulting in cell 
proliferation and survival (101-102). Tight regulation of pre-BCR induced signaling 
is important to avoid abnormal Akt activity, which can result in uncontrolled cellular 
expansion and malignant transformation. The tumor-suppressor phosphatase with 
tensin homology (Pten) is the most important negative regulator of the cell survival 
signaling pathway initiated by PI3K (103).
In addition to the role of the pre-BCR signaling, IL-7 receptor signaling 
plays a central role in cellular survival, proliferation and maturation. Mice deficient in 
components of IL-7R signaling have an arrest of B cell development at the pro-B cell 
stage and impaired VH to DHJH recombination (104). Expression of the pre-BCR by 
pro-B cells upregulates IL-7R expression and thereby increases the responsiveness 
of these cells to IL-7 (90, 104). Integration of IL-7R signaling and pre-BCR dependent 
signals to expand the pool of pre-B cells occurs via the D-type cyclin, cyclin D3 (105). 
Another downstream signaling cascade involves the mitogen activated protein 
kinase (MAPK) pathway which functions independently of signaling via Slp65 and Btk 
(90). This signaling pathway leads from the Ras GTPase to the extracellular signal 
regulated kinases (Erk1 and Erk2) (106). Erk activity has been shown to be important 
for the pre-BCR to collaborate with IL-7 signaling to drive pre-B cell proliferation 
(104). Expression of genes dependent on Erk activation includes genes encoding the 
proliferation-associated transcription factors c-Myc, c-Fos, Egr-1, Egr-2, Egr-3, Fra-1 
and Fra-2 (106-107).
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From large cycling pre-B cells to small resting pre-B cells 
Upon pre-BCR signaling, cells initially undergo a proliferative burst accompanied 
by down regulation of SLC components and downregulation of Rag1/Rag2 protein 
expression, followed by exit from the cell cycle and transition from large pre-B cells 
to small pre-B cells. In small resting pre-B cells Ig L chain rearrangement is initiated. 
Termination of pre-BCR signaling occurs by downregulation of l5 gene expression and 
consequently the termination of SLC expression. The pre-BCR activates a negative 
feedback loop that prevents continuous pre-BCR signaling (67, 108-109).
Pre-BCR signaling leads to activation of Syk, which then phosphorylates Slp65 
and thereby regulates pre-B cell differentiation. Slp65 is required for the downregulation 
of λ5, which terminates SLC expression and the activation of Ig κ L chain recombination 
by induction of the expression of the transcription factors Aiolos, Irf-4, Foxo3a and 
Foxo1 (22, 110-111). At the transition from large cycling into small resting pre-B cells up- 
and downregulation of specific cell surface markers occurs (Figure 3). Small pre-B cells 
downregulate expression of sialoglycoprotein CD43, SLC, metallopeptidase BP-1 and 
the IL-7R and upregulate expression of CD2, CD25, MHCII (11, 90). Other transcription 
factors which are important for Ig κ rearrangement are E2A, Pax5, Irf-8 and Spi-B (111-
113). Germline transcription of the Ig L chain loci is associated with the regulation of 
accessibility of the Ig loci to the VDJ recombinase, because germline transcription 
precedes VDJ recombination of the Ig L chain (114). There are two type of light chains, 
Ig κ and Ig λ, which are expressed at a ratio of approximately 20:1 in mice (112). Ig κ 
genes are activated and undergo recombination before Ig λ, which contributes to the 
preferential usage of the Ig κ L chain in mature B cells (112, 115).
Beyond the pre-B cell stage: immature and mature B cells
After successful rearrangement of the Ig H and L chain locus, the immature B cells are 
the first B lineage cells to express surface BCR, they display surface IgM but little or 
no IgD. Expression of the BCR is a second key checkpoint in B cell development for 
monitoring the production of a functional Ig L chain and to eliminate autoreactive BCR. 
The receptor consists of randomly selected Ig H and L chains and has an unpredictable 
specificity that includes the ability to bind self. Indeed, it has been found that about 
50% of BCR are autoreactive in humans and mice (83, 116-117). Induction of B cell 
tolerance can occur by clonal deletion, cell inactivation (anergy) or receptor editing. 
Receptor editing is the process that alters antigen receptors by allowing secondary 
rearrangements of mainly the Ig L chain. This process is the dominant tolerance 
mechanism for developing B cells (117-119). When autoreactive B cells encounter self-
antigen that induces signaling through the BCR developmental progression is blocked 
and secondary VDJ recombination can take place. Immature B cells differ from mature 
B cells in that they are particularly susceptible to BCR-induced apoptosis. Thus the 
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BCR is an essential regulator of immature B cell development.
Immature B cells that emigrate from the bone marrow (BM) to the periphery are 
referred to as transitional B cells. Transitional B cells can be distinguished from mature 
B cells by a series of cell surface markers. Transitional B cells are short-lived and 
only 10-30% of these cells enter the long-lived mature peripheral B cell compartment. 
Transitional B cells are unable to proliferate and are unable to generate an immune 
response upon BCR crosslinking (11, 120). The transitional cells that lack autoreactivity 
enter the pool of mature recirculating B cells in the spleen. These cells are termed 
follicular B cells because of their localization to the B cell follicle region (121). This is the 
final maturation stage of developing BM B cells (Figure 8). 
Figure 8. Activation of B cells.
Productive interaction of follicular B cells with antigen results in proliferation and differentiation. The 
primary response generates pre-germinal centre plasma cells that are short-lived and usually secrete 
IgM. Some activated follicular B cells form a germinal centre. Antigen-activated lymphoblasts that enter 
a germinal centre are subjected to multiple rounds of SHM and antigen selection. Cells that express 
high-affinity antigen receptors are selected for survival with subsequent differentiation to memory B cells 
or post-germinal centre plasma cells. Post-germinal centre plasma cells that undergo Ig H chain CSR 
typically home to the bone marrow where they reside and become long-lived (122). 
Upon activation of a distinct population of B cells, B-1 cells, by cytokine and/or TLR activation antibody 
secreting cells are formed which secrete natural IgM antibodies, which often recognize bacterial antigens. 
SHM, somatic hypermutation; CSR, class switch recombination. See Appendix for full-color figure.
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Marginal zone (MZ) B cells are a second population of mature splenic B 
lymphocytes which are specifically located in the marginal zone of the spleen (123). 
MZ B cells are preselected to express a BCR repertoire that is biased and they respond 
rapidly to antigenic challenge.
Another B cell subset is the B-1 B cells, which are found in the peritoneal and 
pleural cavities, spleen and gut. B-1 cells persist largely by self renewal. In contrast 
to follicular and MZ B cells, B-1 cells are primarily generated from progenitors in the 
fetal liver and neonatal BM and can be divided into the CD5+ B-1a and CD5- B-1 B 
cells. The most distinctive feature of B-1a cells is the production of ‘natural antibodies’, 
autoantibodies with specificities that include glycoproteins, phosphorylcholine, 
phosphatidylcholine but which are not pathogenic. The choice of differentiation into any 
of the three subsets is dependent on BCR signaling (11). However, recently in our lab 
it was found that constitutive active Btk expression did not change follicular, marginal 
zone, or B-1 B cell fate choice, but resulted in selective expansion and survival of B-1 
cells. Therefore, constitutive Btk activation and consequently active BCR signaling 
results in defective B cell tolerance (124).
Figure 9. Generating antibody diversity. 
Antibodies are encoded by immunoglobulin genes; these include V, D and J regions and C regions. In 
pro-B cells an immunoglobulin gene includes the full range of V,D, J and C regions. V(D)J recombination 
generates an antibody (IgM) with a variable region that recognizes a particular antigen. When the B cell 
encounters antigen, two other processes — both catalysed by the Aid protein — are triggered. Somatic 
hypermutation generates mutations (thin white lines) in the variable regions, potentially generating an 
IgM with higher affinity for its antigen. Class switch recombination results in the excision of some of the 
constant regions, generating antibodies with distinct effector functions (IgG1 is shown here). Figure 
adapted from ref. (125). See Appendix for full-color figure.
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Germinal centre reaction
After being stimulated with antigen, mature B cells undergo two additional processes 
of antigen receptor diversification. Class switch recombination (CSR) and somatic 
hypermutation (SHM) occur mainly in specialized structures in secondary lymphoid 
organs called germinal centres. CSR and SHM are initiated by activation-induced 
cytidine deaminase (Aicda/Aid) (Figure 9) (126-127). Aid is a single-stranded DNA 
deaminase that targets cytidine residues and thereby creates uracil-guanine mismatches 
in DNA that can be processed by many different pathways to produce mutations or DSB 
(128-130). SHM introduces point mutations in the VH regions of Ig H and L chains. B 
cells expressing high affinity Ig are selected by limited amounts of antigen, resulting 
in affinity maturation. CSR is a recombination reaction that does not affect the antigen 
binding specificity of an antibody but exchanges the constant region of the Ig H chain 
and thereby producing antibodies with distinct effector functions. During CSR the Ig H 
chain isotype switches from IgM to IgG, IgA or IgE. Aid expression is normally restricted 
to germinal centre B cells but when expressed in non-germinal centre cells, Aid can 
induce mutation in various highly transcribed genes and thereby acts as a genome-wide 
mutator (131-133). Furthermore, Aid can initiate chromosomal translocations between 
c-Myc and the Ig H locus (134). Thus, all three processes responsible for diversification 
of the antigen receptor genes (V(D)J recombination, SHM and CSR) can initiate the 
formation of oncogenic translocations (127, 135).
Defects in the pre-BCR checkpoint are associated with primary immunodeficiency 
disease 
Deficiencies in antibody production and function are the hallmark of primary 
immunodeficiency diseases that involve B cells. There is a markedly decreased serum 
level of antibodies or an absence of antibody production. There are three major categories 
of antibody deficiencies: (a) defects in early B cell development; (b) hyper-IgM syndromes 
(CSR defects, e.g. because of deficiency of AID or in CD40L, leading to defective T-B 
cel interaction and GC formation); and (c) common variable immunodeficiencies and 
deficiencies of specific Ig subclasses, in particular IgA-deficiency is relatively frequent. 
All antibody deficiencies are associated with an increased susceptibility to infection with 
encapsulated bacteria. 
 Many genetic defects that result in a failure of B cell development involve 
signaling through the pre-BCR. Mutations in Btk, components of the pre-BCR and BCR 
(μ H chain, λ5, Igα and Igβ) or Slp65 account for approximately 90% of patients with 
defects in early B cell development (136-138). Mutations in Btk, the gene responsible 
for X-linked agammaglobulinemia (XLA), account for most of the affected patients.  XLA 
is considered the prototype immunodeficiency and was first described in 1952 by Bruton 
(139). He reported a case of an 8-year old boy with multiple episodes of pneumococcal 
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sepsis associated with complete absence of serum Ig fractions. Patients with XLA have 
markedly reduced numbers of B cells in the circulation and low numbers of plasma 
cells. Serum Ig are very low, but detectable. Hallmark of the disease is frequent and 
recurrent infection of the upper and lower airways. In 1993, two groups reported that 
XLA resulted from mutations in a cytoplasmic tyrosine kinase called Btk (140-141). 
Defects in SLP65 result in an autosomal agammaglobulinemia with a phenotype similar 
to that found in XLA patients (136).
XLA reflects an almost complete arrest of B cell development at the pre-B cell 
stage. Cytoplasmic μ postive cells are generated, but they do not proliferate and they 
are arrested in their development. In contrast to XLA, Btk-deficiency in the mouse is not 
associated with a major early B cell developmental block but with impaired maturation 
and poor survival of peripheral B cells. This X-linked immunodeficiency (xid) phenotype 
is the result of a spontaneous mutation of a CpG site in the Btk gene changing residue 
28 from arginine to a cysteine (R28C) in the pleckstrin homology domain (142-143) 
and is mild compared to XLA patients.  Xid mice are characterized by a mild arrest 
at the large pre-B cell stage, reduction of 50% of the normal numbers of B cells in 
the periphery, more immature B cells in the spleen (IgMhighIgDlow), a lack of B1-a B 
cells, shortened survival of MZ B cells and low serum IgM and IgG3 levels. Peripheral 
B cells from xid mice do not proliferate in response to anti-IgM treatment, and show 
a reduced proliferative response to LPS. In addition, xid mice are not able to mount 
thymus-independent type II (TI-II) response to antigens (144).
Like xid mice, Slp65-deficient mice have a less complete block of B cell 
development than is found in humans. Slp65-deficiency results in a partial arrest at the 
large pre-B cell stage and leads to more immature B cells in the spleen, fewer mature 
B cells and a 5-40% reduction in the number of B cells. In addition, Slp65-deficient 
mice lack B1-a B cells, have low serum levels of IgM and IgG3, respond poorly to TI-II 
antigens, have reduced Ca2+ responses to BCR crosslinking and poor proliferation upon 
CD40 ligation or LPS stimulation (88, 90).
The molecular mechanisms underlying the difference in the degree of severity 
in phenotype between XLA and xid is not known. However, in mice Tec can partially 
replace Btk, while in humans Btk deficiency alone causes severe disease in spite of 
the presence of Tec in human B lymphocytes (145). Furthermore, in mice other adaptor 
proteins (Lat and Slp76) can to some extent replace Slp65 and are also expressed in 
pre-B cells (146). Moreover, the roles of Btk and Slp65 are different in pre-BCR signaling 
in human and mice with respect to the initiation of proliferation. A crucial difference 
in this context is the role of IL-7R signaling. In humans, B cell development appears 
to proceed in the absence of IL-7, but in mice IL-7R signaling plays a central role in 
governing commitment, survival, proliferation and maturation (104, 147). The presence 
of normal numbers of circulating B cells in primary immune deficiency patients with a 
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mutation in genes encoding the IL-7R argues that B cell development does not require 
IL-7R signaling (148-149). A developmental block at the pre-B cell stage is also present 
when V(D)J recombination is defective, e.g. in cases of mutations in Rag-1 or Rag-2. 
However, as V(D)J recombination is also essential for T cell development, such defects 
do not result in isolated B cell defects, but in severe combined immunodeficiency 
syndromes (SCID) (136, 138). 
Current therapy for immunodeficiencies consists of monthly administration of 
intravenous Ig and the use of antibiotics (150). This is only partially effective. Furthermore, 
such treatment is expensive and associated with long-term complications. A definitive 
therapy for immunodeficiency, and in particular XLA, could be gene therapy. In the 
past different groups have shown that gammaretroviral vector based HSC gene therapy 
can provide significant clinical benefits in patients with SCID (151-152). Unfortunately, 
retroviral vector therapy in SCID has led to proto-oncogene (LMO2) transcriptional 
activation and development of T-ALL (151-152). Recently, different groups have focused 
attention on lentiviral vectors as potential delivery platforms for these disorders (153-
154). These studies are the first demonstration of successful lentiviral gene therapy 
in an animal model of XLA. However, additional experiments are still required before 
proceeding toward clinical application in XLA.
Malignancies
The development of lymphoid neoplasia is a complex multistep process of genetic 
alterations and cellular transformations. Lymphoid malignancies are characterized by 
the frequent occurrence of chromosomal abnormalities, often translocations between 
proto-oncogenes and Ig or TCR loci (135). Many of the most known oncogenes, including 
ABL, Bcl-1 and Bcl-2, were discovered because they are located at translocation 
breakpoints in leukemia or lymphomas. This has led to the hypothesis that some of 
these translocations represent the consequence of misregulated V(D)J recombination 
or CSR (36). Alarmingly, and despite success achieved during the last decades in the 
treatment of these malignancies, their incidence is rapidly increasing. The need for 
further improving therapy requires in-depth understanding of the fundamental nature of 
the disease process and of the mechanisms by which lymphoid cells undergo malignant 
transformation and progression. The complexity of the pathogenic mechanism in 
lymphoid neoplasia is related to the fundamental strategy of the immune system. The 
mechanisms of V(D)J recombination, SHM and CSR cause genetic instability and 
impose a constant threat of malignant transformation.
 Due to the unique feature of lymphoid cells to somatically rearrange antigen 
receptor genes, these cells are frequent targets for chromosomal translocations and 
oncogene activation resulting from recombinase targeting mistakes or incorrect repair of 
the V(D)J recombination intermediates (34-35). It was demonstrated in the mouse that 
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chromosomal reinsertion of broken RSS can target cryptic RSS-like elements via a V(D)
J recombination-like mechanism (155). Moreover, cryptic RSS sequences immediately 
internal to the deletion breakpoints in the IKZF1 locus, encoding the transcription factor 
IKAROS, have been identified in human BCR-ABL1-positive ALL (156). Cryptic RSS are 
estimated to have a density of 1 per 600 bp in the genome and have also been identified 
in other loci involved in ALL, including PAX5 and CDKN2A/B in humans and c-Myc and 
Lmo2 in the mouse (157-158). In addition, Rag proteins have the ability to rearrange 
DNA sequences that do not resemble RSS, as reported in follicular lymphoma (159). 
Taken together, these findings suggest that gene deletion or translocation arising from 
aberrant Rag activity contributes to leukemogenesis in human and mouse ALL. 
Malignancies of pre-B cells: acute lymphoblastic leukemia
Precursor-B cell leukemia is one of the most common forms of childhood malignancy 
and reflects clonal proliferation of transformed cells as a result of genetic changes. 
Extensive molecular characterization of these genetic abnormalities, in particular 
chromosomal translocations have allowed the development of sensitive assays for the 
identification of underlying molecular defects, which are applicable to disease diagnosis 
and to monitor response to treatment. Childhood B-lineage ALL can be divided in 
different subtypes based on genetic abnormalities. The two main genetic subtypes, 
TEL-AML1-positive and hyperploidy with more than 50 chromosomes, account for 50% 
of pre-B ALL cases. BCR-ABL1-positive ALL, MLL and E2A-PBX1 rearranged ALL each 
account for less than 5% of pediatric cases of ALL (160).The BCR-ABL1 fusion gene is 
a result of the t(9;22)(q34;q11) translocation and represents the most frequent recurrent 
genetic aberration leading to ALL in adults (161). Next to translocations, a large group 
of pre-B ALL cases has aberrations in the loci of various genes, identified by genome-
wide hybridization studies (156, 162). These include transcription factors such as 
Pax5 (in ~30% of cases), IKAROS, E2A, or EBF1, cell cycle proteins (Cdkan2a/b, Rb), 
DNA repair protein Atm, the microRNAs Mir-15/16 and the apoptotis regulator Btg1. 
Interestingly, in a small fraction of B-lineage ALL the genes encoding cytkine receptors 
Csfr2 (a IL-7R homologue) and IL-3R and the signaling molecules PTEN and SLP65 
are affected (156, 162).  Despite this impressive progress, there is still a deficiency 
in our understanding of how consecutive genetic abnormalities ultimately subvert the 
developmental program of normal precursor-B cells.
 Deficiency of SLP65 has been found in ~50% of childhood precursor-B cell 
ALL cases (163). The loss of SLP65 protein was found to be due to defective splicing, 
leading to premature stop codons. The SLP65 gene contains alternative exons 
(exon 3a and 3b) located in intron 3 and when these alternative exons are included 
into the SLP65 mRNA they interrupt the open reading frame of SLP65 and prevent 
protein expression. Moreover, in precursor-B ALL that where positive for the BCR-ABL 
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translocation the activity of the fusion protein, the BCR-ABL1 kinase, was linked to the 
expression of the same aberrant SLP-65 transcripts (164). Because other expression 
profiling studies with a large number of patients reported a low  frequency (156, 165), it 
is not clear whether the loss of SLP-65 is a common leukemogenic event. Nevertheless, 
the reported findings indicate that loss of SLP-65 and the accompanying pre-B cell 
differentiation arrest may be one of the primary causes of precursor-B ALL. 
Research in this area is strongly facilitated by the availability of an animal model 
for this disease: SLP-65-deficient mice spontaneously develop precursor-B cell tumors 
that show a similar phenotype as found in humans (166-167). Although Btk-deficient 
mice do not develop pre-B cell leukemia, Btk and Slp65 cooperate as tumor suppressors 
whereby Btk exerts its tumor suppressor function independently of its kinase activity 
(168-169). Combined deficiency of Slp65 and Btk result in a more complete arrest at 
the pre-B cell stagev(168) and a higher incidence of pre-B cell leukemia than compared 
with single deficient mice (88, 166-167, 170) suggesting that the developmental block 
is one of the tumor-promoting factors. In addition, expression of the pre-BCR is also 
essential for the development of leukemia as mice which are Rag-deficient or which 
cannot express the Ig μ H chain on the surface (e.g. because of λ5-deficiency), due 
to a disruption of the membrane exon of the Ig μ H chain constant region (μMT), are 
arrested at the pro-B cell stage but do not develop leukemia (66, 74, 166). Furthermore, 
Slp65 has a specific function that suppresses malignant transformation because in Btk/
Plc-2 and Irf-4/Irf-8 double-deficient mice with a nearly complete arrest at the large 
pre-B cell stage no leukemias have been reported (171-172). 
Several lines of evidence have indicated a role for unregulated Rag activity 
in Slp65-deficient pre-B cell leukemia. First, Rag proteins are expressed in strongly 
proliferating Slp65-deficient pre-B cells (166-167). Second, Slp65-deficient pre-B cell 
leukemias mostly co-express Ig H chain, SLC and Ig L chain (168). Third, in human 
pre-B cell leukemia SLP65 deficiency correlates with RAG expression and ongoing VH 
gene rearrangement activity (173). 
Similar to Slp65-deficient mice Eμ-myc transgenic mice, which express 
c-Myc under the control of the IgH intronic enhancer, develop rapid-onset pre-B cell 
malignancies (174). The c-Myc proto-oncogene is a broadly expressed transcription 
factor that is implicated in various cellular processes – cell growth, loss of differentiation 
and apoptosis. Elevated or deregulated myc expression has been found in a wide range 
of human cancers, and is often associated with aggressive, poorly differentiated tumors. 
Such cancers include breast, colon, cervical, small-cell lung carcinomas, osteosarcomas, 
gliobastomas, melanomas and myeloid leukemias (175). In Burkitt’s lymphoma c-MYC 
is oncogenically activated as a result of a translocation between chromosome 8 and 
the Ig H chain locus or the Ig κ or λ L chain locus (176-177). Interestingly, the incidence 
of lymphomas in Em-myc mice is greatly reduced by the introduction of a human IgH 
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transgene (178). In addition, loss of Btk or PLC-g2 synergizes with deregulation of 
c-Myc during lymphoma formation in Eμ-myc mice (179-180). The presence of the Eμ-
myc transgene substantially increases the proliferative potential of B cell progenitors in 
response to IL-7 (179-180). Activation of c-Myc is required for progression of quiescent 
cells into the S phase of the cell cycle, but c-Myc can also induce the p53 protein, which 
protects against oncogenic transformation of proliferating cells (181). c-Myc activates 
the p19Arf tumor suppressor that interferes with the E3 ubiquitin protein ligase Mdm2 
and thereby stabilizes and activates p53, resulting in cell-cycle arrest or apoptosis. 
In Myc-induced lymphomagenesis the p19Arf–Mdm2–p53 circuitry is often disrupted, 
indicating that c-Myc activation strongly selects for spontaneous inactivation of this 
pathway (182).  
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Aim of the thesis
B lymphocytes are necessary to provide humoral immunity against a wide variety of 
possible antigens. A prerequisite for the generation of an effective humoral response 
is the diversity and specificity of the antibody repertoire. Signaling by membrane 
immunoglobulin governs a number of distinct checkpoints in B cell differentiation that 
shape the antibody repertoire by a combination of cellular and molecular selection. A 
central checkpoint is the pre-BCR and its signaling pathways involved in proliferation, 
differentiation and Ig L chain recombination.
 This thesis describes studies aimed at understanding the pre-BCR checkpoint 
and the role of the signaling proteins Btk and Slp65 in pre-B cell differentiation, 
proliferation and the suppression of malignant transformation. In particular, we aimed 
to identify the molecular mechanisms involved in oncogenic transformation of pre-B 
cells lacking functional Slp65. One of the events initiated upon pre-BCR signaling is 
the rearrangement of Ig κ and λ L chains in small pre-B cells. Chapter II describes the 
role of Btk and Slp65 in pre-B cells in the initiation of Ig L chain rearrangements and 
developmental progression. 
The development of lymphoid neoplasia is a complex multistep process of 
genetic alterations and cellular transformations. The complexity of the pathogenic 
mechanisms in lymphoid cells is likely to be related to the fundamental strategy of the 
immune system, in which somatic gene rearrangement ensures diversity, specificity 
and optimal function of the B cell receptor. The cost, however, is genomic instability 
and its potential contribution to malignancy. Similar to Slp65-deficient mice Eμ-myc 
transgenic mice, which express c-Myc under the control of the IgH intronic enhancer, 
develop rapid-onset pre-B cell malignancies. Myc-induced lymphomagenesis often 
disrupts the p19Arf–Mdm2–p53 circuitry, indicating that c-Myc activation strongly 
selects for spontaneous inactivation of this pathway.  In Chapter III we investigated 
whether malignant transformation of Slp65-deficient pre-B cells also requires loss of the 
protective checkpoint function of the p19Arf–Mdm2–p53 pathway.
Pre-B cell leukemias in Slp65-deficient mice have high-level pre-BCR 
expression and this high level of expression is thought to contribute to their strong 
proliferative capacity. In Chapter IV, we investigated whether particular pre-BCR 
specificities may predispose these cells to malignant transformation.
A majority of B- and T-cell leukemias and lymphomas are associated with 
chromosomal abnormalities that bear the hallmarks of aberrant V(D)J or class-switch 
recombination. While leukemic Slp65-deficient pre-B cells express the recombination 
activating genes and manifest ongoing immunoglobulin light chain rearrangement, it has 
been hypothesized that deregulated recombinase activity contributes to their malignant 
transformation. DNA double stranded breaks initiated by V(D)J recombination are 
repaired by the non-homologous end joining pathway, which is active throughout the 
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cell cycle. Due to deregulated V(D)J recombination activity in strongly cycling Slp-65-
deficient pre-B cells, Slp65-deficient pre-B cells may also have DSBs in cycling cells, 
leading to genomic instability. In Chapter V we investigated whether Rag-induced DNA 
damage and illegitimate repair by the non-homologous end joining repair pathway is 
involved in the oncogenic transformation of Slp65-deficient B cells. 
In Slp65-deficient mice, pre-B cell tumors arise from large, cycling pre-B cells 
which are highly proliferative. It is therefore conceivable that cell division in these 
cells may be accompanied by genomic instability or mutations, ultimately leading 
to oncogenic transformation. Therefore, we investigated in Chapter VI whether 
homologous recombination, the pathway which repair DSB in cycling cells, plays a role 
in the malignant transformation of Slp65-deficient pre-B cells.
In Chapter VII we aimed to accomplish sporadic SV40 T gene expression in 
B-cell lineage in mice by introducing the SV40 T gene without its promoter and in opposite 
transcriptional orientation between the Ig H chain D and JH segments. By achieving 
sporadic SV40 T expression in B-lineage cells we aimed to investigate whether the 
V(D)J recombination system active in pro-B cells manifests in vivo transposition activity, 
leading to leukemic formation as soon as the SV40 gene is expressed in a new genomic 
context. 
The General discussion (Chapter VIII) deals with the implications of the studies 
described in this thesis in context of the currently available literature and with directions 
for future research.
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Abstract  
Bruton’s tyrosine kinase (Btk) and the adapter protein SLP-65 transmit pre-B cell receptor 
signals that are essential for efficient developmental progression of large cycling into 
small resting pre-B cells. We show that Btk- and SLP-65-deficient pre-B cells have a 
specific defect in immunoglobulin λ light chain germline transcription. In Btk/SLP-65 
double deficient pre-B cells both k and λ germline transcripts are severely reduced. 
Although these observations point to an important role of Btk and SLP-65 in the initiation 
of light chain gene rearrangement, a possibility remained that these signaling molecules 
are only required for termination of pre-B cell proliferation or for pre-B cell survival, 
whereby differentiation and light chain rearrangement is subsequently initiated in a 
Btk/SLP-65 independent fashion. Because transgenic expression of the anti-apoptotic 
protein Bcl-2 did not rescue the developmental arrest of Btk/SLP-65 double deficient 
pre-B cells, we conclude that defective light chain opening in Btk/SLP-65-deficient small 
resting pre-B cells is not due to their reduced survival.  Next, we analyzed transgenic 
mice expressing the constitutively active Btk mutant E41K. Expression of E41K-Btk in 
immunoglobulin heavy chain negative pro-B cells induced (i) surface marker changes 
that signify cellular differentiation, including downregulation of surrogate light chain 
and upregulation of CD2, CD25 and MHC class II, and (ii) premature rearrangement 
and expression of κ and λ light chains. These findings demonstrate that Btk and SLP-
65 transmit signals that induce cellular maturation and immunoglobulin light chain 
rearrangement, independent of their role in termination of pre-B cell expansion.
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Introduction
During B cell development, Ig gene rearrangement is ordered such that the Ig H chain 
locus generally rearranges before the Ig κ and λ L chain loci (Reviewed in Ref. (1-2). 
Productive V(D)J recombination of the Ig H chain gene results in surface deposition of 
the precursor-B cell receptor (pre-BCR), which consists of μ H chain, the non-rearranging 
VpreB and λ5 surrogate light chain (SLC) proteins and the Ig-α/CD79a and Ig-β/
CD79b signaling components. The pre-BCR is a key checkpoint in B cell development 
to monitor the assembly of a functional Ig H chain and to terminate further H chain 
rearrangements, thus ensuring that only one functional Ig H chain is synthesized, a 
phenomenon referred to as allelic exclusion. Pre-BCR expression induces proliferative 
expansion of cytoplasmic H chain positive pre-B cells and their progression into small 
resting pre-B cells in which Ig L chain rearrangement occurs (1-2). 
In mice deficient for components of pre-BCR complex, including Ig-α, Ig-β, 
SLC, or the downstream tyrosine kinase Syk, μ H chain positive pre-B cells are unable 
to proliferate (Reviewed in Ref. (3). Specifically, the non-Ig-like unique tail of λ5 was 
shown to be essential for the activation of downstream signal transduction pathways 
(4). In contrast, disruption of Bruton’s tyrosine kinase (Btk) or the adapter protein SH2 
domain-containing leukocyte-specific phosphoprotein of 65 kDa (SLP-65, also known 
as BASH or BLNK) showed that these pre-BCR signaling components are crucially 
involved in the termination of IL-7 driven expansion of large cycling pre-B cells (5-6). 
SLP-65-deficient mice spontaneously develop pre-B cell tumors expressing high levels 
of pre-BCR on the cell surface (6-7). Although Btk-deficient mice do not develop tumors, 
Btk cooperates with SLP-65 as a tumor suppressor, since the incidence of pre-B cell 
leukemia is significantly higher in SLP-65/Btk double deficient mice, when compared 
with SLP-65 single deficient mice (8). Using transgenic (Tg) mice expressing the kinase-
inactive Btk mutant K430R, we recently showed that Btk exerts its tumor suppressor 
function independent of its kinase activity (9). 
During the transition of large cycling into small resting pre-B cells in 
the mouse, Btk- or SLP-65-deficient cells show defective downregulation of SLC, 
the metallopeptidase BP-1 and the sialoglycoprotein CD43, as well as defective 
upregulation of the adhesion molecule CD2, the IL-2 receptor CD25 and MHC class II 
(5, 8). Btk-deficient cells also manifest a specific ~3 hours developmental delay within 
the small pre-B cell compartment. Thus, it appears that in addition to their function in 
the termination of IL-7 driven proliferation, Btk and SLP-65 are also involved in cellular 
maturation of cytoplasmic Ig μ+ pre-B cells.
The role of pre-BCR signaling in the induction of pre-B cell differentiation and 
Ig L chain rearrangement is controversial (2, 4). The hypothesis that pre-BCR signals 
are responsible for the redirection of V(D)J recombination activity from the Ig H chain 
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to the L chain loci is based on the observations that Ig H chain surface expression 
correlates with transcription of unrearranged Ig L chain gene segments. This so-called 
germline transcription has been implicated in regulation of accessibility of Ig loci to 
the V(D)J recombinase, because it precedes or coincides with V(D)J recombination 
(See for review: Ref. (2). Second, in the absence of pre-BCR function, e.g. in mice 
with targeted disruption of Ig H chain, Ig-α, Ig-β, SLC components or Syk, Ig κ locus 
rearrangement is diminished. Third, expression of an activated Ras transgene induces 
L chain rearrangement in JH
-/- pro-B cells, which lack the ability to assemble Ig H chain 
variable regions (10). Fourth, the findings of reduced Ig L chain germline transcription 
and gene rearrangement in SLP-65-deficient pre-B cells (7, 11) and of reduced λ L 
chain usage in Btk-deficient mice (12-13) points to important roles for these signaling 
molecules in the initiation of Ig L chain rearrangement. Nevertheless, evidence for a 
direct involvement of pre-BCR signaling in the induction of L chain V(D)J recombination 
is lacking. On the contrary, it has also been reported that rearrangement and expression 
of Ig L chain genes can occur without Ig H chain expression. Ig k transcription and 
rearrangement is detectable in Ig μ- pro-B cells (14) and is increased by activation of 
NF-κB by lipopolysaccharide in transformed pro-B cell lines (15). Removal of IL-7 from 
cultured pro-B cells from JH
-/- or λ5-/- mice, which are incapable of expressing a proper 
pre-BCR, resulted in the apparent differentiation into cells that transcribe and rearrange 
Ig L chain loci (16). Moreover, the observations that SLC- and Ig H chain-deficient pre-B 
cells rearrange Ig L chain at normal frequencies and with normal kinetics, argue for a 
model in which the initiation of Ig L chain rearrangement is independent of pre-BCR 
expression (4, 17).
As deficiency for Btk or SLP-65 affects IL-7 responsiveness, cell surface 
marker expression and Ig L chain rearrangement in pre-B cells, it is possible that Btk 
and SLP-65 are directly involved in all three processes. Alternatively, Btk and SLP-65 
signaling may only be required for the termination of IL-7 driven pre-B cell proliferation 
and thus the differentiation of large cycling to small resting pre-B cells. The subsequent 
cell surface marker changes and Ig L chain rearrangements may then be initiated 
independent of Btk and SLP-65 signaling. In a third model, Btk and SLP-65 also do not 
regulate pre-B cell differentiation or the induction of Ig L chain locus activation, but they 
only support survival of small resting pre-B cells.
To distinguish between these possibilities, in the current report we 
investigated the effects of Btk and SLP-65 deficiency on transcriptional activation of Ig 
L chain loci in pre-B cells. By crossing Btk/SLP-65 double deficient mice onto a Bcl-2 Tg 
background (18), we determined whether providing an extended time window for Ig L 
chain rearrangement rescued their severe arrest at the pre-B to immature B transition. 
Finally, we studied Tg mice that express the constitutively active Btk mutant E41K-Btk 
under the control of the CD19 promoter region (8, 19-21). The CD19 promoter region 
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targets expression of transgenes to all stages of B cell development, including pro-B 
cells (21). Therefore, the E41K-Btk transgenic mice enabled us to investigate whether 
Btk signaling has the capacity to prematurely induce cell surface marker modulations 
and Ig L chain rearrangement in pro-B cells, thus independent of the developmental 
progression of large cycling into small resting pre-B cells.
Materials and Methods
Mice and Genotyping
Mice deficient for Btk (22), RAG-1 (23) or μMT (24) and Eμ-2-22 Bcl-2 Tg mice (18) 
were on the C57BL/6 background; SLP-65- mice (25) were on the Balb/c background. 
The VH81X-μ Tg mouse strain (26) was a generous gift from J.F. Kearney. E41K-Btk 
mice have been described previously (8, 21). The different composite genotypes were 
on a mixed background and in single experiments littermates were compared. All 
mice were bred and maintained at the Erasmus MC animal care facility under specific 
pathogen free conditions. Mice were analyzed at the age of 8-16 weeks. Experimental 
procedures used in this study were reviewed and approved by the Erasmus University 
Committee of Animal Experiments. For mouse genotyping, tail DNA was analyzed by 
Southern blotting of BamHI digests using a partial human Btk cDNA probe (bp 133-
1153), as described previously (21-22). Alternatively, the presence of Btk transgenes, 
endogenous mouse Btk WT or Btk KO alleles were evaluated by PCR (8, 27). PCR 
assays were also used to determine the genotypes for SLP-65 (8), RAG-1 and μMT 
mice, using standard primers (www.jax.org), and to determine the presence of the 
Eμ-2-22 Bcl-2 (12) or VH81X-μ transgenes (forward primer specific for framework I: 
5’-CGCGCGGCCGCGTGGAGTCTGGGGGAGGCT-3’ and reverse primer specific for 
the transgene CDR3 region: 5’-CCCAGACATCGAAGTACCAGCTACTA-CCATG-3’ 
(26).
Flow cytometric analyses
Preparations of single-cell suspensions, flow cytometry procedures and monoclonal 
antibodies have been described previously (5, 22). For intracellular staining of 
cytoplasmic proteins, cells were first stained for cell surface markers and subsequently 
fixed in 2% paraformaldehyde and permeabilized using 0.5% saponin (21). The anti-
SLC hybridoma LM34 ((28) was kindly provided by A. Rolink, University of Basel, 
Switzerland). Events (1-5 x 105) were scored using a FACSCalibur flow cytometer and 
analyzed using CellQuest software (BD Biosciences, Mountain View, CA).
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RNA isolation and analysis
Total bone marrow (BM) cell suspensions were depleted of erythrocytes by standard 
ammonium chloride lysis. For mice that were on the μMT background, cell suspensions 
were enriched for B-lineage cells by magnetic sorting using anti-B220-coated microbeads 
(Miltenyi Biotec). Ig L chain-negative pre-B and Ig L chain-positive immature B cell 
fractions were obtained from in vitro BM cultures. Total BM cultures in the presence of 
IL-7 (Sigma), and quantification of IL-7 dependent proliferative responses of total BM 
cells have been described previously (5). Cells were labeled with biotinylated anti-Igκ 
(187.1) and anti-Igλ (R26-46) antibodies, incubated with streptavidin-coated microbeads 
(Miltenyi Biotec), and subjected to cell separation by AutoMACS (Miltenyi Biotec).
 Total RNA was extracted using the GenElute™ Mammalian Total RNA Miniprep 
system (Sigma). Two μg total RNA was used as a template for double stranded cDNA 
synthesis using reverse transcriptase (Superscript II; Invitrogen) and random hexamer 
primers. Samples were diluted serially threefold before amplification using PCR 
primers specific for the germline Ig L chain transcripts λ10, λ20, λ30, Vλ1/2, κ00.8 and 
κ01.1, functional Vλ1Cλ1 (29-30) RAG-1, RAG-2 (31) and β-actin. PCR products were 
separated by standard agarose electrophoresis and visualized by ethidium bromide 
staining. Densitometric analyses were conducted using ImageQuant analysis software 
(Molecular Dynamics, Sunnyvale, CA), and statistical evaluations were by standard 
t-test. 
Results
Reduced germline λ L chain transcription in the absence of Btk
To investigate the effect of Btk signaling on transcriptional activation of Ig L chain loci, 
we evaluated Ig L chain germline transcription in pre-B and B cells from wild-type and 
Btk-deficient mice. Total BM cell suspensions were cultured in the presence of IL-7 
for 5 days and subsequently without IL-7 for 2 days. Removal of IL-7 strongly induces 
pre-B cells to exit from the cell cycle and to initiate stepwise activation of Ig κ and λ L 
chain gene rearrangement (17, 29-30). We purified surface L chain negative pre-B cell 
and surface L chain positive B cell fractions (Figure 1A), and used RT-PCR to assay 
expression of germline κ and λ transcripts. 
As shown in Figure 1B, we found that Btk+ and Btk- pre-B cells expressed 
comparable levels of κo0.8 and κo1.1 germline transcripts, which are initiated in different 
regions 5’ of Jκ and spliced to the Cκ region (29). In contrast, the expression levels of 
germline λ transcripts were significantly reduced in Btk- pre-B cells, as compared with 
Btk+ pre-B cells. In particular the levels of λ1o and λ2o transcripts, which initiate 5’ of 
the Jλ1 and Jλ2 region and are spliced to Cλ1 and Cλ2, respectively (29), were reduced 
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in Btk-deficient pre-B cells (Figure 1B). Interestingly, this effect of Btk appeared to be 
specific for the germline transcripts of the λ J-C cluster, because transcripts of the Vλ 
region were present at similar levels in Btk+ and Btk- pre-B cells (Figure 1B). Although 
successful VL-to-JL rearrangement results in loss of germline transcription on productive 
alleles, transcription of unrearranged L chain alleles continues in mature B cells (32). 
We therefore also analyzed surface Ig+ B cells and observed a specific reduction in the 
expression of λ1o and λ2o transcripts in Btk-deficient B cells, while Vλ, κo0.8 and κo1.1 
transcripts were present at normal levels (Figure 1B). 
Figure 1. Reduced germline λ L chain transcription in Btk- pre-B and immature B cells.
(A) Flow cytometric characterization of sorted surface Ig- pre-B cell and surface Ig+ immature B cell 
fractions from IL-7 driven BM cultures. (B) Detection of Ig L chain germline and RAG-1/2 transcripts. Ig 
κ + λ L chain negative and positive fractions were obtained by magnetic sorting. Total RNA from these 
cell fractions was reverse transcribed, diluted serially threefold, and used as a template for amplification 
of the transcripts indicated at the left. Amplification of a β-actin (bottom) was performed as a control. 
Products were fractionated by gel electrophoresis and detected with ethidium bromide. Data shown 
are representative for four mice of each genotype. Statistical evaluation of density values showed that 
expression levels of λ01 and λ02 were significantly reduced in Btk-deficient pre-B cells (p<0.004 and 
p<0.02, respectively) and immature B cells (p<0.05 and <0.009, respectively), when compared with wild 
type. No significant differences were found for κ00.8, κ01.1 or λ03 expression.
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Developmental progression of large to small pre-B cells is also accompanied 
by the upregulation of transcription of the recombination activating genes RAG-1 and 
RAG-2 (1).  We observed similar levels of RAG-1/2 transcripts in Btk+ and Btk- pre-B 
cells (Figure 1B), indicating that Btk is not involved in the initiation of RAG transcription 
in pre-B cells. Interestingly, RAG-1 expression was downregulated in Btk+ Ig+ B cells, 
but not in Btk-deficient Ig+ B cells (Figure 1B), suggesting that termination of RAG-1 
expression upon productive L chain recombination is Btk-dependent. 
Taken together, the finding of a specific reduction in the levels of germline λ1o 
and λ2o transcripts in Btk-deficient (pre-)B cell fractions indicates that Btk signals are 
needed for the activation of the Ig λ L chain locus for recombination by opening of the 
λ J-C clusters.
Synergistic roles of Btk and SLP-65 in the induction of L chain rearrangement
The analysis of germline transcription as a marker for L chain locus accessibility in vivo 
is complicated by the fact that ongoing VL-to-JL rearrangement will destroy its germline 
configuration and thereby result in loss of germline transcription. Therefore, we bred 
Btk and SLP-65 single and double mutant mice to RAG-1 deficient mice that carry the 
Ig H chain transgene VH81X (26). In this background, B cell progenitors progress to 
the pre-B cell stage because of the presence of the pre-rearranged Ig H chain, which 
ensures pre-BCR expression and cellular proliferation (33). However, the inactivation of 
RAG-1 precludes any L chain gene rearrangement and cells are arrested at the small 
pre-B cell stage (Figure 2A). 
Detailed flow cytometric analyses of the four groups of mice (WT, Btk-
deficient, SLP-65-deficient and Btk/SLP-65 double deficient mice) on the RAG-1-/-VH81X 
Tg background revealed that Btk- or SLP-65-deficient pre-B cells exhibited elevated 
expression of CD43 and SLC and reduced expression of CD2, CD25 and MHC Class 
II, whereby the defects were most pronounced in the Btk/SLP-65 double mutant (Figure 
2B). These findings show that the previously reported aberrant phenotypes of Btk 
and SLP-65 single or double deficient pre-B cells, which reflect their impaired cellular 
maturation (5, 8), were preserved on the RAG-1-/-VH81X Tg background. We additionally 
found that downregulation of IL-7R and c-kit expression on the surface of pre-B cells 
was impaired in the absence of Btk and SLP-65 (Figure 2B). 
From the four groups of mice, BM cell suspensions were analyzed for the 
expression of Ig κ and λ L chain germline transcripts. In RT-PCR experiments, we 
observed a specific reduction in the expression of λ1o and λ2o transcripts in the absence 
of either Btk or SLP-65. Expression levels of λ3o were not significantly affected by the 
absence of Btk or SLP-65 (Figure 3). We detected a modest reduction in the expression
levels of the κo0.8 and κo1.1 germline transcripts in SLP-65 deficient pre-B cells, when 
compared to wild-type or Btk-deficient mice (Figure 3). In contrast, in the Btk/SLP-65 
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Figure 2. Defective pre-B cell maturation in Btk and SLP-65 deficient pre-B cells.
(A) Flow cytometric characterization of the B cell population from the indicated mice on a RAG-1-/- VH81X 
Tg background. BM lymphoid cells were gated on the basis of forward and side scatter characteristics. 
The expression profile of B220 versus cytoplasmic μ H chain is plotted. (B) Expression of markers 
that are normally downregulated or induced during pre-B cell differentiation. B220+cy-μ+ pre-B cells 
were gated and the expression data of the indicated markers and forward scatter (FSC) are shown as 
histograms. Numbers indicate the percentage of positive cells. Plots are representative for four mice of 
each genotype.
double deficient pre-B cells the levels of both κ and λ germline transcripts were severely 
reduced. 
The observed differences between the four groups of mice did not appear 
to result from differences in the ratio between large cycling and small resting pre-B 
cells, as the forward scatter profiles of the pre-B cell populations in these mice were 
comparable (Figure 2B). Consistent with this, similar differences in surface marker 
expression profiles and Ig κ and λ germline transcription between the four groups of 
RAG-1-/- VH81X Tg mice were observed in in vitro IL-7 driven BM cultures, in which 
developmental progression from large cycling into small resting pre-B cells was induced 
by IL-7 withdrawal (data not shown).  
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Figure 3. Defective germline transcription of Ig L chain loci in Btk and SLP-65 deficient pre-B cells.
Expression of the indicated Ig L chain germline transcripts was analyzed by RT-PCR in the indicated 
four groups of mice on the RAG-1-/- VH81X Tg background.  Total RNA from BM fractions was reverse 
transcribed, diluted serially threefold, and used as a template for amplification of the transcripts indicated 
at the left. Amplification of β-actin (bottom) was performed as a control. Products were fractionated by 
gel electrophoresis and detected with ethidium bromide. Data shown are representative for 3-4 mice 
examined in each group. Statistical evaluation of density values showed that expression of κ00.8/κ01.1 was 
significantly reduced in Btk/SLP-65 double deficient pre-B cells (when compared with wild-type; p<0.03) 
and expression of λ01/λ02 was significantly reduced in Btk or SLP-65 single or double deficient pre-B 
cells (when compared with wild-type; p<0.05). No significant differences were found for λ03 expression. 
The finding that in the absence of either Btk or SLP-65 λ germline transcription 
is reduced while κ germline transcription is not dramatically affected indicates differential 
regulation of κ and λ locus activation. Therefore, either (i) the opening of the λ L chain 
J-C clusters is essentially dependent on Btk- and SLP-65-mediated signaling pathways, 
or alternatively, (ii) in the absence of these signaling proteins development does not 
efficiently progress to a stage critical for λ activation. 
Defective Ig L chain opening in Btk/SLP-65-deficient pre-B cells is not due to their 
reduced survival 
Interestingly, the Btk/SLP-65 dependency of κ and λ germline transcription parallels the 
order of transcriptional activation of the L chain loci (29-30):  the κ locus and the λ V 
cluster, which are only marginally affected by the absence of Btk or SLP-65, open early 
in B cell development, and the λ J-C cluster, which is severely affected by the absence of 
one of the two signaling molecules, opens late in B cell development. Thus, our findings 
can also be explained by a model in which Btk and SLP-65 signals are mainly essential 
for the survival of small resting pre-B cells that initiate Ig L chain rearrangement. The 
almost complete arrest of B cell development in Btk/SLP-65 double deficient mice at the 
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Figure 4. Bcl-2 expression does not rescue the pre-B cell arrest in Btk/SLP-65 double deficient 
mice.
(A) Flow cytometric analysis of BM lymphoid cells from the indicated mouse groups. Expression profiles 
of B220 and μ H chain are displayed as dot plots. Total B220+ B-lineage fractions were gated and 
analyzed for the expression of κ L chain on the cell surface. Next, pro/pre-B cell fractions (B220+, μ-) 
were analyzed for cytoplasmic expression of SLC. Data are shown as histograms, whereby numbers 
indicate the percentage of positive cells. Plots are representative for 3-8 mice of each genotype. (B) In 
vitro survival after IL-7 withdrawal of BM cultures from the indicated mouse genotypes. 
pre-B cell stage (8, 34), and the absence of germline L chain transcripts, would in this 
model reflect the short life span of Btk/SLP-65 double deficient pre-B cells. 
To investigate this issue, we determined whether enforced expression of the 
anti-apoptotic Bcl-2 gene, which is thought to provide an extended time window per cell 
for Ig L chain rearrangement (35), is able to rescue the severe block in B cell development 
in Btk/SLP-65 double deficient mice. We crossed Btk/SLP-65 double deficient mice with 
Eμ-Bcl-2 Tg mice (18) and investigated the size of the immature B cell population by 
flow cytometry. We found that in the presence of the Bcl-2 transgene, the size of the 
immature B cell population was still severely reduced (Figure 4). Moreover, analysis 
of cytoplasmic μ H chain-positive pre-B cells indicated that increasing survival of Btk/
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SLP-65 double deficient pre-B cells did not rescue the defective downregulation of SLC 
expression in these cells (Figure 4).  Likewise, the Bcl-2 transgene failed to correct the 
modulation of the CD43, CD2 and CD25 surface markers (data not shown). We verified 
that Tg Bcl-2 diminished apoptosis in Btk/SLP-65-deficient pre-B cells as effective as 
in wild-type pre-B cells, by analysis of cell survival of cultured BM pre-B cells upon IL-7 
withdrawl (Figure 4B).
Collectively, these findings demonstrate that protection of Btk/SLP-65 double 
deficient pre-B cells from apoptosis does not result in the termination of SLC expression 
or the initiation of L chain rearrangements. Therefore, we conclude that defective Ig L 
chain opening in Btk- and SLP-65-deficient pre-B cells is not due to reduced survival.
E41K-Btk induces cell surface marker changes in μ- pro-B cells
Next, we aimed to investigate whether Btk signaling has the capacity to induce 
cell surface marker modulation and Ig L chain transcription and rearrangements, 
independent of the development progression of large to small pre-B cells. We employed 
Tg mice expressing the constitutively active E41K-Btk mutant under the control of the 
CD19 promoter region, which were crossed onto the Btk-deficient background. 
Although expression of transgenic E41K-Btk resulted in a dose-dependent 
deletion of B cells at the transition of IgMlow to IgMhigh B220low immature B cell stage in 
the BM (8, 21), it nevertheless completely corrected the impaired modulation of pre-B 
cell surface markers in Btk-deficient mice (Figure 5A). In vitro BM culture experiments 
showed that expression of E41K-Btk increased IL-7 responsiveness of pro-B cells and 
reduced IL-7 responsiveness of pre-B cells (Figure 5B-D). E41K-Btk did not increase 
IL-7Rα chain transcription or surface expression in pro-B cells (data not shown), and 
therefore it appears that this effect of E41K-Btk is based on the functional intersection of 
pre-BCR and IL-7R signaling pathways that induce pre-B cell proliferation (36).
To examine the capacity E41K-Btk to mimic pre-BCR activation and 
consequently signal for premature cellular maturation of cytoplasmic μ- pro-B cells in 
vivo, we characterized the CD19+B220low cytoplasmic μ- pro-B cell fractions in the BM 
from Btk+, Btk- and E41K-Btk Tg mice (Figure 6A). In Btk+ and Btk- mice, almost all 
CD19+B220+ cytoplasmic μ- pro-B cells contained SLC. In contrast, in E41K-Btk Tg 
mice ~40% of the pro-B cells did not express detectable levels of SLC in the cytoplasm. 
When compared with Btk+ or Btk- mice, the pro-B cell fraction from E41K-Btk Tg mice 
contained a significantly larger subpopulation of cells expressing CD2, CD25 and MHC 
class II. In all groups of mice, pro-B cells were largely CD43+. To exclude the possibility 
that the analyses of pro-B cells are confounded by Ig μ H chain positive pre-B cells that 
have subsequently lost or downregulated Ig μ H chain expression, we crossed Btk+, Btk-
, and E41K-Btk Tg mice onto the μMT background (24). In μMT mice, cells are arrested 
at the pro-B cell stage, because the membrane exon of the Ig H chain μ constant region 
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is disrupted and therefore Ig μ H chain cannot be expressed on the cell surface. Also on 
the μMT background, we found that expression of E41K-Btk resulted in downregulation 
of SLC and the induction of CD2, CD25 and MHC class II in cytoplasmic μ H chain 
negative pro-B cells (Figure 6B).
The surface marker profiles induced by E41K-Btk in pro-B cells reflected the 
phenotypic changes that are normally associated with developmental progression 
of large cycling into small resting pre-B cells. Therefore, we conclude that E41K-Btk 
expression in pro-B cells mimics pre-BCR signaling, and induces cell surface marker 
changes in these cells, even in the absence of functional Ig μ H chain proteins. 
Figure 5.  The effect of E41K-Btk expression on pre-B cells. 
(A) E41K-Btk expression corrects the impaired modulation of cell surface markers in Btk-deficient pre-B cells. 
Cytoplasmic SLC and CD2 expression was investigated in pre-B cell fractions (B220+IgM-, c-μ H chain+) whereas 
BP-1 and CD25 were analyzed in total pro-B/pre-B cell fractions (B220+IgM-) from the indicated mice. Data shown 
are representative for 6-11 animals per group. (B) E41K-Btk expression corrects increased IL-7 responsiveness of 
Btk-deficient B-lineage cells. Analysis of proliferative responses to IL-7 of total BM fractions from the indicated mice, 
as determined by [3H]-thymidine incorporation after 5 days of culture in the presence or absence of 100 U/ml IL-7. 
Error bars are SEM from 3-7 mice per group. (C) Increased proportions of pro-B cells in BM cultures from BtkAct 
Tg mice. The distribution profile over the indicated B-lineage subpopulations of IL-7 driven total BM cultures of the 
indicated mice after 5 days of culture in the presence of 100 U/ml IL-7. Error bars are the SEM values for pro-B cells 
from 3-7 mice per group. (D) Constitutively active Btk supports expansion of pro-B cells in IL-7 driven BM cultures. 
The bars indicate the relative expansion of c-μ- pro-B and c-μ+ pre-B cells during culture with 10 or 100 U/ml IL-7 at 
day 5, as compared with the pro-B and pre-B cell numbers at the start of the culture, which were set to one.
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Figure 6. E41K-Btk induces phenotypic changes in cytoplasmic μ- pro-B cells.
Flow cytometric expression profiles of the indicated markers in pro-B cells of Btk+, Btk- and E41K-Btk 
mice on a wild type (A) or a μMT background (B, C, D). Flow cytometric analysis of surface B220 
and cytoplasmic μ H chain expression on total CD19+ B-lineage cells in the BM (A, B, upper parts). 
CD19+B220+cμ- pro-B cells were gated and analyzed for the expression of cytoplasmic SLC, surface 
CD43, CD2, CD25 and MHC class II, and cytoplasmic κ L chain (A, B, lower parts). The results are 
displayed as filled histograms in which the percentages of positive cells are indicated. (C) Expression 
profiles of cytoplasmic μ H chain and κ L chain in B220+CD19+ BM fractions of the indicated mice. (D) 
CD19+B220+cμ- pro-B cells from the indicated mice were gated and analyzed for the expression of 
CD25, SLC and κ L chain. Data shown are representative of 4-8 animals examined within each group.
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E41K-Btk induces L chain rearrangement in μ- pro-B cells
Next, we investigated the effect of Tg E41K-Btk expression on Ig L chain rearrangement 
in pro-B cells, both on the wild-type background and on the μMT background. Whereas 
in wild-type mice <5% of CD19+B220low cytoplasmic μ H chain negative pro-B cells 
express detectable levels of Ig κ L chain proteins in their cytoplasm, this proportion was 
significantly increased to ~10-15% of pro-B cells in E41K-Btk Tg mice (Figure 6AB). 
In the total population of E41K-Btk μMT CD19+B220+ pro-B cells approximately equal 
proportions of cells exclusively expressed Ig H or Ig L chains, whereas the fraction of H 
and L chain double positive pro-B cells was low (Figure 6C). This finding indicates that 
in E41K-Btk μMT pro-B cells the majority of functional κ L chain rearrangements are 
performed in the absence of a productive H chain rearrangement. As shown in Figure 
6D, Ig κ	L chain expression was mainly found in those pro-B cells in which expression of 
pre-B cell specific markers was induced. Moreover, the fractions of pro-B cells in which 
SLC expression was downregulated and CD2, CD25 or MHC class II were induced 
were largely overlapping (Figure 6D). 
Using similar flow cytometric techniques we were unable to detect Ig λ L 
chain protein in E41K-Btk pro-B cells. However, when we performed RT-PCR analyses 
using primers specific for Vλ1 and Cλ1, rearranged λ L chain transcripts were readily 
detectable in purified E41K-Btk μMT pro-B cell fractions (Figure 7A). The levels of the 
Vλ1Cλ1 transcripts in E41K-Btk μMT pro-B cells were increased, when compared with 
control Btk+ or Btk- μMT pro-B cell fractions. Consistent with the induction of L chain 
rearrangement by the E41K-Btk transgene, increased levels of κo0.8, κo1.1, λ1o, and λ2o 
germline transcripts were detected in E41K-Btk μMT pro-B cells (Figure 7B). 
Taken together, the finding of germline transcription and recombination of Ig 
L chain gene segments in E41K-Btk pro-B cells, which do not express functional μ H 
chain proteins, demonstrates that E41K-Btk has the capacity to transmit signals that 
induce Ig κ and λ L chain rearrangement. 
Cooperation of IL-7 withdrawal and pre-BCR signaling
Pre-B cell receptor signaling mediates selective response to IL-7 at the pro-B to pre-B 
cell transition via an ERK/MAP kinase-dependent pathway (36). It has however been 
reported that removal of IL-7 induces Ig L chain rearrangement in cultured pro-B cells, 
even in the absence of functional Ig H chain protein (16). To investigate cooperative 
effects of pre-BCR signaling and IL-7 withdrawal, we cultured total BM cells from Btk+, 
Btk- and E41K-Btk mMT mice in the presence of IL-7 for 5 days and subsequently 
without IL-7 for 2 days. Consistent with reported findings (16), we observed that the Btk+ 
μMT pro-B cell cultures contained cytoplasmic κ L chain-positive cells (~20%, Figure 
8). However, the expression of Ig κ L chain was partially dependent on Btk signaling, 
because in Btk- μMT pro-B cell cultures the proportions of cytoplasmic κ L chain-positive 
cells were consistently lower (~10%, Figure 8). Likewise, the levels of germline λ01 and 
λ02 transcripts were severely decreased in Btk- μMT pro-B cell cultures, when compared 
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Figure 7. E41K-Btk induces L chain germline transcription and gene rearrangement in pro-B cells.
RT-PCR analysis for the detection of λ 1 L chain transcripts from rearranged Vλ1-Cλ1 segments (A) and 
κ and λ L chain germline transcripts (B) in Btk+, Btk- and E41K-Btk mice on a μMT background. Total RNA 
from BM fraction, enriched for B220+ cells, was reverse transcribed, diluted serially threefold, and used as 
a template for amplification of the indicated transcripts. Amplification of β-actin (bottom) was performed 
as a control. Products were fractionated by gel electrophoresis and detected with ethidium bromide. 
Data shown are representative for 3 mice examined in each group. Statistical evaluation showed that 
expression of κ00.8, κ01.1, λ01 and λ02 were significantly induced in E41K- Btk transgenic pro-B cells 
(p<0.05), when compared with Btk- pro B cells. No significant differences were found for λ03 expression.
to Btk+ μMT pro-B cell cultures (data not shown). In E41K-Btk μMT pro-B cell cultures 
the proportions of Ig κ+ cells were similar to those found in Btk+ μMT cultures, and levels 
of λ01 and λ02 transcripts were slightly increased (Figure 8 and data not shown). 
In these IL-7 driven pro-B cell cultures, Btk activity had a more dramatic 
effect on the expression of the developmentally regulated markers SLC, CD2 and CD25 
(Figure 8). In E41K-Btk μMT pro-B cell cultures, SLC was expressed in only ~16% 
of cells, as compared with ~42% and ~91% in Btk+ and Btk- μMT pro-B cell cultures, 
respectively. Likewise, CD2 and CD25 expression was induced in ~70% of the cells in 
E41K-Btk μMT pro-B cell cultures, whereas expression of these markers was very low 
in Btk- μMT pro-B cells (Figure 8). 
In summary, these findings indicate that in pro-B cell cultures removal of 
IL-7 and Btk signaling have cooperative effects on initiation of L chain rearrangement, 
but modulation of SLC, CD2 and CD25 expression is essentially dependent on Btk 
signaling. 
Btk and Slp65 and Ig L chain recombination
59
Figure 8. Cooperative effects of pre-BCR signaling and IL-7 withdrawal. 
Flow cytometric expression profiles of the indicated markers in pro-B cells of Btk+, Btk- and E41K-Btk 
mice on μMT background that were cultured in the presence of IL-7 for 5 days and for 2 additional 
days without IL-7. CD19+B220+ pro-B cells were gated and analyzed for the expression of the indicated 
markers. Data shown are representative of 4-8 animals examined within each group. 
Discussion 
The pre-BCR checkpoint monitors functional Ig H chain rearrangement and triggers 
clonal expansion and developmental progression of Ig μ+ pre-B cells (3). Hereby the 
downstream signaling components SLP-65 and Btk serve as feedback inhibitors that 
limit pre-B cell proliferation. Mice deficient for SLP-65 or Btk show a partial block at the 
large cycling pre-B cell stage, while an almost complete arrest is observed in SLP-65/
Btk double-mutant mice (6-8, 11-13, 25, 27, 34, 37). These findings suggest that Btk 
and SLP-65 are involved in cellular maturation of pre-B cells and in the initiation of Ig 
L chain recombination, but evidence for their direct involvement in these processes is 
lacking. A possibility remains that Btk and SLP-65 are only required to terminate pre-B 
cell expansion and to advance pre-B cells to a stage at which Ig L chain rearrangement 
may be initiated in a Btk/SLP-65 independent fashion. Moreover, defective initiation of L 
chain rearrangements in Btk/SLP-65-deficient pre-B cells may also be explained by an 
essential role of these molecules in the survival of small resting pre-B cells. 
In this report, we show (i) that protection of Btk/SLP-65 double deficient pre-B 
cells from apoptosis did not rescue modulation of pre-B cell surface marker expression 
or initiation of L chain rearrangement, and (ii) that expression of the E41K-Btk mutant 
in pro-B cells induced the pre-B cell developmental program, including germline 
transcription and productive rearrangement and expression of Ig L chain as well as 
modulation of cell surface markers. Therefore, we conclude that activated Btk does 
not only act to terminate proliferation or to increase survival of pre-B cells, but has the 
intrinsic capacity to signal for cellular maturation and the initiation of both k and λ L 
chain rearrangement and expression. 
It is highly unlikely that E41K-Btk signals for cellular maturation and Ig L chain 
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recombination by inducing cell cycle arrest in pro-B cells, because expression of E41K-
Btk increased IL-7 responsiveness in pro-B cells (Figure 5). Although we observed 
cooperation of IL-7 withdrawal and pre-BCR signaling in vitro (Figure 8), modulation of 
SLC, CD2 and CD25 expression was not induced by IL-7 withdrawal in the absence of 
Btk signaling. 
The E41K gain-of-function mutation in the pleckstrin homology (PH) domain 
of Btk induces transformation of 3T3 fibroblasts and this capacity is augmented by 
mutation of Y223, the main autophosphorylation site of Btk (19-20). The E41K and E41K-
Y223F mutants are associated with enhanced Btk membrane localization, activation 
and calcium signaling in cultured cell lines (19-20, 38-39). Several lines of evidence 
show that these mutants also represent activated forms of Btk in murine B cells. Tg 
expression of E41K-Btk (i) enhances blast formation of splenic B cells in culture (40), 
(ii) drives peripheral B cells efficiently into IgM plasma cell differentiation in vivo (21), 
and (iii) induces the expression of the early activation antigen CD69 on splenic B cells 
(R.W.H., unpublished). In addition, Tg E41K-Y223F-Btk manifests increased tyrosine 
phosphorylation in resting mature splenic B cells and has the ability to prevent tumor 
formation in SLP-65- pre-B cells (8). This observation indicates that E41K-Y223F-Btk 
may not only mimic activation of Btk, but may also transmit signals that substitute for 
SLP-65 function. Here we demonstrated that E41K-Btk was able to rescue the defects 
in Btk- pre-B cells, and to induce premature developmental progression and Ig κ and 
λ L chain recombination and expression in Ig H chain negative pro-B cells. As Ig λ 
rearrangements are normally initiated in late small resting pre-B cells when most k 
rearrangements cease (29, 41), expression of the E41K-Btk transgenic particularly 
advances Ig λ L recombination. Accordingly, E41K-Btk transgenic mice manifest 
increased Ig λ usage in vivo (~15%, as compared with ~7% in wild-type littermates; 
see ref. (12). Similar effects were also found for the E41K-Y223F Btk mutant (R.W.H., 
unpublished results). We did not detect any in vivo additional effects of the Y223F 
mutation on the phenotype of E41K-Btk mice, further supporting our previous conclusion 
that Y223 autophosphorylation-dependent interactions are not essential for Btk function 
during B cell development (27).
Approximately 10-15% of all E41K-Btk pro-B cells expressed detectable 
levels of κ L chain proteins in the cytoplasm. Since for each κ L chain allele 1 out of 3 L 
chain rearrangements is expected to be productive (and assuming that in the absence 
of Ig µ H chain protein κ+ and κ- pro-B cells do not manifest differences in survival, 
expansion or differentiation capacities), we conclude that V-to-J rearrangements may 
be present in up to ~30% of the total pro-B cell fraction in E41K-Btk mice. 
We observed that deficiency of Btk or SLP-65 in pre-B cells specifically 
reduced λ germline transcription, while κ germline transcription was not dramatically 
affected. These analyses were performed in VH81X transgenic RAG-1-deficient 
pre-B cells (Figure 3), which cannot perform receptor editing, a process that is usually 
Btk and Slp65 and Ig L chain recombination
61
accompanied by increased λ usage (35). Therefore, our findings indicate that Btk/SLP-
65 differentially regulate activation of the κ and λ L chain loci, independent of their 
possible role in receptor editing (12-13). We conclude that the specific reduction of 
λ	germline transcription in Btk- or SLP-65-deficient pre-B cells supports our previous 
hypothesis that Btk transmits signals that regulate the activation of the λ locus for V(D)
J recombination in pre-B cells (12). The finding that the absence of either Btk or SLP-
65 affects germline transcription of the λ locus, but not of the κ locus, is consistent with 
various reports that indicate the importance of pre-BCR signaling specifically in λlocus 
activation. Firstly, Ig κ and λ rearrangements occur independently, whereby already 
in pro-B cells Ig κ germline transcription and rearrangements are present (albeit at 
low levels), while λ rearrangements are only initiated in small resting pre-B cells when 
most κ rearrangements cease (29, 41). Secondly, Btk-deficient mice have reduced Ig 
λ L chain usage (12). However, from the observed cooperative effects of Btk and SLP-
65 on Ig κ germline transcription, it is clear that - in the absence of SLP-65 - Btk is 
also required for full activation of the λ locus. This would also be supported by our 
finding that E41K-Btk induces both Ig κ and λ L chain germline transcription in pro-B 
cells (Figure 7). Nevertheless, this capacity of the E41K-Btk mutant may alternatively 
indicate that its expression does not only mimic activation of Btk, but also transmit 
signals that substitute for SLP-65 function, analogous to our previous findings on the 
Y223F- E41K-Btk mutant (8).
Our experiments do not discriminate whether signals transmitted by Btk/SLP-
65 directly induce opening of the Ig L chain loci for recombination, or whether these 
signals only act indirectly by inducing the pre-B cell differentiation program. However, 
Ig L chain locus activation and pre-B cell maturation are probably closely connected, as 
transcription factors such as E2A, PU.1, Spi-B and IRF-4/8, are implicated both in the 
expression of e.g. MHC class II or SLC and in opening of Ig L chain loci (42-47). This would 
be consistent with recent quantitative analyses of κ 3’ enhancer chromatin structure and 
protein association, which indicate that this enhancer is activated progressively through 
multiple steps as cells mature (48). The transcriptional enhancers within the κ and λ L 
chain loci contain binding sites for the transcription factors E2A and EBF. Interestingly, 
transient transfection of E2A and EBF transcription factors into a non-lymphoid cell line 
was sufficient to activate V(D)J recombination at the Ig κ and λ loci, respectively (43). 
However, these transcription factors also activate transcription of the SLC genes λ5 and 
VpreB (42), which are silenced when Ig L chain rearrangement is initiated. Moreover, 
expression of Tg E41K-Btk in pro-B cells concurrently induced activation of Ig κ and 
λ L chain transcription and downregulation of SLC expression (Figures 6 and 7). In 
RT-PCR analyses, expression of E41K-Btk in pro-B cells did not appear to result in 
a significant increase in the expression levels of EBF or E2A (R.W.H., unpublished 
results). It remains however possible that Btk or SLP-65 are involved in the induction 
of EBF or E2A activity by stage-specific regulation of protein stability or expression of 
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partner molecules that interfere with the action of these transcription factors, such as 
Id proteins or Ikaros (47). Further experiments are required to investigate if Btk/SLP-65 
signaling pathways converge on EBF and E2A. 
Recently, the transcription factors IRF-4/8 and Spi-B were shown to be 
important for downregulation of the λ5 and Vpre-B genes and for the induction of 
germline Ig κ transcription in pre-B cells (44-45). However, Tg expression of E41K-
Btk in pro-B cells did not appear to result in a significant increase in the expression 
levels of IRF-4 or Spi-B transcripts (R.W.H., unpublished results), indicating that these 
transcription factors may not function as nuclear effectors of Btk/SLP-65 signaling. This 
would be supported by recent findings demonstrating that changes in PU.1 and IRF-4 
association during κ locus activation are independent of changes in protein expression 
levels, but rather reflect changes in chromatin accessibility and histone acetylation (48). 
Already in pro-B cells intermediate levels of the transcriptional activators PU.1 and 
IRF-4 associate with the κ 3’ enhancer, which is moderately accessible at this stage. 
Therefore, it is likely that pre-BCR signaling results in Ig L chain chromatin structure 
changes, which are linked to epigenetic marking and affect transcription factor binding 
site occupancy in the 3’ κ enhancer (48). Likewise, it is possible that pre-BCR signaling 
may downregulate the expression of the SLC chain genes by affecting the epigenetic 
status of the recently identified regulatory region within the λ5-VpreB locus, which is 
associated with a tightly localized epigenetic mark of H3 acetylation and histone H3 K4 
methylation (47).
Our finding that Btk- B cells fail to efficiently downregulate RAG-1 expression 
during the pre-B to immature B cell transition in culture (Figure 1B), implicate Btk 
signaling in the termination of V(D)J recombination activity upon productive Ig L chain 
rearrangement in immature B cells. This would be consistent with the finding that 
peripheral B cells from XLA patients, which have mutations in the Btk gene, show a 
distinct antibody repertoire consistent with extensive secondary V(D)J recombination 
(49).  
In summary, we conclude that expression of E41K-Btk, which mimics pre-
BCR signaling, results (i) in the modulation of cell surface markers that signify pre-B 
cell maturation, and (ii) in the induction and successful completion of Ig L chain 
rearrangements in pro-B cells. It is therefore unlikely that in pre-B cells Btk/SLP-65 
signaling is only required for the termination of pre-B cell expansion or for survival of 
small resting pre-B cells. Rather, we conclude that Btk and SLP-65 transmit signals that 
induce cellular maturation and Ig L chain rearrangement in pre-B cells.
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Malignant transformation of Slp65-deficient 
pre-B cells involves disruption of the Arf-
Mdm2-p53 tumor suppressor pathway
Ta VBT, Bruijn MJW, ter Brugge PJ, van Hamburg JP, Diepstraten HJA, 
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Abstract
The adapter protein Slp65 is a key component of the precursor-B (pre-B) cell receptor. 
Slp65-deficient mice spontaneously develop pre-B cell leukemia, but the mechanism 
by which Slp65-/- pre-B cells become malignant is unknown. Loss of Btk, a Tec-family 
kinase that cooperates with Slp65 as a tumor suppressor, synergizes with deregulation 
of the c-Myc oncogene during lymphoma formation. Here, we report that the presence of 
the immunoglobulin heavy chain (IgH) transgene VH81X prevented tumor development 
in Btk-/-Slp65-/- mice. This paralleled the reported effect of a human IgH transgene on 
lymphoma development in Em-myc mice, expressing transgenic c-Myc. As activation 
of c-Myc strongly selects for spontaneous inactivation of the p19Arf–Mdm2–p53 tumor 
suppressor pathway, we investigated if disruption of this pathway is a common alteration 
in Slp65-/- pre-B cell tumors. We found that combined loss of Slp65 and p53 in mice 
transformed pre-B cells very efficiently. Aberrations in p19Arf, Mdm2 or p53 expression 
were found in all Slp65-/- (n=17) and Btk-/-Slp65-/- (n=32) pre-B cell leukemias analyzed. 
Also 9 our of 10 p53-/-Slp65-/- pre-B cell leukemias manifested significant Mdm2 protein 
expression. These data indicate that malignant transformation of Slp65-/- pre-B cells 
involves disruption of the p19Arf–Mdm2–p53 tumor suppressor pathway.  
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Introduction
B cells are produced in the bone marrow (BM) through a complex process of cellular 
differentiation, characterized by the ordered rearrangement of immunoglobulin (Ig) 
heavy (H) and light (L) chain gene segments encoding the B cell antigen receptor (BCR) 
(reviewed in Ref. (1-2)). In pro-B cells productive V(D)J recombination results in cell 
surface deposition of the pre-BCR, comprised of Ig m H chain and the surrogate light 
chain (SLC) components 	 l5 and VpreB(2-4). The pre-BCR serves as an important 
checkpoint to monitor proper expression of a functional IgH chain and triggers clonal 
expansion, whereby pre-B cells acquire the capacity to respond to low concentrations 
of the proliferation factor interleukin (IL)-7(2-4).  After a limited number of cell divisions, 
large pre-B cells stop cycling and differentiate into small, resting pre-B cells in which IgL 
chain rearrangement is initiated.
The adaptor protein Slp65 (also known as Blnk or Bash) is a key component 
in the signaling pathway downstream of the pre-BCR and the BCR. Slp65, when 
phosphorylated by Syk, provides docking sites for various molecules, including Bruton’s 
tyrosine kinase (Btk) and phospholipase C (PLCg). Btk then phosphorylates PLCg, 
which leads to its full activation and the generation of second messengers(3, 5).
In human, mutations in SLP65 or BTK result in defective pre-B cell proliferation 
and an almost complete arrest of B cell development at the pro-B to pre-B cell transition, 
associated with the immunodeficiency disorder agammaglobulinemia (3). In contrast, 
mice deficient for Slp65 or Btk show only a partial arrest at the large cycling pre-B cell 
stage, while a nearly complete block is present in Btk/Slp65 double deficient mice(6-
8). Importantly, at the age of ~6 months 5-10% of Slp65-deficient mice develop pre-B 
cell leukemia expressing high levels of pre-BCR on the cell surface(6, 9). Although 
Btk-deficient mice do not develop pre-B cell tumors, we found that Slp65 and Btk 
cooperate as tumor suppressors, whereby Btk exerts its tumor suppressor function 
independently of its kinase activity(8, 10). It has been reported that in a substantial 
fraction of human pre-B cell acute lymphoblastic leukemia (ALL), including cases 
expressing the oncogenic BCR-ABL1 tyrosine kinase fusion protein, SLP65 expression 
is defective due to aberrant splicing(11-12). As subsequent analyses indicated that 
SLP65 deficiency may be an infrequent event in human pre-B-lineage ALL (13),(14), 
the importance of loss of SLP65 expression as one of the primary causes of pre-B ALL 
in human remains unclear. 
 The mechanism by which Slp65 exerts its tumor suppression function in mice 
has not yet been elucidated. During the transition of large cycling into small resting pre-B 
cells, Slp65-/- or Btk-/- cells fail to efficiently downregulate SLC and IL-7 receptor (IL-7R) 
expression, resulting in an increased proliferative response to IL-7 in vitro(6, 8 ). Recent 
findings show that Slp65 also downregulates IL-7-mediated proliferation and survival 
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through direct inhibition of Jak3, which is an essential IL-7R signaling component(15). 
The IL-7R pathway promotes cellular survival, proliferation and maturation, involving 
induction of the anti-apoptotic protein Bcl-2 and the proto-oncogene c-Myc(16, 17 ). B 
cell development can be partially restored in Jak-3-deficient mice when they are bred to 
mice co-expressing a rearranged IgH chain transgene and a c-Myc transgene(18). 
 Similar to Slp65-/- mice Em-myc transgenic mice, which express c-Myc under 
the control of the IgH intronic enhancer, develop rapid-onset pre-B cell malignancies 
(19). Interestingly, loss of Btk or PLC-g2 synergizes with deregulation of c-Myc during 
lymphoma formation in Em-myc mice(20-21). The presence of the Em-myc transgene 
substantially increases the proliferative potential of B cell progenitors in response to 
IL-7(20-21). Activation of c-Myc is required for progression of quiescent cells into the 
S phase of the cell cycle, but c-Myc can also induce the p53 protein, which protects 
against oncogenic transformation of proliferating cells (see Ref. (22 for review)). c-Myc 
activates the p19Arf tumor suppressor that interferes with the E3 ubiquitin protein 
ligase Mdm2 and thereby stabilizes and activates p53, resulting in cell-cycle arrest or 
apoptosis. It has been shown that in Myc-induced lymphomagenesis the p19Arf–Mdm2–
p53 circuitry is often disrupted, indicating that c-Myc activation strongly selects for 
spontaneous inactivation of this pathway(23).  
We hypothesized that malignant transformation of Slp65-deficient pre-B cells is 
not only dependent on constitutive proliferative signals provided by the pre-BCR and IL-
7R, but also requires loss of the protective checkpoint function of the p19Arf–Mdm2–p53 
pathway. Therefore, we investigated if disruption of the p19Arf–Mdm2–p53 pathway is 
a common alteration in Slp65-/- pre-B cell tumors. We found that loss of p53 enhanced 
lymphoma formation in Slp65-deficient mice and that Slp65-deficient pre-B cell tumors 
harbored aberrations in the p19Arf–Mdm2–p53 tumor suppressor pathway. 
Material and Methods
Mice and genotyping
Btk-/-(24), Eμ-2-22 Bcl-2 transgenic (Tg)(25), p53-/-(26), Aicda-/-(27) and VH81X 
Tg(28) mice were on the C57BL/6 background. Slp65-/- mice(5) were on the Balb/c 
background. The different composite genotypes were on a mixed background and in 
single experiments littermates were compared. For mouse genotyping genomic DNA 
was analyzed by PCR as previously described (8, 27-28). Animals in tumor panels were 
sacrificed after indication of tumor formation, or after a maximum period of 26 weeks. 
Mice were bred and maintained in the Erasmus MC animal care facility under pathogen-
free conditions. Experimental procedures were reviewed and approved by the Erasmus 
MC committee of animal experiments.
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 Tumors were identified as described8, and tumor load in lymphoid tissues 
was determined by flow cytometry on the basis of intracellular expression of SLC 
components and Ig u heavy chain and surface expression of B220 and CD19 (Suppl. 
Tables 3ABC).
Quantitative reverse transcriptase (RT)-PCR analysis
Total RNA was extracted using the GenElute Mammalian Total RNA Miniprep system 
(Sigma-Aldrich). One microgram of total RNA was DNAse digested (Invitrogen, 
Carlsbad, CA) and used as a template for cDNA synthesis, using Superscript II reverse 
transcriptase (Invitrogen) and random hexamer primers. For quantitative RT-PCR, 
primers spanning at least one intron-exon junction were designed manually or using 
ProbeFinder software (Roche Applied Science, Indianapolis, IN) (Supplementary Table 
S1). Quantitative RT-PCR was performed using the ABI Prism 7700 sequence detection 
system (Applied Biosystems, Foster City, CA). Ct-values were obtained using SDS 
v1.9 software (Applied Biosystems) and normalized to glycereraldehyde-3-phosphate 
dehydrogenase (GAPDH).
Southern Blotting
Genomic DNA (10 mg) was digested with various restriction endonucleases (New England 
Biolabs, Beverly, MS) and processed by Southern blotting using nylon membrane 
(Hybond N+, Amersham or Nytran SPC, Whatman). Fragments were visualized using 
a PhosphorImager and analyzed with ImageQuant (Molecular Dynamics, Sunnyvale, 
CA). Probes specific for N-myc, a 990 bp PCR fragment from exon 3, for Gata-3, a 800 
bp cDNA containing exons 1-3, for p53, a 1123 bp PCR fragment from intron 1 (probe 
1) and a 614 bp fragment containing part of intron 10 and exon 11 (probe 2), for Ink4a-
Arf, a 815 bp PCR fragment from exon 1α, were labeled by random priming, according 
to standard procedures.
Flow cytometry, cell culture and in vivo 5-bromo-2’-deoxyuridine (BrdU) labeling
Preparations of single-cell suspensions, flow cytometry procedures, and monoclonal 
antibodies have been described previously(8, 24, 29). BM cell suspensions were 
depleted of erythrocytes by standard ammonium chloride lysis and IL-7 driven cultures 
were performed as described previously(29). For intracellular staining of cytoplasmic 
proteins, cells were first stained for cell surface markers and subsequently fixed in 2% 
paraformaldehyde and permeabilized using 0.5% saponin. Procedures for calcium flux 
measurements have been described previously(10). Events (1–5 x 105) were scored 
using a FACSCalibur flow cytometer and analyzed using CellQuest software (BD 
Biosciences, San Jose, CA).  
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 BrdU (BD Biosciences) was dissolved in Phosphate-buffered saline at 2 mg/ml. 
Mice were injected i.p. with 200 ml, and sacrificed at various time points. Total BM cell 
suspensions were analyzed by flow cytometry for BrdU incorporation, using the BrdU 
flow kit (BD Biosciences) in conjunction with cell surface marker expression.
Spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH)
Tumor cells were cultured overnight in the presence of 100 U/ml IL-7 and 10 ng/
ml colcemid (KaryoMAX Colcemid solution, Gibco-BRL, Gaithersburg, MD) and 
subsequently with 30 ng/ml for 4h to arrest proliferating cells at metaphase. Cells 
were treated with 75 mM KCl and fixed with methanol/acetic acid (3:1). SKY was 
performed using the Applied Spectral Imaging system (ASI, Migdal Ha’Emek, Israel) 
following manufacturer’s protocols. Slides were counterstained with 4’,6-diamidino-2-
phenylindole (DAPI) containing DABCO/Vectashield (Vector Laboratories, Burlingame, 
CA). Chromosomes were analyzed by Zeiss Axioplan 2 microscope equipped with the 
Spectra Cube system (ASI). At least 10 different metaphases from each sample were 
analyzed, using Skyview analysis software (ASI). Dual-colored FISH experiments were 
performed using BAC probes RP23-246B9 for N-Myc and CT7-199M11 for IgH chain 
(Invitrogen, Carlsbad, CA), using standard procedures. 
Pre-B cell stimulation and western blotting
Total BM cells were cultured in the presence of 100 U/mL IL-7 (Sigma-Aldrich, St 
Louis, MO) as described(29). Pre-B cells were stimulated with 20mg/mL F(ab)2 
fragment of polyclonal goat anti-mouse IgM (Jackson Immuno Research, Westgrove, 
PA) at 37°C for 5 minutes. Cultured pre-B cells or pre-B leukemia cells were lysed 
in lysis buffer (20mM TRIS, 137mM NaCl, 10mM EDTA, 100mM NaF, 1% Nonidet 
P-40, 10% glycerol, 1mM pefabloc/AEBSF, 4-(2-Aminoethyl)-benzenesulfonyl fluoride 
hydrochloride (Roche Applied Science, Indianapolis, IN), 1 mM Na3VO4) on ice for 
20 minutes and centrifuged at 16000g at 4°C for 20 minutes. Total cell lysates of were 
immunoprecipitated with antiphosphotyrosine (pTyr-100, Cell Signaling Technology, 
Beverly, MA). Samples were subjected to Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis, and electrotransferred to nitrocellulose membrane (Whatman), using 
standard procedures. Blots were stained with antibodies to Mdm2 (C18), p53 (DO-1 
and FL-393), or Syk (N-19), all purchased from Santa Cruz Biotechnology, Santa Cruz, 
CA, or to p19ARF (ab80) from Abcam, Cambridge, MA. 
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Results
Enhancement of cellular survival does not increase pre-B cell leukemia incidence 
in Slp65-deficient mice
The developmental arrest in Slp65 and Btk single or double deficient mice results in a 
dominating populating of pre-B cells with increased surface expression of SLC and IL-
7R, when compared with wild-type mice(6-7). Although Slp65-/- pre-B cells display an 
increased proliferative response to IL-7 in vitro(6, 9), the pre-B cell population in Slp65-/- 
mice contains significantly fewer cycling cells, when compared wild-type littermates(9). 
In agreement with the absence of increased in vivo proliferation of Slp65-/- pre-B cells, 
we found that BM pre-B cell numbers were not increased in Slp65-/- mice and even 
significantly reduced in Slp65-/-Btk-/- mice (Figure 1A). 
 We previously reported that transgenic expression of the anti-apoptotic 
protein Bcl-2 enhanced in vitro survival upon IL-7 withdrawal, but did not rescue the 
developmental arrest of Slp65-/-Btk-/- pre-B cells(30). It is therefore conceivable that 
Bcl-2 overexpression, which is commonly associated with enhanced malignancy of 
hematological tumors, may increase tumor incidence in Slp65-/- mice. To investigate this, 
we compared pre-B cell leukemia incidence in a panel of Slp65-/-Btk-/- mice and Eμ-2-22 
Bcl-2 Tg Slp65-/-Btk-/- mice. We confirmed that in these crosses Bcl-2 overexpression 
did not rescue pre-B cell differentiation (Figure 1B) and found that the presence of the 
Eμ-2-22 Bcl-2 Tg had no effect on pre-B cell leukemia incidence in Slp65-/-Btk-/- mice 
(Figure 1C) or Slp65-/- mice (not shown). 
These findings show that in Slp65-/- pre-B cells – in which pre-BCR/IL-7R-
mediated proliferation and survival signals are increased – enhancement of cellular 
survival does not augment tumor formation. Therefore, acquisition of additional genetic 
changes is required for malignant transformation of Slp65-/- pre-B cells. 
Expression of the VH81X IgH chain transgene prevents leukemia in Btk-/-Slp65-/- 
mice 
Because (i) pre-BCR/IL-7R signaling induces c-Myc and its family member N-myc in large 
pre-B cells(16), and (ii) loss of Btk or PLCg synergizes with deregulation of the c-Myc 
oncogene during lymphoma formation(20-21), we hypothesized that transformation of 
Slp65-deficient pre-B cells may involve enhanced Myc-activation.
We used quantitative RT-PCR to establish that pre-B cell tumors from Slp65-
/- (n=16) and Btk-/-Slp65-/- (n=27) mice expressed substantial levels of Myc transcripts. 
When compared with cultured wild-type pre-B cells, c-Myc expression in Slp65-/- and 
Btk-/-Slp65-/- pre-B cell tumors was ~8-fold increased, while n-Myc was moderately 
increased only in Slp65-/- pre-B cell tumors (Figure 2A). 
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Figure 1. Enhancement of cellular survival does not increase pre-B cell leukemia incidence in 
Slp65-deficient mice.
(A) Absolute numbers of pre-B cells (CD19+Ig L-cm+) per hind leg in the indicated mice. Bars represent 
average values and the standard error of the mean (SEM) of 9-14 animals per genotype. Asterisks 
indicate significant differences with p< 0.001 (t-test).  (B) Flow cytometric analysis of BM lymphoid cells 
from the indicated mouse groups. Total CD19+ B-lineage cells were gated and CD19/ck profiles are 
displayed as dot plots. Percentages of cells within the indicated gates are given and data shown are 
representative of 3-4 animals per genotype. (C) Kaplan-Meier tumor-free survival estimates for Btk-/-
Slp65-/- mice (n=25) and Bcl-2 Tg Btk-/-Slp65-/- mice (n=7). 
Interestingly, the incidence of lymphomas in Em-myc mice is greatly reduced 
by the introduction of a human IgH transgene(31). Such a transgene is thought 
to accelerate B cell development, thus reducing the population size of cells most 
susceptible to oncogenic transformation by c-Myc. To investigate if expression of an 
IgH chain transgene also reduces pre-B cell tumor incidence in Slp65-deficient mice, 
we employed mice carrying the IgH chain transgene VH81X(28). First, we ascertained 
by flow cytometry that the VH81X transgene did not significantly affect the generation 
of large and small pre-B cell compartments in the BM of WT, Btk-/-, Slp65-/- and Btk-/-
Slp65-/- mice (Suppl. Figure S1). Furthermore, the presence of the VH81X transgene did 
not affect in vivo pre-B cell proliferation: when mice were pulsed with a single dose of 
the thymidine analogue BrdU, which is selectively incorporated into the DNA of large
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 Figure 2. The VH81X Tg prevents tumor formation in Btk/Slp65 double-deficient mice. 
(A) Quantitative RT-PCR analyses of c-Myc and N-Myc expression in Slp65-/- (n=16) and Btk-/-Slp65-/- 
(n=27) pre-B cell tumors, normalized with GAPDH. Values in WT pre-B cells, cultured for 5 days with 
100 U/mL IL-7, were set to one. For each of these groups, the horizontal line represents the mean of 
the relative expression level. (B) Effect of the VH81X Tg on pre-B cell proliferation in vivo. The absolute 
numbers of BrdU+ CD19+cm+ck- pre-B cells in the BM, 4 hr after i.p. injection of a single dose of BrdU, 
as determined by flow cytometry. Average values and SEM of three animals per group are shown. (C) 
Effect of the VH81X Tg on pre-B cell proliferation in vitro. Results are displayed as fold expansion after 
5 days of culture in the presence of IL-7 (100 U/mL), whereby the pre-B cell numbers at the start of the 
culture where set to one. Bars represent average values and SEM of 7-8 animals per genotype. (D) Syk 
phosphorylation in pre-B cell cultures from non-VH81X  Tg Slp65
-/- and VH81X Tg Btk
-/-Slp65-/- mice. Cells 
were either unstimulated (-) or stimulated for 5 minutes with polyclonal anti-IgM F(ab)2 fragments. The 
presence of phosphorylated Syk was detected in antiphosphotyrosine immunoprecipitates from total 
cell lysates, analyzed by Western blotting using Syk-specific antibodies. (E) Kaplan-Meier tumor-free 
survival estimates for Btk-/-Slp65-/- mice (n=20) and VH81X transgenic Btk
-/-Slp65-/- mice (n=25). 
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pre-B cells(29), comparable numbers of BrdU+ CD19+IgL-cm+ pre-B cells were present 
in non-Tg and VH81X Tg Btk
-/-Slp65-/- mice (Figure 2B). The high in vitro proliferative 
capacity of Btk-/-Slp65-/- pre-B cells in IL-7 driven cultures(8) was also not significantly 
affected by the presence of the VH81X transgene (Figure 2C). We therefore conclude 
that the phenotypical abnormalities of Btk-/-, Slp65-/- and Btk-/-Slp65-/- pre-B cells, 
which reflect their impaired cellular maturation from large cycling into small resting 
pre-B cells, were preserved in the presence of the pre-rearranged VH81X IgH chain 
transgene. When cultured VH81X transgenic and non-transgenic Btk
-/-Slp65-/- pre-B 
cells were stimulated with Ig m H chain-specific antibodies, we found similar Syk 
tyrosine kinase phosphorylation (Figure 2D), supporting the signaling competence of 
the VH81X IgH chain. Consistent with the essential role of Slp65 in calcium mobilization, 
we found that pre-BCR signaling-associated calcium fluxes in both VH81X transgenic 
and non-transgenic Btk-/-Slp65-/- pre-B cells were blunted (Suppl. Figure S2). 
 To address the effect of the VH81X transgene on pre-B cell leukemia formation, 
we followed panels of Btk-/-Slp65-/- mice, which did or did not carry the VH81X transgene. 
At 6 months of age, 16 out of 20 Btk-/-Slp65-/- mice developed pre-B cell leukemia. In 
strong contrast, none of the 23 VH81X IgH chain transgenic Btk
-/-Slp65-/- mice developed 
pre-B cell leukemia (Figure 2E). Also, when we examined BM and spleen of these mice 
by flow cytometry at the age of 6 months we did not find evidence for lymphoproliferative 
disease. 
 Thus, expression of the pre-rearranged VH81X H chain transgene in early 
B cell differentiation prevented oncogenic transformation of Btk-/-Slp65-/- pre-B cells, 
equivalent to findings in Em-myc Tg mice(31).
Deficiency of Slp65 and p53 have cooperative effects in tumorigenesis
Next, we investigated the effect of p53-deficiency on pre-B cell tumor formation by 
crossing Slp65-/- mice onto a p53-/- background. In flow cytometric experiments, 
no significant differences were found between the sizes of the individual B-lineage 
subpopulations in Slp65-/- mice and p53-/-Slp65-/- mice: as shown in Figure 3A, Slp65-
/- mice and p53-/-Slp65-/- mice have a similar defect in CD25 upregulation upon pre-
BCR signaling(8), and have a similar reduction in the number of mature recirculating 
IgMlowIgD+ B cells. The proliferative capacity of Slp65-/- pre-B cells in IL-7 driven BM 
cultures in vitro was not affected by the concomitant absence of p53 (data not shown). 
Whereas ~17% (6 out of 36) of Slp65-/- mice developed pre-B cell leukemia at 
6 months, all p53-/-Slp65-/- mice (n=24) developed pre-B cell leukemia within 5 months 
(Figure 3B). All pre-B cell tumors in p53-/-Slp65-/- mice were positive for Ig m H chain and 
SLC, and showed variable surface expression of developmentally regulated markers, 
including CD2 and the metallopeptidase BP-1, similar to those normally found in Slp65-/- 
mice (Figure 3C). In contrast, five out of 17 p53-/- single deficient littermates developed T 
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cell lymphoma before the age of 5 months. Thus, loss of Slp65 on the p53-/- background 
resulted in rapid onset of pre-B cell tumors before the age at which T cell tumors usually 
arise in p53-/- mice. We conclude that Slp65 and p53 cooperate to limit the oncogenic 
potential of DNA damage and/or sustained oncogenic signaling. 
Figure 3. Slp65 and p53 cooperate as tumor suppressors in pre-B cells
(A) Flow cytometric analysis of total lymphoid fractions in BM (top panel). Total CD19+ fractions were 
gated and analyzed for IgM and IgD expression (lower panel). Data are displayed as dot plots, and 
numbers indicate the percentages of cells within the gates and are representative for four 5-week-old 
non–tumor bearing mice. (B) Kaplan-Meier tumor-free survival estimates for Slp65-/- mice (n=36), p53-/- 
mice (n=17), and p53-/-Slp65-/- mice (n=24). (C) Characterization of pre-B cell tumors by flow cytometry. 
Dot plots for surface SLC and µ H chain expression (upper panel) and dot plots for CD2 and BP-1 
expression (lower panel) in gated CD19+ cells from tumor samples of Slp65-/- (S99, S100) and p53-/-
Slp65-/- (PS23, PS27) mice.
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Activation-induced cytidine deaminase (Aid) is not involved in malignant 
transformation of Slp65-/- pre-B cells
One of the malignancy-associated stress signals that activates p53 is DNA damage. We 
therefore investigated a possible role of DNA damage caused by the Aid mutator protein 
or by aberrant V(D)J recombination, leading to chromosomal translocations (32).
 Human pre-B ALL that harbor the t(9;22)(q34;q11) Philadelphia  translocation 
encoding the oncogenic BCR-ABL1 tyrosine kinase have defective pre-BCR signaling, 
express a truncated isoform of SLP65(12, 33) along with AID(12, 33), which acts as a 
BCR-ABL1-induced mutator. Aid expression is normally restricted to germinal center B 
cells where it initiates somatic hypermutation (SHM) and class switch recombination. 
However, when expressed in non-germinal center cells, Aid can induce mutation in 
various highly transcribed genes and thereby act as a genome-wide mutator(34).
 We analyzed Slp65-deficient pre-B cell tumors for Aid expression by quantitative 
RT-PCR. Remarkably, in most of the samples Aid transcripts were detected, albeit at 
variable levels. In a small fraction of leukemic samples Aid expression was in the same 
range as in Peyer’s Patches (Suppl. Figure S3A). It was thus conceivable that Aid-
induced DNA damage could contribute to tumorigenesis in Slp65-deficient pre-B cells. 
However, when we sequenced putative Aid target regions, including the 5’ regions of 
the l5 and p53 genes, as well as the JH4 intron of the IgH locus, from a panel of 15 Btk-
/-Slp65-/- tumors, we did not find evidence for SHM (data not shown). Next, we reasoned 
that if Aid would play an important role in malignant transformation of Slp65-/- pre-B cells, 
the frequency of pre-B cell leukemias would be significantly reduced in the absence of 
the Aicda gene encoding Aid. But, we found that the pre-B cell tumor incidences in 
Slp65-/- or Btk-/-Slp65-/- mice were similar in the presence (Aicda+/-) or absence (Aicda-/-) 
of Aid (Suppl. Figure S3B). 
 Therefore, we conclude that Aid-induced DNA damage is not involved in 
malignant transformation of Slp65-/- pre-B cells. 
Chromosome 12 abnormalities in Slp65-/- pre-B cell tumors
When DNA breaks mediated by the V(D)J recombination machinery are not resolved 
properly, they can give rise to chromosomal alterations, in particular translocations, 
and lymphoid tumors(32). We examined metaphase spreads from Btk-/-Slp65-/- and 
p53-/-Slp65-/- tumor cells by SKY and found evidence for chromosomal instability 
mainly characterized by chromosome gains, in particular of chromosome 12 and 14 
(Supplementary Table S2). Interestingly, BCR-Abl transgenic mouse lymphomas often 
show gain of chromosome 12 and 14(35). 
 Two leukemia samples, BS56 (Btk-/-Slp65-/-) and PS11 (p53-/-Slp65-/-) harbored an 
aberration involving intrachromosomal gain of chromosome 12 material (Supplementary 
Figure S4A). Similar enlargements of chromosome 12 have been identified in pro-B cell 
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leukemia’s derived from mice deficient for p53 and Artemis, a component of the non-
homologous end-joining DNA repair pathway(36). As the observed chromosome 12 
enlargement points to the possibility of N-myc amplification, FISH experiments were 
performed. We found a duplication (BS56) and dramatic amplification (PS11) of the 
N-myc locus (Supplementary Figure S4B). Southern blotting of genomic EcoRI digests 
with an N-myc-specific probe confirmed amplification of N-myc in the BS56 and PS11 
tumors and identified a third pre-B cell leukemia (PS08) with N-myc amplification (3 out 
of 38 analyzed tumors) (Supplementary Figure S4C). Quantitative RT-PCR experiments 
demonstrated that the two p53-/-Slp65-/- pre-B cell leukemias (PS08 in red and PS11 in 
green) that harbored substantial N-myc gene amplification expressed extremely high 
levels of N-myc and severely reduced levels of c-Myc transcripts (Supplementary Figure 
S4D). Similar cross-regulation of Myc family members has been reported in the context 
of N-myc-related transformation(36). In contrast to chromosome 12 enlargements 
involving N-myc in Artemis/p53 double-deficient mice(36-37), we did not detect co-
amplification of IgH chain locus sequences in FISH and Southern blotting experiments 
(data not shown). 
 In summary, although part of the Slp65-/- pre-B cell leukemias exhibit 
chromosomal instability, we found no evidence for Rag-mediated translocations. Our 
SKY analyses revealed gain of chromosome 12 or N-myc amplification in 6 out of 19 
(~32%) pre-B cell tumors.
Only a small subset of Slp65-deficient tumors expresses p53 protein
The p53 response can also be activated by oncogenic signaling. In particular, it has 
been shown that Myc-induced lymphomagenesis strongly selects for spontaneous 
inactivation of the p19Arf–Mdm2–p53 tumor suppressor pathway(23). Therefore, we next 
investigated whether malignant transformation of Slp65-/- pre-B cells involves disruption 
of this pathway.
 Loss of p53 function can occur through deletions or point mutations. We did not 
detect gross deletions in the p53 gene by Southern blot analyses in a panel of 23 Slp65-
/- and Btk-/-Slp65-/- tumors (Suppl Figure S5A). Next, we sequenced p53 transcripts and 
genomic DNA encompassing exons 2-8 (encoding the DNA-binding domain where p53 
most frequently undergoes mutation in tumors) from a panel of 29 Slp65-/- and Btk-/-
Slp65-/- tumors (Suppl.  Tables S3A and S3B). This analysis revealed a mutation only in 
a single Slp65-/- tumor (S13): a R270C missense mutation. This mutation has previously 
been identified in Em-myc Tg lymphoma and corresponds with a mutation hot-spot of 
p53 found in human tumors(38). Missense mutations often result in accumulation of 
mutant p53 protein to supraphysiologic levels, because mutant p53 is often more stable 
than wild-type(39). Western blot analyses confirmed very high p53 protein expression 
in the tumor with the R270C p53 mutation (sample S13; Figure 4A).
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Table 1. Arf - Mdm2 - p53 protein expression in Slp65-deficient leukemias
Tumor p53 p19ARF Mdm2
aberrant p53
S13 high1) high expressed
S92 expressed low expressed
S96 expressed expressed expressed
S100 low high expressed
S102 low high expressed
S116 low high expressed
S203 low high expressed
S208 low high expressed
p53 wild type, Arf expressed/ high
S14 undetected high expressed
S25 undetected high expressed
S75 undetected high undetected
S99 undetected high expressed
S101 undetected high expressed
S107 undetected high expressed
S109 undetected high expressed
S114 undetected high expressed
BS27 undetected high expressed
BS29 undetected high expressed
BS30 undetected expressed expressed
BS36 undetected high low
BS45 undetected high low
BS50 undetected high low
BS53 undetected high expressed
BS70 undetected high expressed
BS91 undetected high expressed
BS103 undetected high expressed
BS105 undetected high expressed
BS108 undetected high expressed
BS115 undetected high expressed
BS118 undetected high low
BS119 undetected high expressed
BS123 undetected high expressed
BS124 undetected high expressed
BS301 undetected high expressed
BS303 undetected high expressed
BS304 undetected high expressed
BS305 undetected high expressed
BS306 undetected high expressed
BS309 undetected high expressed
BS310 undetected high expressed
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Tumor p53 p19ARF Mdm2
BS311 undetected expressed expressed
BS312 undetected expressed expressed
BS316 undetected high expressed
BS318 undetected expressed expressed
BS326 undetected high expressed
BS327 undetected high expressed
Arf low/ undetected
S98 undetected low expressed
BS72 undetected undetected low
BS93 undetected undetected expressed
p53 deficient tumors, Arf expressed
PS15 undetected high expressed
PS16 undetected high expressed
PS18 undetected high expressed
PS19 undetected expressed expressed
PS21 undetected high expressed
PS23 undetected high expressed
PS24 undetected high expressed
p53 deficient tumors, Arf undetected
PS17 undetected undetected expressed
PS22 undetected undetected low
PS27 undetected undetected expressed
1) Immunoblotting experiments were performed twice and a summary of those experiments is shown.
 In 7 out of 17 Slp-65-/- tumors analyzed we found low to moderate p53 protein 
levels (Figure 4A; Table 1). Sequencing of three of these tumors (S96, S100 and S102) 
did not reveal point mutations in exons 2-8 (Suppl. Table S3A). Furthermore, p53 
protein was not detected in any of the 32 tumors from Btk-/-Slp65-/- mice (Figure 4C; 
Table 1). To examine p53 functional activity in these tumors, we compared transcription 
of the p53 target p21Cip1 in Slp65-/- tumors without detectable p53 protein expression and 
tumors with p53 protein (Figure 4B). We did not observe increased p21Cip1 transcription 
in tumors expressing p53, indicating that p53 protein in these tumors has lost part of its 
normal function. 
 Taken together, in 8 out of 49 Slp65-/- or Btk-/-Slp65-/- tumors we found p53 
protein expression, whereby only in a single case we were able to identify a p53 
missense mutation.   
Table 1. Arf - Mdm2 - p53 protein expression in Slp65-deficient leukemias (Continued)
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Figure 4. Aberrations of the p19Arf–Mdm2–p53 pathway in Slp65-deficient leukemias. 
(A) Western blot analysis of total cell lysates from pre-B cell tumors from Slp65-/- mice for the expression 
of p53, p19Arf, Mdm2 and Syk (loading control). (B) Quantitative RT-PCR analyses of p21Cip1 expression 
in Slp65-/- pre-B cell tumors without or with detectable p53 protein, normalized to GAPDH. Values in 
sorted WT BM B220+ cells were set to one. Horizontal lines represent mean values of the relative 
expression levels. (C) Western blot analysis of total cell lysates from pre-B cell tumors from Btk-/-Slp65-/- 
mice for the expression of p53, p19Arf, Mdm2 and Syk (loading control). (D) Western blot analysis of total 
cell lysates from pre-B cell tumors from p53-/-Slp65-/- mice for the expression of p19Arf, Mdm2 and Syk 
(loading control). Protein of p53 was not detected in p53-/-Slp65-/- tumors.
All Slp65-deficient tumors manifest aberrations of the p19Arf–Mdm2–p53 pathway
Consistent with disruption of the p53-p19Arf feedback loop, p19Arf expression was 
significantly increased in the pre-B cell tumor with the R270C p53 mutation (S13; Figure 
4A) and in 6 of 7 additional Slp65-/- samples with detectable p53. Remarkably, substantial 
levels of p19ARF were also present in 38 of 41 Slp65-/- or Btk-/-Slp65-/- tumors in which p53 
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protein was undetectable. The presence of p19Arf protein indicates inactivation of the 
p53 response, because p53 is a negative regulator of p19ARF. 
In only two samples p19ARF was undetectable (BS72; BS93; Figure 4C; Table 
1).  Inactivation of the p53 pathway can also occur through loss of p19ARF, which 
requires deletion of both Arf alleles (40). The Ink4a-Arf locus encodes two linked tumor-
suppressor genes: p16Ink4a and p19ARF. PCR amplification of exon 1a (Ink4a-specific) 
and exon 1b (Arf-specific) in combination with Southern blot analyses for exon 1a, 2 
and 3 did not reveal any deletions in the Ink4a-Arf locus in these two samples. 
 Elevated expression of the Mdm2 oncogene augments proliferation, reduces 
susceptibility to p53-dependent apoptosis and induces chromosomal instability(41). 
High levels of Mdm2 protein were found in all eight tumors with detectable p53 and in 
32 of 38 tumors that expressed p19ARF. In six p19ARF-expressing tumors Mdm2 levels 
were low (BS30, BS36, BS45, BS50 BS118) or undetectable (S75) (Figure 4AC, Table 
1). From those three tumors that had low or undectable p19ARF two exhibited significant 
Mdm2 expression.  
 In summary, we found that all Slp65-/- (n=17) and Btk-/-Slp65-/- (n=32) pre-B 
cell leukemias analyzed expressed either p19ARF or Mdm2, perhaps with the exception 
one sample, BS72, with no detectable expression of p53 or p19ARFand only low Mdm2 
expression. These results provide evidence for the involvement of disruption of the Arf–
Mdm2–p53 tumor suppressor pathway in malignant transformation of Slp65-deficient 
pre-B cells.  
Additional aberrations in p19Arf and Mdm2 in p53-deficient pre-B cell tumors
The finding that most Slp65-deficient pre-B cell tumors expressed Mdm2 raised the 
possibility that Mdm2 might be induced even in the absence of functional p53. To 
investigate this issue, we analyzed p19ARF and Mdm2 expression in a panel of 10 p53-
/-Slp65-/- pre-B cell tumors and found that seven expressed both p19ARF and Mdm2 
(Figure 4D; Table 1). In three samples p19ARF was not detected. Because in cells 
lacking p53 the levels if p19ARF are normally increased, this finding indicates that the 
p53- p19ARF feedback loop was interrupted. This did not appear to result from genomic 
Arf loss, because no aberrations were found in the Ink4a-Arf locus by genomic PCR 
and Southern blotting analyses (Suppl. Figure S5BD). In these three tumors without 
detectable p19ARF, we found that Mdm2 expression was high in two cases and low in 
one case (Table 1). 
 In summary, p53-deficient pre-B cell tumors have additional aberrations 
in p19ARF and Mdm2, suggesting that Mdm2 promotes transformation of Slp65-
deficient pre-B cells by targeting effectors other than p53.
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Discussion
In this study we provide evidence for disruption of the p19Arf–Mdm2–p53 tumor 
suppressor pathway in malignant transformation of Slp65-/- pre-B cells. We demonstrated 
that combined loss of Slp65 and p53 in mice transformed pre-B cells very efficiently. 
Furthermore, we found aberrations in p19Arf, Mdm2 or p53 in all 49 Slp65-/- and Btk-/-
Slp65-/- pre-B cell leukemias analyzed. 
 Our findings reveal striking parallels in pre-B cell tumor formation between 
Slp65-/- and Em-myc Tg mice. First, in both models the expression of a pre-rearranged 
IgH chain transgene in early B cell differentiation reduces oncogenic transformation. 
Second, malignant transformation of both Slp65-/- and Em-myc Tg pre-B cells involves 
disruption of the p19Arf–Mdm2–p53 tumor suppressor pathway. Third, Aid-induced DNA 
damage is not required for tumor development in either of the two models. Also the 
reported cooperation of Btk as a tumor suppressor in both Slp65-/- and Em-myc Tg 
pre-B cells point to parallel transformation mechanisms. On top of the failure of Slp65-
deficient pre-B cells to efficiently downregulate pre-BCR and IL-7R signaling, it was 
recently shown that Slp65 has the capacity to inhibit IL-7R signaling by direct inhibition 
of Jak3 and that Slp65-/- tumors acquire autonomous IL-7R signaling by autocrine IL-7 
production(15). As c-Myc is induced by IL-7R signaling, it is very well possible that 
sustained IL-7R signaling results in constitutive high levels of c-Myc expression in 
Slp65-deficient pre-B cells. 
The finding that Slp65-deficient pre-B cell tumors display disruptions of the Arf–
Mdm2–p53 pathway implies that oncogenic transformation of Slp65-/- pre-B cells does 
not exclusively result from sustained IL-7R signaling and endocrine IL-7 production(15). 
Instead, it is conceivable that mutations have accumulated before this stage, which 
would be supported by the finding that expression of the pre-rearranged VH81X IgH 
chain transgene in early B cell differentiation stages prevents malignant transformation. 
Because early expression of a functional IgH chain is known to considerably shorten or 
even bypass pro-B cell development(42), acceleration of the passage of B cell precursors 
through the pro-B cell stage may prevent oncogenic transformation by reducing the 
size of the cell population most susceptible to transformation by e.g. c-Myc, N-myc or 
Abl(31). However, there are alternative explanations for the tumor suppressive effect 
of VH81X IgH chain. We cannot exclude that VH81X IgH chain transgene prevents 
tumor formation by limiting the time window for V(D)J recombination activity. Several 
reported findings indicate that V(D)J recombination is ongoing in Slp65-/- large pre-B 
cells. First, Slp65-/- pre-B cell tumors mostly co-express IgH chain, SLC, IgL chain(8) 
and the recombination activation genes Rag1 and Rag2 (V.B.T.T., unpublished data, 
October 2007l). Second, pre-B cell fractions from CD19-/-Slp65-/- mice show increased 
expression of Rag2 protein(9). Third, In human pre-B cell leukemia SLP65 deficiency 
correlates with RAG expression and ongoing VH gene rearrangement activity(43). 
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However, recently it has been found that Rag1 does not contribute to lymphomagenesis 
in Em-myc Tg mice(44), suggesting that malignant transformation of Slp65-/- pre-B cells 
mediated by Myc does not require deregulated Rag activity. Furthermore, it is possible 
that transformation of Slp65-/- pre-B cells is dependent on the expression of IgH chains 
with specific structural properties that induce strong autonomous pre-BCR signaling. 
Recently, Kohler et al(45) have described functional similarities between the pre-BCR 
and autoreactive BCRs, indicating that recognition of self-antigens by the pre-BCR 
might play a role in the initiation of pre-B cell proliferation. This explanation requires 
further investigation of the properties of IgH chains in Slp65-deficient pre-B cell tumors. 
Finally, it is unlikely that the VH81X IgH chain is signaling incompetent, because it can 
pair efficiently with IgL chains, it induces strong proliferation and Syk phosphorylation 
and its presence does not significantly affect pre-B cell differentiation.
 We found high levels of p19Arf protein, in the absence of detectable p53 gene 
mutations or deletions, indicating that these tumors have inactivated p53 through 
some other mechanism. In this context, we found by RT-PCR that Slp65-/- and Btk-/-
Slp65-/- pre-B cell tumors contain high levels of p53 transcripts and that p53 protein was 
induced upon 10 gray irradiation in four pre-B cell tumors tested (V.B.T.T., unpublished 
data, August 2008). Thus, it is possible that p53 protein stability is low in these tumors, 
e.g. because of the high levels of Mdm2 that was present in the majority of tumors. 
Nevertheless, six Slp65-/- or Btk-/-Slp65-/- pre-B cell leukemias with high p19Arf levels 
(Table 1) and without detectable p53 did not exhibit Mdm2 overexpression. Importantly, 
p19Arf has p53-independent functions, e.g it promotes the progression of lymphomas by 
mediating autophagy, a process of lysosome-mediated self-digestion that occurs during 
periods of nutrient deprivation(40, 46). Silencing of p19Arf inhibits the progression of 
Myc-driven lymphoma cells containing mutant or no p53(46). Thus, Slp65-/- tumors may 
retain p19Arf to promote survival under metabolic stress.
  Slp65 regulates the activity of the forkhead-box transcription factors Foxo3a 
and Foxo1, which do not only promote IgL chain recombination, but also suppress Myc-
driven lymphomagenesis via direct p19Arf activation(2),(47). This leads us to propose the 
following mechanism for malignant transformation of Slp65-/- pre-B cells. The absence 
of Slp65 results in sustained expression of the pre-BCR and the IL-7R in large cycling 
pre-B cells. Since IL-7R signaling induces c-Myc this also results in constitutively high 
levels of c-Myc. At this stage, FoxO transcription factors that normally suppress c-Myc-
driven lymphomagenesis via direct activation of p19Arf are not properly activated because 
of the absence of Slp65. Activation of c-Myc in combination with sporadic alterations in 
the p19Arf–Mdm2–p53 pathway may finally lead to oncogenic transformation of Slp65-/- 
pre-B cells. 
Our mouse model links defective pre-BCR signaling to oncogenic c-Myc 
activation and disruption of the p19Arf–Mdm2–p53 tumor suppressor pathway, which 
also play an essential role in the pre-B cell transformation process mediated by Abelson 
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murine leukemia virus(48). Although defective expression of Btk or Slp65 may only be 
involved in a limited fraction of childhood ALL, and IL-7 signaling does not play a role in 
human pre-B cell development, our findings have relevance for human ALL. Deletion of 
CDKN2A (INK4A-ARF) is a significant secondary abnormality in childhood ALL which 
strongly correlates with phenotype and genotype(49-50). Furthermore, overexpression 
of the MDM2 gene was found in childhood acute lymphoblastic leukemia cells expressing 
wild-type p53(51). 
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Supplementary Table S2. Chromosomal Alterations in Slp65-deficient pre-B cell leukemias
                                          Karyotype
Tumor Numerical Structural
BS29 +12, +14 der (18;10)
BS30 +12 -
BS36 +14 -
BS47 +14, +19 -
BS48 - -
BS49 - der (7;14)
BS50 +14 -
BS51 +19 -
BS52 +12 -
BS53 +12 -
BS56 +14 der (12;12)
BS67 +14 -
BS68 - -
BS69 - -
PS2 -Y, +9 der (2;1)
PS5 +11, +17 del (2), del (13)
PS11 - del (2), der (3;14)
PS14 +3, +11, +16, +17 der (12;12)
PS20 -13 -
1) Structural alterations in chromosomes are listed when observed in more than 50% of metaphases (as 
determined by SKY). BS, Btk-/-Slp65-/-; PS, p53-/-Slp65-/-
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Supplementary Table S3C. Overview of purity of p53-/-Slp65-/- pre-B cell tumor samples used in various 
assays
 Western Blot              Southern Blot Ink4a/Arf
Tumors Tissue Tumor load  Tissue Tumor Load  
PS15 Tu 87% Spl 17%
PS16 Tu 95% Tu 95%
PS17 Tu 88% Tu 88%
PS18 Spl 88% LN 68%
PS19 Spl 76% LN 54%
PS20 Spl 58% Spl 58%
PS21 Tu 94% Spl 94%
PS22 Tu 96% Tu 96%
PS23 Tu 91% Tu 91%
PS24 Tu 78%
PS27 Spl 84% Spl 84%
PS28 Spl 95% Spl 56%
1) Leukemic samples were cultured for 4 to 12 days with 100 U/mL IL-7 to obtain a higher purity
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Supplementary Figure S1. Phenotypical abnormalities of Btk and Slp65 single or double mutant 
pre-B cells are preserved in the presence of the VH81X IgH chain transgene.
We compared eight groups of mice by flow cytometry: WT, Btk-/-, Slp65-/- and Btk-/-Slp65-/- mice, which 
either did or did not carry the VH81X transgene. (A) B220/μ H chain profiles from BM lymphoid cells 
are displayed as dot plots. Total B220+ B-lineage cells were gated and percentages within the indicated 
gates are shown. Data are representative for 4 independent experiments. In agreement with reported 
findings (1,2) in the absence of Btk or Slp65 the proportions of B220highIgμ H chain recirculating B cells 
in the BM were reduced, while in Btk-/-Slp65-/- mice B cell development was almost completely blocked 
at the B220lowIgμ+ pre-B cell stage. (B) Cytoplasmic μ H chain+ B-lineage fractions from total BM were 
analyzed for κλ IgL chain surface expression. Data are shown as dot plots, whereby the numbers indicate 
the proportions of κλ IgL chain surface expression of B220+cytoplasmic μ+ B cells. The proportions of 
surface IgL chain positive B cells appeared slightly reduced in BM and spleen, when compared with 
mice of the same genotype that did not carry the transgene. (C) B220+κ-λ- pro-/pre-B cells were gated 
and analyzed for the expression of CD43, cytoplasmic SLC, CD2, CD25 and MHCII. The results are 
displayed as histogram overlays of non-VH81X Tg (shaded histograms) and VH81X Tg (black lines) 
pro-/pre-B cell fractions of the mice indicated on the left. Plots are representative for 4-5 animals of each 
genotype. In the absence of Btk or Slp65 pre-B cells failed to efficiently downregulate CD43 and SLC, 
and to efficiently initiate CD2, CD25 and MHC II expression, as reported previously (1,3). For all four 
genotypes, the presence of the VH81X transgene did not significantly affect the expression of these 
developmentally regulated markers. 
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(1) Kersseboom R, Middendorp S, Dingjan GM, et al. Bruton’s tyrosine kinase cooperates with the B cell 
linker protein SLP-65 as a tumor suppressor in pre-B cells. J Exp Med. 2003;198:91-98.
(2) Jumaa H, Mitterer M, Reth M, Nielsen PJ. The absence of SLP65 and Btk blocks B cell development 
at the preB cell receptor-positive stage. Eur J Immunol. 2001;31:2164-2169.
(3) Middendorp S, Dingjan GM, Hendriks RW. Impaired precursor B cell differentiation in Bruton’s 
tyrosine kinase–deficient mice. J Immunol. 2002;168:2695-2703.
Supplementary Figure S2. Ca2+ fluxes are blunted in Btk-/-Slp65-/- pre-B cells and VH81X Tg Btk-/-
Slp65-/- pre-B cells when compared with mature B cells.
Ca2+ fluxes were measured in splenic B cells of WT mice (upper panel), pre-B cells from Btk-/-Slp65-/- 
(middle panel) and VH81X Tg Btk-/-Slp65-/- mice (lower panel) that were cultured for 4 days with 100 U/
mL IL-7. Cells were loaded with Indo-1 AM and stimulated with anti-IgM F(ab)2 fragments (20 μg/ml) and 
ionomycin as a control. Arrows indicate the addition of anti-IgM F(ab)2 fragments. Histogram plots of 
gated B220+ cells are representative for 3 to 4 mice of each genotype.
Supplementary Figure S3. AID is not involved in malignant transformation of Slp65-/- pre-B cells
(A) Quantitative RT-PCR analysis of AID expression in Slp65-/- (n=16) and Btk-/-Slp65-/- (n=27) pre-B cell 
tumors, normalized with GAPDH. Values in total Peyer’s patches were set to one. Horizontal lines represent 
mean values of the relative expression levels. (B) Kaplan-Meier tumor-free survival estimates for Aicda+/-
Slp65-/- (n=43), Aicda-/-Slp65-/- (n=27), Aicda+/-Btk-/-Slp65-/- (n=30) and Aicda-/-Btk-/-Slp65-/- (n=22) mice.
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Supplementary Figure S4. Chromosome 12 enlargement and N-myc amplification in Slp65-/- 
pre-B cell tumors 
(A) SKY image of a metaphase spread from a Btk-/-Slp65-/- tumor (BS56) with an enlarged copy of 
chromosome 12. SKY images are on the left and computer-classified colors are on the right. (B) FISH 
analysis of a control chromosome and an enlarged chromosome from tumor BS56 and tumor PS11 
(p53-/-Slp65-/-). Panels show N-myc-specific and IgH-specific probes. (C) Analysis of N-myc amplification 
by Southern blotting of genomic DNA from tumor samples and a BM control digested with EcoRI and 
hybridized with a N-myc probe and a Gata3 probe as a loading control. Fold amplification relative to 
the control lane is indicated below each lane. (D) Quantitative RT-PCR analyses of c-Myc and N-Myc 
expression in p53-/-Slp65-/- (n=19) pre-B cell tumors, normalized to GAPDH. Values in sorted WT BM 
B220+ cells were set to one. Horizontal lines represent mean values of the relative expression levels.
Slp65-deficient pre-B cell leukemia and the Arf-Mdm2-p53 pathway
99
Supplementary Figure S5. Slp65-/- pre-B cell tumors do not harbor deletions of the p53 or Ink4a-
Arf loci.
(A) Schematic map of the p53 locus including all relevant restriction sites, fragment lengths (in kilobases), 
and Southern blot probes 1 and 2 (map not drawn to scale).Southern blot analysis of genomic DNA from 
Slp65-/- tumors (n=4) and Btk-/-Slp65-/- tumors (n=19) to detect deletions at the p53 locus. Genomic DNA 
was digested with NdeI and MfeI and probed with a mixture of probes 1 and 2. (B) Schematic map of 
the Ink4a-Arf loci including all relevant restriction sites, fragment length (in kb), and Southern blot probe 
3 (map was not drawn to scale). Southern blot analysis of genomic DNA from Slp65-/- tumors (n=11), 
Btk-/-Slp65-/- tumors (n=16) and p53-/-Slp65-/- tumors (n=11) to detect deletions of exon 1a, 2 and 3. 
Genomic DNA was digested with AflII and probed with probe 3. (C) PCR amplification of exon 1a and 
exon 1b of the Ink4a/Arf locus in Slp65-/- tumors (n=15) and Btk-/-Slp65-/- tumors (n=23). Amplification 
of the Slp65 knock out (KO) allele was performed as a control. (D) Overview of status of the Ink4a-Arf 
locus and purity of Btk-/-Slp65-/- (BS) and p53-/-Slp65-/- (PS) tumor samples used in Southern blot and 
genomic PCR assays.

Chapter IV
Highly restricted usage of VH14 family 
gene segments in Slp65-deficient 
pre-B cell leukemia
Ta VBT, Zoller M, Uebelhart R, de Bruijn MJW, Jumaa H, Wardemann H, 
Langerak AW, Hendriks RW (in preparation)
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Abstract 
The adapter protein Slp65 is a key component of precursor-B cell receptor (pre-BCR) 
signaling. Slp65-deficient mice spontaneously develop pre-B cell leukemia, but the 
mechanisms by which Slp65-deficient pre-B cells become malignant remain to be 
identified. Because high-level pre-BCR expression on Slp65-deficient leukemia cells 
is thought to contribute to their strong proliferative capacity, we investigated whether 
particular pre-BCR specificities may predispose these cells to malignant transformation. 
DNA sequence analysis of immunoglobulin heavy (IgH) chain V regions of Slp65-
deficient leukemias revealed that 55 out of 60 (~92%) used a VH14 gene segment, 
despite the small size of this VH family. In particular, VH14.1 en VH14.2 segments were 
used in 24 (~40%) and 19 (~32%) of cases, respectively. By contrast, the CDR3 regions 
of these IgH chains were heterogeneous in length and sequence.  
 When combined with surrogate light chain or various conventional light chains, 
yielding pre-BCR and BCR, respectively, the VH14 IgH chains did not exhibit enhanced 
poly- or autoreactivity. It is therefore not likely that the VH14 IgH chains provide 
enhanced proliferative signals. However, Slp65-deficient leukemia cells also exhibited 
preferential VH14 segment usage on non-productively rearranged IgH alleles, strongly 
indicating altered IgH chain V region accessibility. We therefore conclude that malignant 
transformation of Slp65-deficient pre-B cells occurs almost exclusively in those cells 
that have aberrant IgH chain accessibility favoring VH14 segment recombination at the 
pro-B cell stage. 
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Introduction
Diversity of the antibody repertoire is generated by recombination of various gene 
segments at the immunoglobulin heavy (IgH) and light (IgL) chain loci to assemble 
a B cell antigen receptor (BCR) (1-4). In pro-B cells productive V(D)J recombination 
results in cell surface deposition of the pre-BCR, comprised of IgH m chain and the 
surrogate light chain (SLC) components l5 and VpreB (3, 5-6). The pre-BCR serves 
as an important checkpoint to monitor proper expression of a functional IgH chain and 
triggers clonal expansion, whereby pre-B cells acquire the capacity to respond to low 
concentrations of the proliferation factor interleukin (IL)-7 (3, 5-6). After a limited number 
of cell divisions, large pre-B cells stop cycling and differentiate into small, resting pre-B 
cells in which IgL chain rearrangement is initiated.
 It has been hypothesized that the pre-BCR signals in a cell-autonomous fashion 
(7). Hereby the non-Ig tail of the l5 SLC component induces ligand-independent pre-
BCR cross-linking, signaling for pre-B cell expansion. Recently, Jumaa and colleagues 
have shown that functional pre-BCR formation and autonomous signaling requires the 
N-linked glycosylation site in the CH1 domain of µ IgH chain (N46), whereby binding 
of the SLC component l5 to N46 mediates autonomous crosslinking (8). However, it 
remains controversial whether the proliferative expansion of pre-B cells can also be 
initiated or enhanced by binding of particular self-antigens. This seems possible since 
the pre-BCR shapes the VH repertoire at the transition from pro-B to large pre-B cells 
(9). Furthermore, findings of interaction between the pre-BCR and galectin-1 (10) and 
binding of the pre-BCR, via the non-Ig tail of λ5, to stromal-cell-associated heparin 
sulphate (11) would support this notion.  Recently, it has been shown that the pre-BCR 
is polyreactive and capable of recognizing multiple (self-)antigens, including DNA, LPS 
and insulin, via the non-Ig part of λ5 (Kohler 2008). Thus, pre-BCR autoreactivity may 
serve to clonally expand those cells that produce a functional μ H chain and ensures 
that this selection can occur in the absence of foreign antigens. In support of this idea, 
in SLC-deficient mice mainly autoreactive pre-B cells are selected, resulting in the 
accumulation of autoreactive antibodies (12). But also in the presence of SLC, more 
than half of the antibodies expressed in early B cell compartments of healthy individuals 
are polyreactive (13).
The adaptor protein Slp65 (also known as Blnk or Bash) and the tyrosine 
kinase Btk are key components in the signaling pathway downstream of the pre-BCR 
and the BCR. In human, mutations in SLP65 or BTK result in defective pre-B cell 
proliferation and an almost complete arrest of B cell development at the pro-B to pre-B 
cell transition, associated with the immunodeficiency disorder agammaglobulinemia (5, 
14). In contrast, mice deficient for Slp65 or Btk show only a partial arrest at the large 
cycling pre-B cell stage, while a nearly complete block is present in Btk/Slp65 double 
deficient mice (15-17). 
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Importantly, at the age of ~6 months 5-10% of Slp65-deficient mice develop 
pre-B cell leukemia, expressing high levels of pre-BCR on the cell surface (15, 18). 
The lack of Slp65 results in defective pre-BCR internalization (15, 19). Although high-
level pre-BCR expression on Slp65-deficient leukemia cells is thought to contribute to 
their strong proliferative capacity, we showed previously that transgenic overexpression 
of SLC components is not sufficient to induce leukemia (19). Btk-deficient mice 
do not develop pre-B cell tumors, but Btk does cooperate with Slp65 as a tumor 
suppressor, whereby it exerts tumor suppressor function independently of its kinase 
activity (17, 20). Recent findings show that Slp65 also downregulates IL-7-mediated 
proliferation and survival through direct inhibition of Jak3, which is an essential IL-7R 
signaling component (21). The IL-7R pathway promotes cellular survival, proliferation 
and maturation, involving induction of the anti-apoptotic protein Bcl-2 and the proto-
oncogene c-Myc (22-23). Furthermore, loss of p53 enhanced lymphoma formation in 
Slp65-deficient mice and Slp65-deficient pre-B cell tumors harbored aberrations in the 
p19Arf–Mdm2–p53 tumor suppressor pathway (24). 
Because pre-BCR signals in Slp65-deficient leukemia cells may contribute 
to their strong proliferative capacity, we investigated whether particular pre-BCR 
specificities may predispose these cells to malignant transformation. We performed 
DNA sequence analysis of immunoglobulin heavy (IgH) chain V regions of 60 Slp65-
deficient leukemias and found highly restricted usage of the VH14 gene family. 
Results and Discussion
Restricted VH repertoire of expressed IgH m chains in Slp65-deficient pre-B cell 
leukemias
To investigate whether particular pre-BCR specificities may predispose Slp65-deficient 
pre-B cells to malignant transformation, we sequenced the expressed IgH chain V 
regions in a panel of pre-B cell leukemias from mice that were deficient for Slp65 (n=17) 
or double deficient for Slp65 and Btk (n=26) or p53 (n=17). Remarkably, we found 
that 55 out of 60 (~92%) used a VH14 (SM7) gene segment (Table 1; Supplementary 
Table S1), despite the small size of this VH family with only four members. In particular, 
the members VH14.1 en VH14.2 were used in 24 (~40%) and 19 (~32%) of the cases, 
respectively. This restricted VH14 usage is in stark contrast with the diverse repertoire 
found in large pre-B cells of normal mice: VH genes belonging to the VH1 (VHJ558), VH2 
(VHQ52), and VH5 (VH7183) family are represented in more than 80% of pre-B cells in 
normal mice (9). However, in Slp65-deficient tumors <8% used a member of either the 
VH1, VH2 or VH5 family.
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Table 1. VH representation in 60 Slp65-deficient pre-B cell leukemias
VH family VH representation
VH14.1 24    (40.0%)
VH14.2 19    (31.7%)
VH14.3 3      (5.0%)
VH14.4 9      (15.0%)
VH1 3      (5.0%)
VH2 1      (1.7%)
VH4 1
      (1.7%)
Large IgH CDR3 region diversity in Slp65-deficient pre-B cell leukemias
Next, we analyzed the CDR3 region diversity of expressed IgH m chains. These CDR3 
regions were heterogeneous in sequence and in length (Table 2). 
 The average CDR3 length of the 60 IgH m chains of Slp65-deficient leukemias 
was 14.8 ± 2.1 amino acids, which is a substantial increase when compared with the 
reported average CDR3 length of ~12 amino acids in normal pre-B cells (25). Moreover, 
the 60 IgH m chains from Slp65-deficient tumors did not show a normal distribution, 
with mainly CDR3 lengths of 14-17 amino acids (Figure 1A). The average number of 
N nucleotide additions in the IgH m chains from Slp65-deficient tumors was 10.2 ± 4.0 
(Figure 1B), which is a substantial increase in comparison with the reported number of 
~7 nucleotides in wild-type pre-B cells (26). 
 Hayashi et al. (18) have reported that counter-selection of pro-B cells 
expressing Dm protein (Dm selection) was abolished in Slp65 mutant mice, resulting in 
similar usage of the three D gene segment reading frames (RF). However, our Slp65-
deficient leukemias analyzed still displayed RF2 counter-selection (Figure 1C). The IgH 
m chains of Slp65-deficient leukemias showed preferential usage of JH4 (Figure 1D), 
in contrast to equal JH usage normally found (25-26). The four JH segments differ in 
length, with JH4 being the longest one and contributing up to 20 nt to the CDR3 region. 
Therefore, preferential JH4 usage and increased N nucleotide addition both contributed 
to the increased CDR3 length of IgH m chains of Slp65-deficient leukemias.
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Table 2. CDR3 analysis in Slp65-/- pre-B cell leukemias
VH gene Tumor code CDR3 sequence CDR3 length pIa
VH14-1 BS29 CASGGSSYVYYAMDYWb 14 13
VH14-1 BS30 CAGGGVYYTFYAMDYW 14 13
VH14-1 BS36 CASGGSMITTWAMDYW 14 13
VH14-1 BS38 CASGGTMVTLYAMDYW 14 13
VH14-1 BS39 CAIGGSTMAFYAMDYW 14 13
VH14-1 BS41 CASGGVVTTRYAMDYW 14 6,44
VH14-1 BS42 CASGGMVTTFYAMDYW 14 13
VH14-1 BS44 CTTTVVGYW 7 13
VH14-1 BS45 CASGGYYRYRYAMDYW 14 8,83
VH14-1 BS47 CASGGTGTVPHAMDYW 14 5,45
VH14-1 BS50 CASGGVVTKVYAMDYW 14 6,43
VH14-1 BS52 CASGPPTMVTTYPFYAMDYW 18 13
VH14-1 BS56 CASGGTMIYYYAMDYW 14 13
VH14-1 BS57 CGIGGMVTTFYAMDYW 14 13
VH14-1 BS73 CASGGPTIGTTRVWYFDVW 17 6,44
VH14-1 BS93 CASGAPTEYYYAMDYW 14 13
VH14-1 PS14 CASGPPITTVVLYAMDYW 16 13
VH14-1 PS15 CASGPPMVTLYYYAMDYW 16 13
VH14-1 PS17 CASGGAMVTTSPWYFDVW 16 13
VH14-1 PS19 CASGGTTRRVYAMDYW 14 9,07
VH14-1 S13 CASGGSMMVTTRWYFDVW 16 6,44
VH14-1 S14 CALGMPSMVFYAMDYW 14 13
VH14-1 S37 CASGAPTMVTTDAMDYW 15 13
VH14-1 S75 CASGGPTMVVYAMDYW 14 13
VH14-2 BS27 CASGGLLWLPLYAMDYW 15 13
VH14-2 BS43 CALGGPLPTVVTYYFDYW 16 13
VH14-2 BS53 CARRAYDYDDAHYYAMDYW 17 4,86
VH14-2 BS54 CGVGGYAPYYYAMDYW 14 13
VH14-2 BS70 CGRSHYYDGSPYAMDYW 15 5,61
VH14-2 BS74 CASGGTVVAYWYFDVW 14 13
VH14-2 PS20 CASGGYYYYGVVTSMDYW 16 13
VH14-2 PS24 CARRSTMITTPYYYAMDYW 17 8,89
VH14-2 PS27 CARRVTTVVAPYYYAMDYW 17 8,89
VH14-2 PS28 CARRSPTTVVDYVPYYYAMDYW 20 6,57
VH14-2 PS29 CGRSSNYRGDYYAMDYW 15 6,58
VH14-2 PS32 CGRNYDGTPYYYAMDYW 15 4,4
VH14-2 S97 CGRGGYYVYAMDYW 12 6,42
VH14-2 S98 CGRSNYYDGSPYAMDYW 15 4,4
VH14-2 S99 CGSGSMMVTTFYAMDYW 15 13
VH14-2 S109 CASGGYYYAPYAMDYW 14 13
VH14-2 S203 CASGGPYYSNPYAMDYW 15 13
VH14-2 S101 CAGGGRDYYAFYAMDYW 15 4,4
VH14-2 S102 CGRGTYYYDGPYAMDYW 15 4,4
VH14-3 BS40 CASGGPYGSSYVWYFDVW 16 13
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VH gene Tumor code CDR3 sequence CDR3 length pIa
VH14-3 BS91 CASGGYYGSSYVYAMDYW 16 13
VH14-3 S25 CGEGGPYYGSSPYAMDYW 16 13
VH14-4 BS66 CTTGPPFITTVVVVPPWFAYW 19 13
VH14-4 PS18 CTTGPPITTVVAWYFDVW 16 13
VH14-4 PS21 CTTARNWDVAWFAYW 13 6,44
VH14-4 PS22 CTRGPPRYIFYAMDYW 14 8,96
VH14-4 PS30 CTTGGPIVTTPYYYAMDYW 17 13
VH14-4 S19 CKTGMITTPGFAYW 12 9,07
VH14-4 S96 CTTGPPTVVAPHWYFDVW 16 5,45
VH14-4 S114 CTTGPPITTVVATWYFDVW 17 13
VH14-4 S100 CTTSGWEEWFAYW 11 13
VH1-52 BS72 CARRREGYFFDYW 11 9,07
VH1-64 PS08 CARLRSTMITTGDYW 13 9,24
VH1-75 S92 CARSELPIVTLYYYAMDYW 17 4,4
VH2-2 PS11 CARFYYGSSYYAMDYW 14 6,42
VH4-1 PS16 CASYYRYGAYW 9 8,89
a pI indicates isoelectric point
b Positively and negatively charged amino acids are underlined. Positively charged underlined amino 
acids are arginine (R), histidine (H), Lysine (K). Negatively charged underlined amino acids are aspartic 
acid (D) and glutamate (E).
Finally, the CDR3 regions shared characteristics of IgH chains of autoreactive 
antibodies, including long CDR3 regions that were enriched in aromatic and positively 
charged amino acids (Figure 1E). In most cases there was at least one arginine or 
aspartate acid present (Table 2). While arginines are abundant in CDR3 regions from 
autoreactive antibodies, in healthy mice only about a quarter of pre-B cells contain 
arginines in their CDR3 regions (12, 27). 
 Taken together, these findings indicate that CDR3s of Slp65-deficient tumors 
are very diverse and have characteristics of polyreactive or autoreactive antibodies, as 
these are often found to have long CDR3 regions and to contain many charged amino 
acids, a pattern that is thought to favor self-reactivity especially against DNA binding 
(13).
IgH m chains from Slp65-deficient pre-B cell leukemias are not highly poly- or 
autoreactive
We hypothesized that the unique features of the IgH m chains of Slp65-deficient leukemic 
cells, i.e. restricted VH14 usage, long CDR3 regions with many aromatic and charged 
amino acids, reflected a specific selective advantage of these cells at the large cycling 
pre-B cell stage. Pre-B cell proliferation is thought to be induced by binding of the SLC 
component l5 to N-linked sugar groups of the CH1 domain of µ IgH chain (8) and may 
Table 2. CDR3 analysis in Slp65-/- pre-B cell leukemias (continued)
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Figure 1. Characteristics of CDR3 regions of IgH m chains of Slp65-deficient leukemias.
DNA sequences from expressed IgH m chains from Slp65-deficient leukemias (n=60) were analysed. 
(A) Distribution of VHDJH CDR3 lengths. CDR3 length is in amino acids (aa). The average CDR3 length 
was 14.8 aa. (B) Distribution of N nucleotide additions. For determination of N nucleotide addition, P 
nucleotides were not included. The average value was N= 10.2 nucleotises (nt). (C) DH reading frame 
(RF) usage (D) Observed relative frequency of JH usage. (E) Proportions of IgH CDR3s with charged 
amino acids. Positive (arginine, lysine and histidine) and negatively charged amino acids (aspartic acid 
and glutamate) were included.
 
be enhanced by binding self-antigens (10-11). Although to date the VH14 family has not 
been associated with autoreactivity as found in rheumatoid arthritis or SLE in human 
or mice (27-28), it is conceivable that the IgH m chains of Slp65-deficient leukemic 
cells have increased pre-BCR polyreactivity or autoreactivity due to their unique CDR3 
characterisitics. 
Ten different VH14 Ig H chains (BS40, BS70, BS73, BS93, PS14, PS19, PS27, 
S13, S25, S99) and five non-VH14 Ig H chains (S92, BS72, PS08, PS11, PS16) were 
cloned and expressed together with SLC and various IgL chains, including the non-
polyreactive Ig L chains of murine B1-8, the non-polyreactive human mGO53 and the 
polyreactive human Ig L chain BC62 (29). We used Human epithelial (Hep)-2 enzyme 
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linked immunosorbent assay (ELISA) and indirect immunofluorescence assay (IFA) 
techniques (30) to determine polyreactivity, autoreactivity and subcellular staining 
patterns of the panel of 15 IgH chains of Slp65-deficient leukemias. When combined 
with SLC to form the pre-BCR, most IgH m chains showed Hep-2 reactivity (Figure 2A) 
and efficient binding to all antigens tested by ELISA, including ssDNA, dsDNA, LPS and 
insulin (Figure 2B; Supplemental Figure 1; Supplemental Table S2), as been previously 
described for other pre-BCRs (31). Only two (PS14, S13) did not show Hep-2 reactivity, 
but we could not confirm by Western blotting whether the two pre-BCR were completely 
assembled. When combined with the two non-polyreactive and the polyreactive Ig 
L chain, we found that the IgH m chains of Slp65-deficient leukemic cells behaved 
quite differently, whereby 8-11 out of the 15 (~53-73%) IgH m chains tested were not 
polyreactive or autoreactive. Thus, the IgH m chains of Slp65-deficient leukemias tested 
were not intrinsically strongly polyreactive or autoreactive. From these findings, we 
conlcuded that, similar to regular IgH m chains, the reactivity of the IgH m chains of 
Slp65-deficient leukemic pre-B cells is influenced by the specificity of the paring Ig L 
chain. Although we cannot rule out that the IgH m chains of Slp65-deficient leukemic 
cells have unique structural properties that are associated with strong proliferation 
induction when combined with surrogate light chain components, this capacity does not 
appear to be based on enhanced poly- or autoreactivity. 
Figure 2. IgH m chains of Slp65-deficient leukemias do not show increased poly – or autoreactivity.
Ig H chains of Slp65-deficient tumors were tested for selfreactivity by Hep-2 cell lysate IFA (A) or ELISA 
(B), in combination with SLC and the indicated IgL chains. Ten different VH14 and five non-VH14 Ig H 
chains were tested.  Murine B1-8 and human mGO53 are nonpolyreactive L chains, while BC62 is a 
human polyreactive Ig L chain. (A) Pie charts summarize the frequency of Hep-2 cells with nuclear 
(black), nuclear plus cytoplasmic (dark gray), and cytoplasmic (light gray) IFA staining patterns, and the 
frequency of nonreactive antibodies (white). The number of tested antibodies is indicated in each pie 
chart centre.  (B) Data are from ELISAs for reactivity with ssDNA, dsDNA, insulin, and LPS. Percentages 
represent frequency of polyreactive (black) or non-polyreactive (white) antibodies.
Chapter 4
110
Restricted VH segment usage reflect increased accessibility of the VH14 family 
gene segments
An alternative explanation for restricted VH14 family usage and concomitant large 
CDR3 diversity in the IgH m chains of Slp65-deficient leukemias would be aberrant VH 
gene segment accessibility during the VH to DH-JH recombination process at the pro-B 
cell stage. 
 The VH14 gene family is closely related to the VHJ558 (VH1) family, but maps 
3’ of VHJ558 (32) (Figure 3). The VH family usage in Slp65-deficient leukemias could 
not be explained solely on the basis of a restricted VH region accessibility, because 
(i) three Slp65-deficient leukemias utilized distally located VHJ558 members, and (ii) 
VH gene segments belonging to various other families, e.g. VH11, VHS107, VH36-60 or 
VHGam3.8, which are interspersed between and adjacent to the VH14 gene members, 
were not used in Slp65-deficient tumors (Figure 3).
 To investigate whether restricted VH14 usage could be due to increased 
accessibility of particular VH14 gene segments in the IgH m chain locus of Slp65-
deficient leukemias, we determined the V(D)J gene configuration of the non-productively 
rearranged Ig H chain alleles. As these non-expressed alleles do not confer a selective 
advantage or disadvantage to pre-B cells, their V(D)J gene configuration should reveal 
the accessibility of individual VH gene segments in pro-B cells. 
Figure 3. Schematic map of the mouse IgH chain locus and the localization of V gene segments 
used in Slp65-deficient pre-B cell tumors. 
Chromosomal localization of VH gene segments utilized in IgH m chains of Slp65-deficient leukemias. 
The localization of the specific VH genes that were used is indicated. Below a more detailed view is given 
of the VH genes present between and around the VH14 family members. The black/gray scale shows the 
usage of individual VH14 family members, with in white interspersed V gene segments that are not used.
VH14 usage in Slp65-deficient pre-B cell leukemia
111
We analysed genomic DNA from our panel of Slp65-deficient pre-B cell 
leukemias by a set of four PCR reactions. In these experiments, we were able to identify 
the configuration of the non-productively rearranged allele in 50/60 tumor samples. In 
ten samples this configuration could not unambiguously be determined, e.g. because of 
too low tumor load, because some VH segments may be poorly amplified by degenerate 
VH primers or because of chromosome loss. 
Non-productively rearranged alleles were first analyzed by performing genomic 
PCR reactions (i) with primers localized near DQ52 and JH1 to identify alleles with a 
complete germline configuration, and (ii) with primers for a DHJH4 PCR, to detect alleles 
with DH-JH rearrangements only, in the absence of VH gene segment recombination. 
These analyses showed that 28/50 (~56%) of the non-productive alleles were either 
in the germline configuration or contained a DH-JH rearrangement (Figure 4A; Table 3). 
Table 3. VH representation on non-productive alleles of Slp65-deficient pre-B cell leukemias
Non-productive allele
Productive allele Germline DHJH non VH14 VH14 Total
VH14.1 3 11 4 2 20
VH14.2 5 4 6 2 17
VH14.3 0 1 0 1 2
VH14.4 2 1 2 3 8
non VH14 0 1 1 1 3
Total 10 18 13 9 50
Next, using a VH14-JH4 PCR to detect recombination of VH14 gene segments 
on both alleles but containing a JH segment, we observed that 8 out of 50 Slp65-
deficient tumors contained a rearrangement with VH14 on both alleles (Figure 4B; Table 
3). Remarkably, one pre-B cell leukemia (PS16) expressing a non- VH14 heavy chain 
(VH4-1) had a VH14 segment recombination on the non-productively rearranged allele. 
Finally, using a PCR with two high degenerate primers located in the framework 1 region 
(33) together with a primer located in the 5’ cμ region (34), we identified 13 pre-B cell 
leukemias with a rearrangement with a non-VH14 segment on the non-productive allele 
(Table 3). To confirm the clonality of the amplified PCR products, we used heteroduplex 
analysis (35). In these assays, homoduplexes and heteroduplexes resulting from 
denaturation and renaturation of IgH V region PCR products were separated in 
nondenaturing polyacrylamide gels based on their conformation (data not shown). 
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Figure 4. Analyses of non-productive alleles in Slp65-deficient pre-B cell leukemias. 
(A) PCR analyses of DHJH rearrangements with a forward primer located in the leader of the DH segments 
(upper panel); PCR analyses of Germline configuration of the Ig H chain locus with a primers localized 
near DHQ52 and JH1 (second panel); (B) PCR analyses of VH14 usage (third panel) with amplification of 
Mtap performed as a control (lower panel). 
 Taken together, the finding of VH14 usage in 9 out of 24 (~38%) alleles with a 
non-productive VH-D-JH-rearrangement indicate altered Ig H chain accessibility at the 
pro-B cell stage favoring VH14 segment recombination. At the moment, the reason for 
increased accessibility of VH14 family members in Slp65-deficient pro-B cells that are 
prone to develop into leukemic cells at the large cycling pre-B cell stage is unknown. 
One explanation might be that only those Slp65-deficient pre-B cells are selectively 
transformed that carry an additional mutation that affects, next to pre-B cell survival 
or proliferation, also IgH chain V region accessibility. On obvious candidate would 
be mutation of the IL-7R signaling pathway: Slp65-deficient pre-B cell tumors carry 
mutations, e.g. autocrine IL-7 production, leading to constitutive activation of the Jak3/ 
Stat5 pathway. This pathway does not only support proliferative expansion of pre-B cells, 
but is also thought to be involved in opening of the Ig H chain for recombination in pro-B 
cells (21, 36-37). In addition, recombination activating gene (Rag)-deficient pro-B cells 
that are cultured in high levels of IL-7 have active histone marks (H3Kme2 and H3K9ac) 
specifically at the VH3609 and VH14 gene segments (38), indicating high accessibility. 
Mutations in Slp65-deficient early B-lineage cells, e.g. resulting in constitutive Jak3/
Stat5 signaling, may therefore lead to enhanced VH14 gene segment accessibility at 
the pro-B cell stage and subsequently contribute to the malignant transformation at the 
large cycling pre-B cell stage. 
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Concluding remarks
In this report, we show that Slp65-deficient pre-B cell leukemias had restricted usage 
of VH14 gene segments, while their CDR3 regions were heterogeneous in sequence 
and length. To date the VH14 gene family has not been associated with autoimmunity 
in mice or humans and, accordingly, we showed that VH14 IgH m chains expressed by 
Slp65-deficient pre-B cell leukemias do not have enhanced polyreactive or autoreactive 
capacities. Importantly, also non-productively rearranged IgH alleles exhibited 
preferential VH14 gene segment recombination, indicating increased accessibility of 
particular VH14 family gene segments during the V to DH-JH recombination process 
in Slp65-deficient pro-B cells. We therefore conclude that malignant transformation 
of Slp65-deficient preferentially occurs in those pre-B cells that had aberrant IgH 
chain accessibility favoring VH14 segment recombination at the pro-B cell stage. We 
hypothesize that in Slp65-deficient mice preferentially those pre-B cells are transformed 
that have acquired mutations leading to increased accessibility of VH14 family gene 
segments at the pro-B cells stage, e.g. related to constitutive Jak/Stat5 signaling. 
Nevertheless, in our panel VH14 usage on productive alleles (~92%) was higher than 
on non-productive alleles (~38%). Although this can e.g. be explained by the induction 
of increased VH14 gene segment accessibility only after a first non-productive non-
VH14 rearrangement has occurred, at the moment we cannot exclude that VH14 IgH 
µ chains have a selective advantage at the pre-BCR-checkpoint, contributing to the 
highly restricted VH14 usage. The presence of VH14 IgH µ chains would then result 
in increased proliferation, independent of autoreactivity. To investigate this issue, we 
currently aim to measure the signaling capacity of VH14 and non-V H14 pre-BCRs, using 
the reported reconstitution system of Rag2/λ5/Slp65 triple deficent B-lineage cells (TKO 
cells) to introduce combinations of various Ig H chains with SLC (31, 39).
 Preferential usage of particular IgH VH gene families is not unique to Slp65-
deficient pre-B cell leukemias in mice, but has been reported for several leukemias 
and lymphomas in human and mice, including chronic lymphocytic leukemia (CLL) 
(40-41). However, on the basis of the presence of stereotypic CDR3 regions and high 
levels of somatic hypermutation (40), it has been hypothesized that preferential IgH VH 
gene usage in CLL reflects antigenic selection rather than preferential V gene segment 
recombination. To the best of our knowledge, we here for the first time report that a 
restricted VH repertoire would originate from altered VH to D-JH gene recombination, 
instead of BCR-mediated antigenic selection. It is conceivable that also in other types 
of leukemias or lymphomas restricted VH to D-JH gene recombination may partially 
contribute to stereotypic V gene usage. 
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Materials and methods
PCR analysis
The following primers were used in PCR amplifications: DHJH rearrangements 
were amplified with the DH L forward primer (42) and a reverse primer located in 
JH4 (TGAGGAGACGGTGACTGAGG); Germline configuration was analyzed by 
using the DHQ52 primer (43) and a JH1 primer (TGAGGAGACGGTGACCGTGG); 
PCR for VH14 rearrangements was performed with a VH14 forward primer 
(CACAGCTTCTGGCTTCAACA) and the JH4 reverse primer. Primers to 
amplify Mtap were located in exon 8 (F: CAGCGCTAAGGAGCCAATAC, R: 
CGCTCGACATTAACACTGGA). 
Heteroduplex PCR and DNA sequencing
Heteroduplex analyses were performed as described (35). For DNA sequence analyses, 
DNA and cDNA samples were amplified using 2 high degeneracy primers located in the 
framework 1 region (33) in combination with a primer located in the 5’ cm region (34). 
PCR products were directly sequenced using the BigDye terminator cycle sequencing 
kit with AmpliTaq DNApolymerase on an ABI PRISM 377 automated sequencer (Applied 
Biosystems). All Ig H chain regions were sequenced in 2 directions from at least 2 
independent PCR products and analyzed by IMGT/V-Quest (www.IMGT.org, IMGT, the 
international ImMunoGeneTics information system).
ELISA Studies and Indirect Immunofluorescence Assays
Antibody production and ELISA studies were performed as described (Wardemann et al., 
2003). 293A human embryonic kidney fibroblasts were cultured in DMEM supplemented 
with 10% ultra-low IgG FCS (GIBCO) and cotransfected with 12.5 mg of IgH and IgL 
chain encoding plasmid DNA by calcium phosphate precipitation. Eight to twelve hours 
after transfection, cells were washed with serum-free DMEM and thereafter cultured 
in DMEM supplemented with 1% Nutridoma SP (Roche). Supernatants were collected 
after 8 days of culture and purified on protein G Sepharose (Amersham Pharmacia 
Biosciences). For reactivity with specific antigens, microtiterplates (COSTAR Easywash 
Polystyrene Plates, Corning) were coated with 10 mg/ml of ssDNA, dsDNA, or LPS 
(Sigma) or 5 mg/ml recombinant human insulin (Fitzgerald). Tissueculture supernatants 
were used at 1 mg/ml antibody concentrations and three 1:4 dilutions in PBS. All 
ELISAs were developed with HRP-labeled goat anti-human IgG Fc Ab (Jackson 
ImmunoReseach) and HRP Substrate
(BIO-RAD). OD405 was measured using a microplate reader (Molecular Devices). 
For IFAs Hep-2 cell coated slides (Bion Enterprises, LTD.) were incubated at RT with 
purified antibodies at 50-100μg/ml for 30 min, washed in PBS and visualized with FITC 
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anti-human Ig by fluorescence microscopy. Control staining ED38 was included in all 
experiments. 
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Supplemental Table 1. Characterization of Ig H chains of Slp65-deficient tumors
Tumor 
code
IMGTa 
VH segment VH Family
N, P
nucleotides DH Segment
N, P
nucleotides JH Segment
DH 
RFb
BS29 VH14-1 SM7 tggg DFL16.1 gtc JH4 3
BS30 VH14-1 SM7 ggggggggggt DST4.2 ccttt JH4 3
BS36 VH14-1 SM7 cggggggt DSP2.2 ttgg JH4 1
BS38 VH14-1 SM7 cggagg DSP2.1 cct JH4 1
BS39 VH14-1 SM7 tagggg gac DSP2.4 cgtt JH4 1
BS41 VH14-1 SM7 tggggg DFL16.1 acg JH4 1
BS42 VH14-1 SM7 tgggg DSP2.8 ctt JH4 1
BS44 VH14-1 SM7 - DFL16.1 ggg JH2 1
BS45 VH14-1 SM7 tggtggg DSP2.10 cgg JH4 2
BS47 VH14-1 SM7 cggg D3-3 ttcctc JH4 1
BS50 VH14-1 SM7 tgggggag DSP2.1 aggt JH4 1
BS52 VH14-1 SM7 cgggccc DSP2.7 gtacccctt JH4 1
BS56 VH14-1 SM7 tggagg DSP2.2 t JH4 1
BS57 VH14-1 SM7 gcatagggggg DSP2.1 ctt JH4 1
BS73 VH14-1 SM7 tgggggac DSP2.10 agggt JH1 3
BS93 VH14-1 SM7 cggggcgc DSP2.10 aat JH4 3
PS14 VH14-1 SM7 tgggccccc DFL16.1 cct JH4 1
PS15 VH14-1 SM7 tggccccc DSP2.4 ctat JH4 1
PS17 VH14-1 SM7 tggagggg DSP2.1 ctcccc JH1 1
PS19 VH14-1 SM7 tgg DSP2.10 aggagagt JH4 3
S13 VH14-1 SM7 cgggg ga D-SP2.9 gagg JH1 1
S14 VH14-1 SM7 cctaggtat g DSP2.8 ctt JH4 1
S37 VH14-1 SM7 tggcgct DSP2.7 gg JH4 1
S75 VH14-1 SM7 tgggg gg DSP2.7 gt JH4 1
S109 VH14-2 SM7 cggggg DFL16.1 cccc JH4 3
BS27 VH14-2 SM7 cggagg DSP2.4 ccct JH4 2
BS43 VH14-2 SM7 ttaggaggtcccc DFL16.1 acct JH2 1
BS53 VH14-2 SM7 gagggc DSP2.2 gacgccc JH4 3
BS54 VH14-2 SM7 gagtggg DST4 gcccc at JH4 2
BS70 VH14-2 SM7 tccc DFL16.1 cc JH4 3
BS74 VH14-2 SM7 tggggg DFL16.1 - JH1 1
PS20 VH14-2 SM7 tgggggtta DFL16.1 agtagtcacgt JH4 3
PS24 VH14-2 SM7 aga DSP2.2 gccc t JH4 1
PS27 VH14-2 SM7 cgag DFL16.1 ccttt JH4 1
PS28 VH14-2 SM7 gcgctctcc DFL16.1 actacgtacctt JH4 1
PS29 VH14-2 SM7 tc DST4.2 cgggggg JH4 3
PS32 VH14-2 SM7 a DFL16.1 gacgccct JH4 3
S203 VH14-2 SM7 cggggggc DST4.2 cc JH4 3
S101 VH14-2 SM7 gggggcagag DFL16.2 t JH4 3
S102 VH14-2 SM7 gggac DFL16.1 ccct JH4 3
S97 VH14-2 SM7 gg D-SP2.9 gt JH4 3
S98 VH14-2 SM7 tcga DFL16.1 cc JH4 3
S99 VH14-2 SM7 ggagtg ga D-SP2.9 - JH4 1
BS40 VH14-3 SM7 tgggggtcc DFL16.1 gt JH1 3
Chapter 4
120
Tumor 
code
IMGTa 
VH segment VH Family
N, P
nucleotides DH Segment
N, P
nucleotides JH Segment
DH 
RFb
BS91 VH14-3 SM7 cgggggg DFL16.1 gt JH4 3
S25 VH14-3 SM7 gagaggggggacc DFL16.1 cc JH4 3
S114 VH14-4 SM7 ggccccccc DFL16.1 t JH1 1
BS66 VH14-4 SM7 gggccaccc DFL16.1 tagtccccccg JH3 1
PS18 VH14-4 SM7 gggccccca DFL16.1 - JH1 1
PS21 VH14-4 SM7 cgcac g DQ52 gtt g JH3 2
PS22 VH14-4 SM7 gg D3-3 cgctatat JH4 1
PS30 VH14-4 SM7 ggggggc DST4.2 ccc at JH4 1
S100 VH14-4 SM7 - DST4 gggaggag JH3 2
S19 VH14-4 SM7 aaacggg DSP2.2 cccgg JH3 1
S96 VH14-4 SM7 gggcctc DFL16.1 ccctc JH1 1
BS72 VH1-52 J558 - DST4 aaggtt JH2 1
PS08 VH1-64 J558 t tac ga DSP2.2 ggg JH2 1
S92 tu VH1-75 J558 tccgaactcc DSP2.12 t JH4 1
PS11 VH2-2 Q52 tt DFL16.1 - JH4 3
PS16 VH4-1 X-24 t DSP2.10 g JH3 2
a IMGT indicates the international ImMunoGeneTics information system (www.imgt.org).
b RF indicates the reading frame of the DH segments 
c Bold nucleotides refer to P (palindromic) nucleotides 
Supplemental Table 1. Characterization of Ig H chains of Slp65-deficient tumors (continued)
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Supplemental Figure 1. Ig H chains expressed in Slp65-deficient tumors are not highly 
polyreactive. 
ELISA showing binding to different antigens of ten different VH14 Ig H chains (green) and five non VH14 
Ig H chains (red) were cloned and expressed together with SLC and various IgL chains, including the 
non-polyreactive Ig L chains of murine B1-8, the non-polyreactive human mGO53 and the polyreactive 
human Ig L chain BC62. The monoclonal polyreactive ED38 (Wardemann, 2003 Science and Meffre, 
2004 J Exp Med) and intermediately polyreactive eiJB40 served as control (Wardemann, 2003 Science).
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Abstract 
The adapter protein Slp65 and Bruton’s tyrosine kinase (Btk) are key components 
of the precursor-B (pre-B) cell receptor signaling pathway. Slp65-deficient mice 
spontaneously develop pre-B cell leukemia, expressing high levels of the pre-B cell 
receptor (pre-BCR) on their cell surface. Because leukemic Slp65-deficient pre-B 
cells express the recombination activating genes (Rag)1 and Rag2 and manifest 
ongoing immunoglobulin light chain rearrangement, it has been hypothesized that 
deregulated recombinase activity contributes to malignant transformation. In this 
report, we investigated whether Rag-induced DNA damage is involved in oncogenic 
transformation of Slp65-deficient B cells. We employed Btk/Slp65 double-deficient 
mice carrying an autoreactive 3-83μd BCR transgene. When developing B cells in their 
bone marrow express this BCR, the V(D)J recombination machinery will be activated, 
allowing for secondary immunoglobulin light chain gene rearrangements to occur. This 
phenomenon, called receptor editing, will rescue autoreactive B cells from apoptosis. 
We observed that 3-83μd transgenic Btk/Slp65 double-deficient mice developed B cell 
leukemias expressing both the 3-83μd BCR and the pre-BCR components l5/VpreB. 
Importantly, such leukemias were found at similar frequencies in mice concomitantly 
deficient for Rag1 or the non-homologous end-joining factor DNA-PKcs. We therefore 
conclude that malignant transformation of Btk/Slp65 double-deficient pre-B cells is 
independent of deregulated VD)J recombination activity.
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Introduction
Diversity of immunoglobulin (Ig) and T cell receptor specificities is generated through 
DNA gene rearrangement initiated by lymphocyte-specific proteins encoded by 
the recombination activating genes Rag1 and Rag2 (see for review: Ref. (1-3). The 
Rag complex recognizes and cleaves specific DNA elements, called recombination 
recognition sequences (RSS), which  flank rearranging V, D, and J gene segments. The 
arising double-strand DNA breaks are subsequently resolved by the non-homologous 
end joining (NHEJ) pathway. Due to this unique feature of lymphoid cells to somatically 
rearrange antigen receptor genes, these cells are frequent targets for chromosomal 
translocations and oncogene activation resulting from recombinase targeting mistakes 
or incorrect repair of the V(D)J recombination intermediates (4-5). It was demonstrated 
in the mouse that chromosomal reinsertion of broken RSS can target cryptic RSS-
like elements via a V(D)J recombination-like mechanism (6). Moreover, cryptic RSS 
sequences immediately internal to the deletion breakpoints in the IKZF1 locus, 
encoding the transcription factor IKAROS, have been identified in human BCR-ABL1+ 
acute lymphoblastic leukemia (ALL) (7). Cryptic RSS are estimated to have a density 
of 1 per 600 bp in the genome and have been identified in other loci involved in ALL, 
including PAX5 and CDKN2A/B in human and c-Myc and Lmo2 in the mouse (8-9). 
In addition, Rag proteins have the ability to rearrange DNA sequences that do not 
resemble RSS, as reported in follicular lymphoma (10). Taken together, these findings 
suggest that gene deletion or translocation arising from aberrant Rag activity contributes 
to leukemogenesis in human and mouse ALL. 
 Productive Ig heavy (H) chain V(D)J recombination in pro-B cells results in 
deposition of IgH μ chain on the cell surface together with the non-rearranging surrogate 
light chain (SLC) components λ5 and VpreB (11-14). Signaling from this pre-BCR 
monitors expression of a functional IgH chain and triggers clonal expansion, leading to 
differentiation into large cycling pre-B cells as pre-B cells acquire the capacity to respond 
to low concentrations of the proliferation factor interleukin (IL)-7 (11-13, 15). In large 
cycling pre-B cells, Rag proteins are transiently downregulated to terminate further IgH 
chain rearrangement, thus ensuring that only one functional IgH chain is assembled, 
a phenomenon termed allelic exclusion. Moreover, as ongoing recombinase activity 
during mitosis will interfere with faithful transmission of the genome to daughter cells, 
Rag2 proteins are degraded during cell division, thus linking V(D)J recombination to the 
cell cycle (16).  Developmental progression from large cycling into small resting pre-B 
cells is associated with reactivation of the V(D)J recombination machinery for Ig light (L) 
chain gene rearrangement and with cell surface marker changes (11-14).
 The adapter protein Slp65 (also known as Blnk or Bash) and Bruton’s tyrosine 
kinase (Btk) are key components in the signaling pathway downstream of the pre-
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BCR and the BCR. Slp65, when phosphorylated by the Syk kinase, provides docking 
sites for various molecules, including Btk and phospholipase C (PLCg). Btk then 
phosphorylates PLCg, which leads to its full activation and the generation of second 
messengers (11-14). In human, mutations in SLP65 or BTK result in defective pre-B 
cell proliferation and an almost complete arrest of early B cell development, associated 
with the immunodeficiency disorder agammaglobulinemia (11, 17). In mice, deficiency 
for Slp65 or Btk leads to a partial arrest of early B cell development (11). Importantly, 
5-10% of Slp65-deficient mice develop pre-B cell leukemia expressing high levels of 
pre-BCR on the cell surface (18-19). Btk cooperates with Slp65 as a tumor suppressor, 
independently of its kinase activity (20-21). In a substantial fraction of human pre-B ALL, 
including cases expressing the oncogenic BCR-ABL1 tyrosine kinase fusion protein, 
SLP65 expression is defective due to aberrant splicing (22-23). But it has also been 
reported that SLP65 deficiency may be an infrequent event in human pre-B-lineage 
ALL (7, 24), and thus the importance of loss of SLP65 expression as one of the primary 
causes of pre-B ALL in human remains unclear. 
 Slp65 function is essential for proper progression of large cycling into small 
resting pre-B cells. Slp65 collaborates with Btk to down-regulate SLC and IL-7 receptor 
(IL-7R) expression (18, 20). It also directly inhibits the IL-7R signaling component Jak3 
(25), thereby terminating the proliferative response to IL-7 and reducing expression 
of bcl-2 family anti-apoptotic proteins and c-Myc. Finally it has been shown that 
Slp65 induces cell cycle arrest through upregulation of Ikaros, which controls gene 
expression through its association with chromatin remodeling complexes (26). The 
mechanism by which Slp65 exerts its tumor suppression function in mice has not 
been completely elucidated to date, but striking parallels exist with pre-B cell tumors 
initiated by deregulated expression of the c-Myc oncogene. Malignant transformation 
of both Slp65-deficient and Eμ-myc transgenic pre-B cells (i) involves disruption of the 
p19Arf–Mdm2–p53 tumor suppressor pathway (27-28), (ii) is reduced by expression 
of a pre-rearranged IgH chain transgene in early B cell differentiation (28-29), and is 
(iii) independent of activation induced deaminase (AID) (28, 30). Moreover, loss of 
Btk or PLC-g2 synergizes with deregulation of c-Myc during lymphoma formation in 
Em-myc mice (31-32). Several lines of evidence have indicated a role for unregulated 
Rag activity in Slp65-deficient pre-B cell leukemia. First, Rag proteins are expressed in 
strongly proliferating Slp65-deficient pre-B cells (18-19). Second, Slp65-deficient pre-B 
cell leukemias mostly co-express IgH chain, SLC, IgL chain (20). Third, in human pre-B 
cell leukemia SLP65 deficiency correlates with RAG expression and ongoing VH gene 
rearrangement activity (33). 
 Importantly, it has been recently demonstrated that Rag-mediated DNA 
breaks are not essential for malignant transformation in Eμ-Myc Tg mice (30). We 
have previously demonstrated the effects of transgenic IgH chain expression and p53-
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deficiency on oncogenic transformation of Slp65-deficient pre-B cells (28). However, 
genetic experiments addressing the requirement of Rag-mediated V(D)J recombination 
events in leukemia formation have not been performed. Therefore, we investigated 
whether oncogenic transformation of Slp65 deficient pre-B cells could occur on a Rag1-
deficient background. We found that leukemia in Btk/Slp65 double-deficient mice arises 
independently of V(D)J recombination activity or illegitimate repair by NHEJ. 
Material and Methods
Mice and genotyping
Mice deficient for Btk (34), Rag1 (35) and DNA-PKcs (Jackson Laboratories) were on 
the C57BL/6 background. 3-83μδ mice (36) were on a non-deleting B10.D2 background. 
Slp65-deficient mice (37) were on the Balb/c background. The different composite 
genotypes were on a mixed background and in single experiments littermates were 
compared. For mouse genotyping genomic DNA was analyzed by polymerase chain 
reaction (PCR), as previously described (20, 28). Animals in tumor panels were 
sacrificed after indication of tumor formation, or after a maximum period of 40 weeks 
of age. Mice were bred and maintained in the Erasmus MC animal care facility under 
pathogen-free conditions. Experimental procedures were reviewed and approved by 
the Erasmus MC committee of animal experiments.
Southern Blotting
Genomic DNA (10 μg) was digested with HindIII (New England Biolabs, Beverly, MS) 
and processed by Southern blotting using nylon membrane (Nytran SPC, Whatman) 
and standard procedures. Fragments were visualized by phosphor-Imager (Storm, 
Molecular Dynamics) and analyzed with ImageQuant (Molecular Dynamics, Sunnyvale, 
CA). Probe specific for Jκ, a 1.6kb EcoRI fragment, was labeled by random priming. 
Flow cytometry and in vivo 5-bromo-2’-deoxyuridine (BrdU) labeling
Preparations of single-cell suspensions, flow cytometry procedures, and mAbs have 
been described previously (20, 34, 38). The anti-3-83μδ hybridoma 54-1 (39) was 
kindly provided by D. Nemazee (The Scripps Research Institute, La Jolla, Ca). Bone 
marrow (BM) cell suspensions were depleted of erythrocytes by standard ammonium 
chloride lysis and IL-7 driven cultures were performed as described previously (38). 
For intracellular staining of cytoplasmic proteins, cells were first stained for cell surface 
markers and subsequently fixed in 2% paraformaldehyde and permeabilized using 0.5% 
saponin. Events (1–5 x 105) were scored using a BD FACSCalibur or LSRII flow cytometer 
(BD Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR).  
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 BrdU (BD Biosciences) was dissolved in PBS at 2 mg/ml. Mice were injected 
i.p. with 200 μl. Total BM cell suspensions were analyzed by flow cytometry for BrdU 
incorporation, using the BrdU flow kit (BD Biosciences) in conjunction with cell surface 
marker expression, as previously described (38). 
Results 
Ongoing IgL chain gene recombination in Slp65-deficient pre-B cell leukemias
By flow cytometry we found co-expression of IgL chain and SLC, as previously reported 
(20), in most Slp65-deficient or Btk/Slp65 double-deficient pre-B cell leukemias. The 
proportions of Ig k or λ L chain expressing leukemic cells were 16±2% (n=30) and 
1.5±0.3% (n=22), respectively. Normally, large cycling pre-B cells contain low levels 
of Rag transcripts (3), but when we analyzed the pre-B cell leukemias by quantitative 
RT-PCR we found substantial expression (Figure 1A). Transcription of Rag1 and Rag2 
was ~2-3 fold higher in Btk/Slp65 double-deficient pre-B leukemias than in Slp65-
deficient leukemias, most likely reflecting the more severe phenotype of Btk/Slp65 
double-mutant mice, as compared with Slp-65 single mutant mice (20, 40). Consistent 
with the expression of Ig k L chain protein, various clonal Vk-Jk rearrangement patterns 
were detected next to the germline Jκ restriction fragment in Southern blotting analyses, 
using a Jk-specific probe (Figure 1B, 1C). In most of the leukemia samples analyzed, 
we observed multiple Jk restriction fragments, indicating oligoclonality. IgL chain 
recombination is generally initiated in small resting pre-B cells that have terminated 
SLC expression (1, 11). Therefore, the finding that Slp65-deficient or Btk/Slp65 double-
deficient pre-B cell leukemias contained oligoclonal Ig k+ B cell fractions co-expressing 
SLC suggested ongoing IgL chain gene rearrangement after leukemic transformation 
of pre-B cells.
 
Slp65/Btk double-deficient pro-B cells are not susceptible to malignant 
transformation
To investigate the involvement of V(D)J recombination in malignant transformation, we 
first crossed Btk/Slp65 double-deficient mice with mice deficient for Rag1. Because 
Btk/Slp65/Rag triple-deficient mice cannot express a functional IgH μ chain, they 
manifested an arrest of B cell development at the pro-B cell stage, as was found for 
the Rag1 single-deficient mice (35). Btk/Slp65/Rag triple-deficient mice did not develop 
leukemia (Table 1), in agreement with the previously reported finding that proliferation is 
mediated by high pre-BCR expression and not due to the absence of Slp65 per se (18). 
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Figure 1. Ongoing V(D)J recombinase activity in Slp65-deficient  leukemia 
(A) Quantitative RT-PCR analyses of Rag1 and Rag2 expression in Slp65-deficient (n=17) and Btk/
Slp65-deficient (n=27) pre-B cell leukemias, normalized with GAPDH. Values in WT B220+ B cells in the 
BM were set to one. For each of these groups, the horizontal line represents the mean of the relative 
expression level. *p< 0.001 (t-test). (B) Schematic representation of the germline Ig k L chain locus. 
Restriction sites of HindIII and the 2.8 kb k germline fragment are shown. (C) Southern blotting analysis 
of HindIII digests of genomic DNA from the indicated tissues from Slp65-deficient (S) and Btk/Slp65 
double-deficient (BS) leukemias. Ig k L chain gene rearrangements were analyzed using a Jk probe. The 
arrow indicates the 2.8 kb Ig Jk germline band. BM = bone marrow; LN = lymph node; Tu = tumor; Sp = 
spleen; Cult = cultured leukemic cells.
 
Table 1. Leukemia development in panels of Btk/Slp65 double-deficient mice
             
Mouse genotype
Btk-/-Slp65-/- Tumor incidence Onset range (days) Follow-up period (days)
Rag-1+/-
Rag-1-/-
DNA-PKcs+/-
DNA-PKcs-/-
16/20
0/25
15/35
0/23
47 - 145
n.a.
60 - 153
n.a. 
180
180
180
180
n.a. = not applicable 
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Defective NHEJ does not enhance malignant transformation of Slp65/Btk double-
deficient pro-B or pre-B cells 
Next, we analyzed whether defective NHEJ, which is associated with increased Rag-
mediated double-strand DNA breaks that remain unresolved in B and T lymphocytes, 
contributed to leukemia formation. We crossed Btk/Slp65 double-deficient mice with 
mice that harbor a defect in the NHEJ pathway component DNA-PKcs, encoded by the 
Prkdc gene (41). In contrast to Rag1-deficient mice, DNA-PKcs-deficient mice have an 
incomplete block at the pro-B cell stage and very low but detectable numbers of pre-B 
cells are present in the BM (42-44). When compared with these DNA-PKcs-deficient 
mice, the numbers of intracellular IgH μ chain positive pre-B cells in Btk/Slp65/DNA-
PKcs triple deficient mice were slightly increased, probably due to enhanced proliferative 
expansion of pre-B cells (Figure 2A). Accordingly, we found that the membrane IgL 
chain-negative cell fraction contained more surface SLC+ pre-B cells in Btk/Slp65/DNA-
PKcs triple than in DNA-PKcs single-deficient mice (Figure 1B). Next, we investigated if 
the increased proliferation capacity of Btk/Slp65-deficient pre-B cells (20) could correct 
the low generation of pre-B cells in DNA-PKcs-mutant mice. When mice were pulsed 
with a single dose of the thymidine analogue BrdU, which is selectively incorporated into 
the DNA of large pre-B cells (38), the absolute numbers of BrdU+ large pre-B cells in the 
BM of DNA-PKcs-deficient mice were severely reduced, when compared to wild-type 
mice (Figure 2C). The absolute numbers of BrdU+ large pre-B cells in Btk/Slp65/DNA-
PKcs triple mutant mice were variable and only slightly increased, when compared with 
DNA-PKcs-deficient mice. Within the fractions of pre-B cells the proportions of BrdU+ 
cells were comparable between wild-type and mice defcient for  DNA-PKcs, Btk/Slp65 
or Btk/Slp65/DNA-PKcs (Figure 2D). Therefore, proliferation of Btk/Slp65/DNA-PKcs 
triple mutant pre-B cells was not substantially increased in vivo, when compared to Btk/
Slp65 double mutant mice, even though the BM in these mice may contain more empty 
niches or available space because of the block in B cell development.   
 Whereas in the Btk/Slp65 double deficient control group 15 out of 36 mice 
developed pre-B cell leukemia (Table 1), none of the 22 Btk/Slp65/DNA-PKcs triple 
mutant mice that were followed for 6 months showed signs of leukemia formation, even 
when we examined BM and spleen of these mice in detail by flow cytometry (data not 
shown). We conclude that pro-B cells and pre-B cells generated in Btk/Slp65/DNA-
PKcs triple mutant mice are not particularly susceptible to malignant transformation, in 
spite of defective NHEJ. 
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Figure 2. The small pre-B cell population in Btk/Slp65/DNA-PKcs triple-deficient mice is not 
highly susceptible to malignant transformation.
(A) Phenotypic characterization of BM from the indicated mouse genotypes. B220+cμ H chain+ B cells 
were gated. Data are displayed as dot plots, and numbers indicate the percentages of cells within 
the gates.  (B) Flow cytometric analyses of surface expression of MHCII and SLC on CD19+ Ig κ-λ- 
pro-B and pre-B cells. Data are representative for four to six 8-week-old mice. (C) Absolute numbers of 
BrdU+ CD19+Ig κ-λ- pre-B cells, 4 hr after i.p. injection of a single dose of BrdU, as determined by flow 
cytometry. (D) Percentages of BrdU+ CD19+Ig κ-λ- pre-B cells in the BM. Average values and SEM of four 
to six animals per group are shown. PK-/-=Prkdc-/-.
Autoreactive receptor editing Slp65/Btk double-deficient B cells express high 
levels of pre-BCR 
The complete absence or severe reduction of the size of the pre-B cell compartment in 
Btk/Slp65 mutant mice with additional mutations in the Rag1 or Prkdc genes, precluded 
the analysis of leukemia development in these mice. However, when the developmental 
block at the pro-B cell stage was rescued by transgenic expression of the pre-
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rearranged IgH chain transgene VH81X, tumor development was also prevented in 
Btk/Slp65 mutant mice (28). This could be explained by an acceleration of the passage 
of B-cell precursors through the pro-B cell stage, which may reduce the size of the cell 
population most susceptible to transformation. 
 Therefore, we employed Btk/Slp65 deficient mice carrying the 3-83μδ 
transgene, which consists of pre-rearranged Ig μ and δ H chain genes and an Ig k L 
chain gene encoding an antibody that specifically recognizes MHC class I H-2Kb,d (36). 
In developing B cells in the BM, on a centrally deleting H-2Kb C57BL/6 background, 
the expressed BCR is autoreactive and therefore the V(D)J recombination machinery 
remains active. As a result, secondary immunoglobulin L gene rearrangements occur 
and hence autoreactive B cells can be rescued from apoptosis, a phenomenon called 
receptor editing (45-47). By contrast, the 3-83 μδ Tg on a non-H2-Kb,d background 
reflects an innocuous BCR and the arising B cells are not autoreactive and will not be 
deleted or edited (45-47).
 On a non-deleting background, splenic B cells from 3-83μδ transgenic mice 
expressed the 3-83μδ BCR, as analyzed by staining with the anti-idiotypic antibody 
54-1 (Figure 3A). As previously described splenic B cell numbers were very low in Btk/
Slp65 double-deficient mice (20), irrespective of the presence of the 3-83μδ transgene 
(Figure 3A). When the 3-83μδ Tg was expressed on a WT deleting background, those 
B cells present had lost 54-1 reactivity and increased usage of Ig λ L chain, indicating 
that they had edited the 3-83μδ BCR. On a deleting background, 3-83μδ transgenic Btk/
Slp65 double-deficient mice had only very few splenic B cells, but those B cells present 
were 54-1low and had detectable Ig λ usage (Figure 3A), demonstrating that receptor 
editing is operational in Btk/Slp65 double-deficient mice. 
 In the BM, the presence of the 3-83μδ transgene on a deleting background 
resulted in BCR downregulation, as evidenced by low signals for surface μ H chain 
and 54-1 (Figure 3B). These B cells still expressed high levels of μ H chain in their 
cytoplasm, but SLC expression was limited precluding abundant surface expression of 
the pre-BCR. Also 3-83μδ transgenic Btk/Slp65 double-deficient B cells on a deleting 
background showed downregulation of μ H chain expression, albeit more modest, and 
had reduced staining with 54-1. As these B cells expressed high levels of SLC, we 
conclude that these 3-83μδ transgenic Btk/Slp65 double-deficient B cells expressed the 
3-83μδ H chain together with SLC as a pre-BCR (Figure 3B). 
 Taken together, these findings show that on a centrally deleting background 
autoreactive 3-83μδ transgenic Btk/Slp65 double-deficient B cells undergo receptor 
editing, whereby the expression of pre-BCR is significantly increased, when compared 
with WT 3-83μδ transgenic mice. 
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Figure 3. Receptor editing in Btk/Slp65 double-deficient B cells carrying the 3-83μδ BCR.
(A) Flow cytometric analysis of B cells in the spleen from the indicated mice. Total B220+CD19+ fractions 
were gated (upper panel) and analyzed for the 54-1 idiotype and Ig λ expression (lower panel). Data are 
displayed as dot plots, and numbers indicate the percentages of cells within the gates. Data represent 
four to eight 8-weeks old mice analyzed per genotype. (B) BM expression profiles of B220 and μ H 
chain are shown as dot plots (upper panel). B220+CD19+ B-lineage cells were gated and analyzed for 
expression profiles of 54-1/Ig λ and cSLC/cμ H chain. Numbers indicate the percentages of cells within 
the gates.
 
Leukemia in Btk/Slp65 double-deficient mice arises independently of V(D)J 
recombination activity
As editing 3-83μδ transgenic Btk/Slp65 double-deficient B cells expressed high levels 
of SLC and IL-7R it was conceivable that these mice were also susceptible to leukemia 
formation. Indeed when we followed panels of 3-83μδ transgenic Btk/Slp65 double-
Chapter 5
134
Figure 4. 3-83μδ Tg B cell leukemias have pre-B cell characteristics.
Flow cytometric analysis of two Rag-1+/- (EBS1, EBS2) and two Rag-1-/- (EBSR3, EBSR4) 3-83μδ 
Tg Btk/Slp65 double-deficient leukemias. On the right, a non-3-83μδ Tg Btk/Slp65 double-deficient 
leukemia is shown as a control. Lymphoid cells from lymph nodes (LN) and spleen (Spl) were gated and 
B220/54-1 profiles are shown as dot plots (upper panel).  Total B220+CD19+ B-lineage cells were gated 
and analyzed for the expression of surface Ig κ L chain, surface SLC (sSLC), CD2, IL-7R, CD43 and μ 
H chain (lower panels). Data are shown as dot plots, whereby the numbers indicate the percentages of 
cells within the quadrants.
deficient mice for 40 weeks, about 10% developed leukemia. Therefore, this model 
was suitable to investigate the involvement of V(D)J recombination in malignant 
transformation of Slp65-deficient pre-B cells. First, we crossed the mice with mice 
deficient for Rag1. When we followed panels of 3-83μδ transgenic Btk/Slp65 double-
deficient mice that were either Rag1+/- or Rag1-/-, we found that tumor frequencies were 
similar: 2/23 and 2/20, respectively (Table 2). Irrespective of their Rag1 genotype, all 
these leukemias were positive for the anti-idiotypic antibody 54-1 (Figure 4). They all 
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expressed SLC and IL-7R and showed variable expression of the differentiation markers 
CD2 and CD43 (Figure 4). In this respect, these leukemias were not different from those 
found in Slp65 single or Btk/Slp65 double mutant mice (20). From these findings, we 
conclude that leukemias in Btk/Slp65 double-deficient mice can arise in the absence of 
an intact V(D)J recombination machinery. 
 Finally, we wanted to test whether an increase of unresolved V(D)J recombinase-
mediated double-strand DNA breaks would affect leukemia incidence. To this end, we 
followed panels of 3-83μδ transgenic Btk/Slp65 double-deficient mice that were either 
Prkdc+/- or Prkdc-/- for 40 weeks. Again, we did not find differences in leukemia onset or 
incidence (Table 2). Consequently, we conclude that defective NHEJ does not enhance 
B cell leukemia development in Btk/Slp65 double-deficient mice. 
Table 2. Leukemia development in panels of 3-83μδ Tg Btk/Slp65 double-deficient mice
       
Mouse genotype
3-83μδ Tg Btk-/-Slp65-/- Tumor incidence Onset (days) Follow-up period (days)
Rag-1+/-
Rag-1-/-
DNA-PKcs+/-
DNA-PKcs-/-
2/23
2/20
2/17
3/21
251, 249
227, 216
147, 226
244, 232, 238
280
280
280
280
Discussion
It has been reported that strongly proliferating Slp65-deficient pre-B cells express 
Rag proteins in mice (18-19) and that SLP65 deficiency in human pre-B cell leukemia 
correlates with RAG expression and ongoing VH gene rearrangement activity (33). 
Furthermore, reconstitution of SLP65-expression in human SLP65-deficient leukemia 
and lymphoma cells resulted in downregulation of RAG1/2 expression and V(D)J 
recombination events (33). In agreement with these findings in human SLP65-deficient 
malignancies, we found that Slp65-deficient pre-B cell leukemias in mice contained 
oligoclonal Ig k+ B cell fractions co-expressing IgH and SLC, suggesting ongoing IgL 
chain gene rearrangement after leukemic transformation of pre-B cells. Therefore, 
deregulated V(D)J recombinase activity, involving multiple DNA double-strand DNA 
break events, in pre-B cells may well introduce genetic aberrations contributing to 
malignant transformation or progression of Slp65-deficient pre-B cells. 
 However, in this report we observed that Btk/Slp65 double deficient mice, in 
which the V(D)J recombination machinery is activated during receptor editing, develop 
leukemia at similar frequencies when they are concomitantly mutant for Rag1 or the 
NHEJ factor DNA-PKcs. We therefore conclude that malignant transformation of Btk/
Slp65 double-deficient pre-B cells is independent of deregulated V(D)J recombination 
activity or defective NHEJ. In this respect, Slp65-deficient pre-B cell leukemia does not 
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differ from leukemia in mice with enforced c-Myc expression (30). It is of note that during 
normal B cell development, expression of the proto-oncogene c-Myc is induced by the 
IL-7R pathway (48) and that recently it has been shown that Slp65-deficient leukemias 
acquire autonomous IL-7R signaling by autocrine IL-7 production (25). As c-Myc 
is induced by IL-7R signaling, it is very well possible that sustained IL-7R signaling 
results in elevated levels of c-Myc expression (constitutively or transiently), contributing 
to transformation of Slp65-deficient pre-B cells. Consistent with this hypothesis, we 
detected c-Myc expression in Slp65-deficient leukemias by RT-PCR (28). Nevertheless, 
in contrast to Rag1 deficient c-Myc transgenic mice that may develop IgH m- pro-B cell 
tumors, it has been shown that transformation of Slp65-deficient B-lineage cells is fully 
dependent on pre-BCR expression and thus on functional IgH chain recombination 
(18).
 Our conclusion that ongoing V(D)J recombination activity is not involved in 
malignant transformation of Slp65-deficient pre-B cells is in agreement with our previous 
observation that Slp65-deficient pre-B cell leukemias exhibited chromosomal instability 
but showed no evidence for Rag-mediated translocations by spectral karyotyping 
analysis (28). Therefore, ongoing Rag-mediated recombination activity in Slp65-deficient 
pre-B cell leukemias might well be a consequence of malignant transformation, resulting 
in correct IgL chain recombination, but not in aberrant V(D)J recombination events 
that would contribute to tumor progression. Spectral karyotyping analysis of Slp65-
deficient pre-B cell leukemias  revealed chromosomal abnormalities, characterized by 
chromosomal gains, losses and gene amplifications that were heterogeneous in nature 
and did not appear to specifically affect the Ig or T cell receptor gene loci (28). Since 
we found duplications of the N-myc locus that were associated with N-myc amplification 
on the p53-deficient background (28), it may be interesting to investigate whether 
these leukemias contain more regions with deletions or duplications involving tumor 
suppressors or oncogenes. 
 The proportions of mice developing leukemia in 3-83μδ Tg Btk/Slp65 double-
deficient mice is low (~10%), when compared with Btk/Slp65 double-deficient mice that 
do not harbor an Ig transgene (~50-80%, dependent on mouse strain background). 
This is consistent with the previously reported observation that transgenic expression 
of a functional IgH chain prevents malignant transformation of c-Myc transgenic (29) 
or Slp65-deficient pre-B cells (28). Such premature transgenic IgH chain expression 
considerably accelerates the passage of B-cell precursors through the pro-B cell stage, 
thereby likely reducing the size of the cell population most susceptible to transformation 
(29, 49). In particular, it was recently shown that an IgH chain induces Stat5 
dephosphorylation downstream of IL-7R signaling (50). Because Slp65 is essential 
for pre-BCR-mediated downregulation of IL-7R-Jak3-Stat5 signaling (25, 50-51) and 
Slp65-deficient pre-B cell leukemias exhibit autocrine IL-7 production, it is attractive 
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to speculate that transformation of Slp65-deficient pre-B cells is dependent on early 
oncogenic events that induce constitutive Jak3-Stat5 signaling at the pro-B cell stage. 
It may be argued that dilution of SLC-mediated proliferative signals by the 3-83μδ 
Tg conventional L chains contributes to the low leukemia incidence in 3-83μδ Tg Btk/
Slp65 double-deficient mice. This would be supported by the finding that conventional 
light chains inhibit the autonomous signaling capacity of the BCR (52). However, the 
opposite is more likely, because the 3-83μδ is an autoreative B cell receptor that mimics 
autonomous pre-B cell receptor signaling and induces proliferation of early B cells (53). 
It is therefore very well possible that Btk/Slp65 double-deficient mice transgenic for 
only the 3-83μδ IgH chain (which is not autoreactive) would not develop leukemia or at 
frequencies much lower than 10%. In this context, it is important to note that leukemia 
formation was completely lacking in Btk/Slp65 double-deficient mice that harbored a 
VH81X IgH transgene, (in contrast to the frequency of ~10% in the presence of the 
autoreactive 3-83μδ IgH+L chain transgene). Possibly, transformation of Slp65-deficient 
pre-B cells is restricted to IgH chains with specific structural properties. Particular IgH 
chain V regions may be associated with strong autonomous pre-BCR signaling, e.g. 
because they enhance interaction with self-antigens (53) or with carbohydrates in the μ 
IgH chain (54). In such a model the 3-83μδ H chain but not the VH81X IgH chain would 
have these specific structural properties.
 Because of the low leukemia frequencies in our mouse panels (~10% for all our 
genotypes, Table 2), we cannot formally rule out that Rag1 activity may to some extent 
contribute to the transformation process in a fraction of the leukemias. But, importantly, 
the finding that two Rag1/Btk/Slp65 triple-deficient mice developed leukemia in our 
3-83μδ receptor editing model, demonstrates that Rag1 activity is not absolutely 
essential for malignant transformation of Btk/Slp65-deficient (pre-)B cells. Conversely, 
defective NHEJ, which is associated with oncogenic misjoining of Rag-induced breaks 
(55-56), did not appear to enhance lymphoma formation. Taken together, we therefore 
conclude that pre-B cell leukemias in Btk/Slp65-deficient mice arise independently of 
ongoing V(D)J recombination activity. 
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Abstract 
Mice deficient for the precursor-B cell receptor (pre-BCR) signaling proteins Slp65 and 
Bruton’s tyrosine kinase (Btk) manifest an arrest at the large pre-B cell stage, which is 
a highly proliferative phase in B cell development. Slp65-deficient mice spontaneously 
develop pre-B cell leukemia and the incidence is increased by concomitant deficiency 
for Btk. Although the molecular mechanism of malignant transformation is still unclear, 
we have recently shown that it is independent of deregulated V(D)J activity and that it 
involves disruption of the Arf-Mdm2-p53 pathway. Interestingly, Slp65-deficient pre-B 
cells have high levels of IL-7 receptor and pre-BCR, both of which provide proliferative 
signals. It is therefore conceivable that cell division in these cells may be accompanied 
by genomic instability, ultimately leading to oncogenic transformation. To investigate the 
involvement of genomic instability in proliferating large pre-B cells, we crossed Btk/Slp65 
double deficient mice with mice deficient for the DNA repair protein Rad54 involved in 
homologous recombination (HR). Paradoxically, we found that Rad54-deficiency actually 
protected, rather than enhanced, Btk/Slp65-double deficient pre-B cells from malignant 
transformation. At 6 months of age Rad54/Btk/Slp65 triple deficient mice manifested 
reduced tumor incidence (4 out of 24, ~17%), when compared with Btk/Slp65-double 
deficient mice (9 out of 21, ~43%). Comparative genomic hybridization analysis of pre-B 
cell leukemias from Rad54/Btk/Slp65 triple deficient mice showed a similar frequency of 
genetic aberrations, when compared with those from Btk/Slp65-double deficient mice. 
However, several gene duplications abundant in Btk/Slp65-double deficient pre-B cell 
tumors, ranging in size up to 400 kb, were not present in the concomitant absence of 
Rad54. These results indicate that repair via Rad54 and HR operates on a razors edge: 
although it has been assumed that repair by HR ensures high fidelity repair, our findings 
indicate that Rad54 activity can be corrupted at certain locations to promote aberrant 
HR, resulting in genomic rearrangements. For the first time, we demonstrate that a DNA 
repair protein can contribute to malignant transformation.
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Introduction
B lymphocytes provide humoral immunity and are produced in the bone marrow through 
a complex process of cellular differentiation. B cell development is characterized by 
the ordered rearrangement of immunoglobulin (Ig) heavy (H) and light (L) chains and 
the expression of specific cell surface markers (1-3). In pro-B cells productive in-frame 
recombination of Ig H chain V, D and J segments results in the expression of Ig μ 
chain protein, which marks the transition to the precursor-B (pre-B) cell stage. The Ig 
μ chain is expressed on the cell surface, together with the surrogate light chain (SLC) 
components λ5 and VpreB and the signaling subunits Igα and Igβ, as the pre-B cell 
receptor (pre-BCR) complex. The expression of the pre-BCR functions as an important 
checkpoint in B cell development (2, 4-5). Pre-BCR signaling initiates proliferative 
expansion, because pre-B cells acquire the capacity to respond to low concentrations 
of the proliferation factor interleukin (IL)-7 (4-5). It also induces cellular differentiation, 
thereby redirecting V(D)J recombination activity from the Ig H chain to the Ig k and l L 
chain loci (2, 4-5). Productive Ig L chain recombination leads to surface expression of 
the BCR. 
The adapter protein Slp65 (also known as Blnk or Bash) and the non-receptor 
kinase Bruton’s tyrosine kinase (Btk) are key components in the signaling pathway 
downstream of the pre-BCR and the BCR. Slp65, when phosphorylated by Syk, provides 
docking sites for Btk and phospholipase C γ (PLCγ). Btk then phosphorylates PLCγ 
leading to its full activation and the generation of second messengers (2, 4-6). In human, 
mutations in SLP65 or BTK result in defective pre-B cell proliferation and an almost 
complete arrest of early B cell development, associated with the immunodeficiency 
disorder agammaglobulinemia (6-7). In addition, deficiency of SLP65, due to defective 
splicing, has been found in ~50% of childhood precursor-B cell acute lymphoblastic 
leukaemia (ALL) cases (8). Because additional studies with large numbers of patients 
indicated a low frequency of SLP65 defects (9-10), it is currently not clear if SLP65 loss 
is a common leukemogenic event. 
Slp65-deficient mice spontaneously develop pre-B cell leukemia expressing 
high levels of pre-BCR on the cell surface (11-12). Although Btk-deficient mice do not 
develop pre-B cell leukemia, Btk and Slp65 cooperate as tumor suppressors whereby 
Btk exerts its tumor suppressor function independently of its kinase activity (13-14). 
Combined deficiency of Slp65 and Btk results in a more complete arrest at the pre-B 
cell stage (13). Recent findings show that Slp65 limits IL-7-mediated proliferation and 
survival through downregulation of IL-7R expression (15) and by direct inhibition of 
Jak3 (16). Conversely, in Slp65-deficient leukemia the Jak/Stat5 signaling pathway is 
constitutively activated, mostly due to autocrine production of IL-7 (16).
 Although the molecular mechanism of malignant transformation is still unclear, 
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we have recently found that it involves disruption of the Arf-Mdm2-p53 pathway (17). 
We were able to show that malignant transformation is not dependent on defective 
repair - by the non-homologous end-joining pathway - of double strand DNA breaks 
(DSB) generated by V(D)J recombination activity (18). As in Slp65-deficient mice B cell 
differentiation is arrested at the stage of large cycling pre-B cells, it is conceivable that 
cell division in these strongly cycling cells may be accompanied by genomic instability, 
ultimately leading to oncogenic transformation. We therefore argued that erroneous 
homologous recombination (HR), the pathway which repairs DSBs in cycling cells 
(19), may be involved in the malignant transformation of Slp65-deficient pre-B cells. 
In this report, we investigated the effect of Rad54 deficiency, Rad54 is a member of 
the SWI2/SNF2 subfamily of ATPase (20). Rad54 was shown to interact with Rad51 
and this interaction is functionally important in multiple steps of HR (21). Rad51 has a 
central role in HR, assembling onto single-stranded DNA and catalysing the invasion 
and exchange of homologous DNA sequences. 
 Our previous gene targeting experiments demonstrated that HR in Rad54-
deficient cells is reduced compared to wild-type cells, but that Rad54-deficient mice 
exhibit normal V(D)J recombination and Ig H chain class switch (22). In this report, 
we provide evidence that oncogenic activity of Rad54 contributes to malignant 
transformation in Btk/Slp65-double deficient pre-B cell leukemia. 
Materials and Methods
Mice 
Btk-deficient(23) and Rad54-deficient (22) mice were on the C57BL/6 background and 
Slp65-/- mice(24) were on the BALB/c background. For mouse genotyping genomic DNA 
was analyzed by PCR as previously described (13, 22). Animals in tumor panels were 
sacrificed after indication of tumor formation, or after a maximum period of 26 weeks. 
Mice were bred and maintained in the Erasmus MC animal care facility under pathogen-
free conditions. Experimental procedures were reviewed and approved by the Erasmus 
MC committee for animal experiments.
Flowcytometry
Preparations of single-cell suspensions, flow cytometry procedures, and mAbs have 
been described (13, 25). BM cell suspensions were depleted of erythrocytes by 
standard ammonium chloride lysis and IL-7 driven cultures were performed as described 
previously (25). Events (1–5 x 105) were scored using a FACSCalibur flow cytometer 
(BD Bioscience and analyzed using FlowJo software (Tree Star, Ashland, OR). 
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Pre-B cell cultures and visualization of Rad54GFP/GFP cells
Bone marrow cell suspensions were depleted of erythrocytes by standard ammonium 
chloride lysis and IL-7 driven cultures were performed as described previously (25). 
Rad54GFP/GFP cells were visualized using a Zeiss LSM510 fluorescent microscope. 
Array based CGH
Analyses were performed by using 180K Genomic mouse DNA Arrays (Agilent 
Technologies, Palo Alto, CA) according to manufacturer’s instructions. Slides were 
scanned with an Agilent scanner and data was analyzed with Agilent Genomic 
Workbench (Agilent). 
Results and Discussion
Rad54 expression is mainly confined to proliferating cell stages
First, we investigated during which stage of B cell development Rad54 is being 
expressed.  Transcripts of Rad54 are abundantly present in thymus, spleen and testis, 
but were low in most other tissues (26). This expression pattern of Rad54 would be 
consistent both with a role for Rad54 in DNA repair of V(D)J recombination-associated 
DSBs in resting cells and with a role for Rad54 in DNA repair in highly proliferative cells. 
We used mice carrying a Rad54-GFP knock-in allele to analyze the expression pattern 
of Rad54 at different stages of B cell development (Suppl. Figure 1). The functionality 
of the Rad54-GFP fusion protein was tested by performing clonal survival assays in 
response to DNA damage induction by g-irradiation (Suppl. Figure 1B).
 Rad54-GFP expression was analyzed in pro-B/large pre-B cell (CD19+CD2-
IgM-), small pre-B cell (CD19+CD2+IgM-) and immature/mature B cell (CD19+CD2+IgM+) 
fractions (Figure 1A). Rad54-GFP signals were detected in the pro-B cell/large pre-B 
cell and in the small pre-B cell fractions, mainly in large cells with high forward scatter 
values and not in small resting cells with low forward scatter values. Rad54-GFP+ cells 
present in the CD19+CD2+IgM- small pre-B cell fraction were large pre-B cells that had 
started the upregulation of surface CD2 expression. In parallel, in the thymus Rad54-
GFP expression was almost exclusively detected in large, cycling cells that have past 
b-selection in the double negative (CD3-CD4-CD8-) compartments DN3 (CD44-CD25+) 
and DN4 (CD44-CD25-) and in the immature single positive (CD3-CD4-CD8+FSChigh) 
fraction (data not shown).
Next, total bone marrow cell suspensions were cultured in vitro with IL-7 for 5 
days enriching for large, cycling pre-B cells (Rolink, Grawunder et al. 1993). Upon IL-7 
removal, culture for 2 additional days strongly induces pre-B cells to exit the cell cycle 
and to initiate stepwise activation of Ig L chain rearrangements (27-28). Pre-B cells 
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cultured in the presence of IL-7 displayed nuclear localization of Rad54-GFP (Figure 
1B). In contrast, small resting pre-B cells present in the cultures without IL-7 essentially 
did not express Rad54-GFP. Taken together, these findings indicate that during B cell 
differentiation Rad54 expression is mainly confined to proliferating cell stages and not 
in cells that are resting and may undergo V(D)J recombination.
Figure 1. Rad54-GFP expression in proliferating B cells.
(A) Flow cytometry profiles of GFP and forward scatter (FSC) are shown as dot plots for pro-B/large 
pre-B cells (CD19+CD2-IgM-), small pre-B cells (CD19+CD2+IgM-), immature and mature B cells 
(CD19+CD2+IgM+) from WT and Rad54GFP/GFP mice. (B) Confocal microscopy images of Rad54GFP/GFP 
pre-B cells cultured for 5 days with IL-7 (top) and for 2 additional days with or without IL-7 (bottom). See 
Appendix for full-color figure. 
Rad54-deficiency reduced leukemia incidence Btk/Slp65-double deficient mice
We investigated the possible involvement of HR in oncogenic transformation of 
pre-B cells by crossing Slp65-deficient mice on the Rad54-deficient background. We 
followed panels of Rad54+/+Slp65-/- and Rad54-/-Slp65-/-mice for 6 months. On the Balb/c 
background, ~10% of Slp65-deficient mice develop pre-B cell leukemia (11-12). We 
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noticed that only 1/28 Slp65-deficient mice developed pre-B cell leukemia (1/28). In 
the concomitant absence of Rad54 none of the 25 mice developed a tumor. The low 
leukemia frequency observed might thus be related to the C57BL/6 genetic background 
of these mice. 
 To increase the sensitivity of our analyses, we used Btk/Slp65-double deficient 
mice in which we previously found tumor frequencies in the range of ~50-80%, dependent 
on the background strain. We followed panels of Rad54+/+Btk-/-Slp65-/-and Rad54-/-
Btk-/-Slp65-/- mice. Consistent with previous findings (13-14, 17), we found that at the 
age of 6 months 9 out of 21 (~43%) Btk/Slp65-double deficient mice developed pre-B 
cell leukemia (Figure 2). Surprisingly, we found that deficiency of Rad54 significantly 
reduced leukemia incidence in Btk/Slp65-double deficient mice, because only 4 out 
of 24 (17%) Rad54/Btk/Slp65 triple deficient mice developed a pre-B cell tumor at 6 
months of age (p<0.03) (Figure 2). The pre-B cell leukemias found in Rad54/Btk/Slp65 
triple deficient mice all expressed high levels of SLC and IL-7R and showed variable 
expression of the differentiation markers CD2, CD25 and CD43 (data not shown). In 
this respect, these leukemias were not different from those found in Slp65 single or Btk/
Slp65 double mutant mice (13-14). 
 Collectively, these data show that Rad54-deficiency reduced the incidence of 
pre-B leukemia formation in Btk/Slp65-double deficient mice, suggesting that Rad54 
has oncogenic properties. 
Figure 2. Deficiency of Rad54 protects against malignant transformation.
Kaplan-Meier tumor-free survival estimates for Btk-/-Slp65-/- mice (n=21) and Rad54-/-Btk-/-Slp65-/- mice 
(n=24). Tumor-free survival in Rad54-/-Btk-/-Slp65-/- mice was significantly increased (P<0.03) compared 
with Btk-/-Slp65-/- mice.
Rad54-dependent aberrations in Btk/Slp65-double deficient pre-B cell leukemias
The finding of oncogenic activity of Rad54 is quite remarkable, as deficiency of 
a component of the HR pathway is expected to increase genomic instability and to 
enhance malignant transformation. In particular, since point mutations in RAD54 have 
been found in primary human tumors (29).
 Because gene duplications mediated by HR between Alu repeat elements have 
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been reported in circulating lymphocytes as well as human T-ALL (30), we argued that 
erroneous Rad54-mediated HR may result in duplications or deletions that contribute 
to malignant transformation of Slp65-deficient pre-B cells. To investigate this issue, we 
performed a genome-wide analysis of genetic aberrations present in pre-B leukemia 
cells from six Btk/Slp65-double deficient and four Rad54/Btk/Slp65-triple deficient 
mice by comparative genomic hybridization (CGH). We found evidence for genomic 
duplications and deletions in all samples, with substantial differences in their frequency 
per chromosome. For example, for chromosome 1, we found that in the absence of 
Rad54 duplications/deletions were substantially increased, but this was not the case for 
chromosome 17 (Figure 3). Whereas in Btk/Slp65-deficient leukemias chromosome 17 
manifested 11 ± 3.7 deletions and 23 ± 7.7 amplifications, these values in Rad54/Btk/
Slp65 triple deficient mice were 11 ± 4.5 and 15 ± 3.5, respectively. 
Figure 3. Deficiency of Rad54 does not lead to increased genetic instability.
Array CGH of pre-B cell tumors reveals a similar number of deletions and amplifications present on 
chromosome 1, 5 and 17 when Btk/Slp65-double deficient tumors (n=6) (BS) are compared with Rad54/
Btk/Slp65-triple deficient tumors (n=4) (RBS). Open bars represent BS tumors (n=6) and filled bars 
represent RBS (n=4) tumors. Deletions are shown on the left and amplifications are shown on the right. 
Bars represent average normalized values and SEM. Chr, chromosome. 
Detailed analyses showed that several genomic duplications (up to 430 kb in 
size) were consistently present in all six Btk/Slp65-double deficient pre-B cell tumors. 
Interestingly, many of these were not present in the concomitant absence of Rad54. 
Two examples of these Rad54-dependent duplications are shown in Figure 4, a 39 kb 
fragment on chromosome 1 qH3 and a 430 kb fragment on chromosome 17 qA3.3. In 
general, these amplified fragments contained multiple genes: natural killer cell receptor 
2B4 (CD244), BTB (POZ) domain containing 9 protein-protein interactions (Btbd9), 
glyoxalase 1 and the dynein axomal heavy chain 8 protein (Dnahc8). These findings 
show that several duplications were specific for Btk/Slp65-double deficient tumors 
and not present in Rad54/Btk/Slp65-triple deficient tumors. It is therefore possible 
that particular aberrations contributing to malignant transformation did not occur in the 
Rad54 and Slp65-deficient pre-B cell leukemia
151
Figure 4. Focal amplifications only present in Btk/Slp65-double deficient tumors.
Overlays of CGH analyses of chromosome 1 (upper panel) and 17 (lower panel) views of Btk/Slp65-
double deficient tumors (BS; n=6) (left) and Rad54/Btk/Slp65-triple deficient tumors (RBS; n=4) (right), 
showing different sizes of aberrations exclusively present in BS tumors and not in RBS tumors. Chr, 
chromosome. See Appendix for full-color figure.
absence of Rad54, thus leading to a lower incidence of leukemia in Rad54/Btk/Slp65-
triple deficient mice. Although these genes may not be critical for leukemogenesis (as 
tumors did also arise in Rad54/Btk/Slp65-triple deficient tumors), they may facilitate 
malignant transformation of Slp65-deficient pre-B cells. In addition, further analyses 
are required to determine if genes involved in genetic alterations which were found in 
Slp65-deficient tumors play a role in malignant transformation. In particular, deletions 
or amplifications common for both Btk/Slp65-double deficient tumors and Rad54/Btk/
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Slp65-triple deficient tumors could contain genes which are involved in the malignant 
transformation of Slp65-deficient pre-B cells. Therefore, our mouse model could be 
used to screen for new oncogenes or tumor suppressor genes.
Next to these consistently recurrent genomic duplications in Btk/Slp65-double 
deficient pre-B cell tumors, other genomic alterations (amplifications and deletions) 
were identified in only a portion of Btk/Slp65-double deficient or Rad54/Btk/Slp65-
triple deficient tumors as is shown for chromosome 4 qD1, chromosome 6 qB3 and 
chromosome 8 qA4 (Figure 5). It was striking that all Btk/Slp65-double deficient pre-B 
cell tumors contained apparently identical duplications, starting and ending at the same 
probe. Breakpoint analyses are required to determine the mechanism by which Rad54 
mediates amplification. The involvement of repetitive DNA sequences in recurrent 
chromosomal rearrangements have been found in human tumors (31) and breakpoint 
regions in Btk/Slp65-double deficient tumors could contain repetitive elements that 
facilitate amplification, since intrachromosomal rearrangements between Alu elements 
occur in meiotic cells. Next to repetitive elements, regions of homology could be present 
and provide a template for disrepair by Rad54-mediated HR. More general properties 
of eukaryotic chromatin could play a role as common fragile sites are hot spots for 
chromosomal rearrangements and deletions (32).  
The finding of oncogenic activity of Rad54 is quite remarkable, as faithful DNA 
repair contributes to maintaining chromosomal stability (19, 33-34) and deficiency of 
proteins involved in DNA repair pathways leads to increased genomic instability and 
malignant transformation (35-39). BRCA1 and BRCA2 are associated in nuclear foci 
with Rad51. Individuals with a germline mutation in BRCA1 or BRCA2 are predisposed 
to breast, ovarian and a few other cancers (40-42). Furthermore, point mutations of 
RAD54 have been found in primary human tumors (29, 43) resulting in the absence 
of RAD54 due to aberrant splicing (44). Although no mutations in the HR key protein 
RAD51 have been found in cancer, overexpression of RAD51 is observed in a wide 
range of human tumors (45-48). Increased Rad51 expression does not come from 
amplification but is due to increased transcription (45). High levels of RAD51 lead to 
increased genomic instability resulting in chromosomal rearrangements (49). Therapies 
based on inhibition of RAD51 are under investigation (50). 
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Figure 5. Overview of several genetic lesions in Slp65-deficient tumors.
Overlays of CGH analyses of chromosome 4 (upper panel), 6 (middle panel) and 8 (lower panel) views 
of Btk/Slp65-double deficient tumors (BS; n=6) (left) and Rad54/Btk/Slp65-triple deficient tumors (RBS; 
n=4) (right), showing different sizes of aberrations. Chr, chromosome. See Appendix for full-color 
figure.
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Concluding Remarks 
In this report, we show that oncogenic Rad54 activity contributes to malignant 
transformation of Slp65-deficient pre-B cells. Remarkably, deficiency of Rad54 partially 
protects against malignant transformation. This is in contrast with the current views as 
HR is thought to promote genome stability through precise repair of DSBs and since 
mutations in genes encoding HR proteins are associated with tumorigenesis (51). Our 
results indicate that Rad54-mediated HR operates on a razors edge, as Rad54-mediated 
HR could result in misrecognition and disrepair. We therefore conclude that Rad54-
mediated HR has the capacity to contribute to oncogenic transformation. To investigate 
the mechanism by which Rad54 mediates malignant transformation, we currently aim 
to determine the characteristics and specific requirements of the breakpoint areas 
involved in aberrations found in Slp65-deficient tumors.
Our findings open new perspectives since DNA repair proteins can have the 
capacity to function as oncogenes. It would be interesting to investigate whether Rad54 
also has the capacity to function as an oncogene in other tumor models and whether 
other proteins involved in HR also have oncogenic properties. 
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Suppl Figure 1. Generation of the Rad54-GFP mouse model.
(A) Schematic representation of the Rad54 locus and the gene targeting construct. Black boxes indicate 
exons I-XVIII. The targeting construct contains the human Rad54 cDNA sequence spanning exons 
IV-XVIII fused to GFP coding sequence. PGK indicates the puromycine resistance gene. The targeting 
construct replaces the region between exons III and VIII. Integration results in the expression of GFP-
tagged Rad54 from the endogenous promoter. (B) Embryonic stem cells of the indicated genotypes 
were irradiated and followed for survival. Experiments were performed in triplicate and the error bars 
represent SEM. 
Chapter VII
A mouse model for chronic lymphocytic 
leukemia based on expression of the 
SV40 large T antigen
Ter Brugge PJ, Ta VBT, de Bruijn MJW, Keijzers G, Maas A, 
van Gent DC, Hendriks RW. Blood. 2009 Jul
Chapter 7
160
Abstract
The simian virus 40 (SV40) T antigen is a potent oncogene able to transform many 
cell types and has been implicated in leukemia and lymphoma. In this report, we have 
achieved sporadic SV40 T antigen expression in mature B cells in mice, by insertion 
of a SV40 T antigen gene in opposite transcriptional orientation in the immunoglobulin 
(Ig) heavy (H) chain locus between the D en JH segments. SV40 T antigen expression 
appeared to result from retention of the targeted germline allele and concomitant anti-
sense transcription of SV40 large T in mature B cells, leading to chronic lymphocytic 
leukemia (CLL). Although B cell development was unperturbed in young mice, aging 
mice showed accumulation of a monoclonal B cell population in which the targeted IgH 
allele was in germline configuration and the wild-type IgH allele had a productive V(D)
J recombination. These leukemic B cells were IgDlowCD5+ and manifested nonrandom 
usage of V, D, and J segments. VH regions were either unmutated, with preferential 
usage of the VH11 family, or manifested extensive somatic hypermutation. Our findings 
provide an animal model for B-CLL and show that pathways activated by SV40 T antigen 
play important roles in the pathogenesis of B-CLL.
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Introduction
B cell chronic lymphocytic leukemia (B-CLL) (reviewed in Ref.(1),(2)), the most common 
leukemia in the Western world, is characterized by the accumulation of a monoclonal 
population of mature B cells that aberrantly express CD5(3-4). The clinical course 
of CLL is extremely heterogeneous: whereas some patients survive over a decade 
with stable disease, others succumb to the disease within months despite aggressive 
treatment. This heterogeneity is associated with variability in the expression pattern of 
a number of different proteins, and also with the presence of different chromosomal 
aberrations(5). Approximately half of the CLL cases have 13q14deletions, apparently 
involving the linked microRNA molecules miR15 and miR16, which are thought to be 
negative regulators of the anti-apoptotic gene Bcl2(2). Deletions on chromosome 17p, 
affecting the p53 protein, are less frequent and are associated with poor prognosis(6-7). 
CLLs manifest a unique gene-expression signature that differs from other lymphoid 
cancers, suggesting a common mechanism of transformation or a homogeneous cell 
population of origin(2). 
CLL has been subdivided into two prognostic subsets, based on the presence 
of somatic mutations of the immunoglobulin (Ig) heavy (H) chain variable (VH) genes. 
50-70% of CLL patients have mutated VH genes, likely reflecting antigen-driven post-
germinal center (GC) selection, and have a more favorable prognosis than those with 
unmutated B cell receptors. CLL Ig VH regions also exhibit unique complementarity 
determining region 3 (CDR3) features that characterize and differentiate aggressive 
unmutated from more indolent mutated CLLs. In particular, unmutated poor outcome 
cases frequently contain long CDR3s with amino acid residues that favor polyreactivity. 
Interestingly, both unmutated and mutated CLLs are thought to derive from self-reactive 
B cell precursors (8). In this context, it has been found that ~3-4% of healthy individuals 
over 40 years of age have a population of monoclonal lymphocytes in their blood with 
immunophenotypic characteristics of CLL cells(2).
The simian virus 40 (SV40) T antigen is a potent oncogene able to transform 
many cell types(9-10) and has been implicated in the etiology of various cancers(11-12). 
The SV40 T antigen has transforming activity by inactivating p53 and Rb proteins and 
inducing genomic instability(13). Several studies point to a causative role of SV40 in the 
formation of human B-cell malignancies, including non-Hodgkin’s lymphoma(14-16). 
Transgenic expression of the SV40 T gene under the control of the IgH enhancer induced 
hyperproliferation of multi-lineage hematopoiesis, reminiscent of myelodysplastic 
syndromes in humans(17). 
 In this report, we aimed to accomplish sporadic SV40 T gene expression in 
the B-cell lineage in mice. We introduced the SV40 T gene, without its promoter and in 
opposite transcriptional orientation between the IgH chain D en JH segments. As anti-
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sense transcription takes place across the D-JH region in pro-B cells(18), it is possible 
that in our mouse model SV40 T is expressed as a part of a large anti-sense transcript in 
early pro-B cells that have not yet performed IgH D to JH recombination. But, in allmost 
all pro-B cells the SV40 T gene will be excised during normal IgH D-to-JH rearrangement. 
Only in those rare B cells, in which the non-productive targeted allele has a germline 
configuration and thus still contains the SV40 T gene, it may possibly be expressed in 
more mature B cell stages. In addition, given the ability of the recombination activating 
gene (Rag)-1 and -2 proteins to catalyze DNA translocation and transposition reactions 
both in vitro(19-20) and in vivo(21-23), it is conceivable that V(D)J-mediated reinsertion 
of D-JH circles containing the SV40 T oncogene compromises genomic integrity, leading 
to tumor formation.
In our model we found that expression of SV40 T antigen is associated with 
the development of B-cell malignancies with striking similarities to human B-CLL. 
Tumor formation appears to result from retention of the targeted germline allele and 
concomitant antisense transcription of SV40 large T in mature B cells. 
Materials and methods
 
Generation of mouse models
To generate the IgH.T (and IgH.TEμ, with an extra copy of the IgH intronic enhancer) 
targeting constructs, containing the thymidine kinase gene, neomycin resistance 
gene, SV40 T antigen, internal ribosome entry site, splice accepter (SA) and flanking 
homology arms (created by long-range polymerase chain reaction (PCR) from 129 
mouse genomic DNA) we performed multiple cloning steps (strategy available upon 
request). Constructs were linearized and electroporated into E14 embryonic stem (ES) 
cells, which were subsequently cultured with G418 and gancyclovir. Expanded ES cell 
clones were screened for homologous recombination by Southern blotting. Chimeric 
mice were generated by injection of ES cells into blastocysts and bred to C57BL/6 
mice. Germline transmission of the targeted allele was verified by Southern blotting and 
offspring was genotyped by PCR analysis of DNA from tail snips using SV40 T-specific 
primers. Excision of the neo-cassette was achieved by crosses with transgenic mice 
expressing Cre-recombinase ubiquitously under the control of the cytomegalovirus 
immediate early enhancer-chicken beta-actin hybrid promoter. 
 IgH.T, IgH.TEμ, and p53-/- (Jackson Laboratory, Bar Harbor, Maine) mice were 
bred and maintained in the Erasmus MC animal care facility under specific pathogen-
free conditions. Experimental procedures were reviewed and approved by the Erasmus 
MC committee. 
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Southern blotting 
Genomic DNA samples were digested with SacI or XbaI overnight at 37°C and 
processed using standard procedures. A 760 bp neomycin probe was generated by 
PCR. The DQ52up probe is an 840 bp BspHI-PciI fragment, located just upstream of 
DQ52 (Figure 1B). The CH3 probe is a 1131 bp NspI-XcmI fragment spanning the m 
CH3 exon. A 1.2 kb XhoI-XbaI fragment (XX1.2; Figure 4D) was used as a probe for 
the H chain DQ52-Eµ region. Probes were labeled using the Prime-it II kit (Stratagene, 
La Jolla, CA) and hybridized overnight at 65°C. Fragments were visualized using a 
phospho-Imager and analyzed with ImageQuant (GE Healthcare, Little Chalfont, United 
Kingdom).
Flow cytometry, cell purification and blood smears
Blood was collected from the tail vein and erythrocytes were lysed using NH4Cl. 
Preparation of single-cell suspensions and monoclonal antibody (BD Biosciences, San 
Jose, CA) incubations for 4-color cytometry have been described(24). Viable cells were 
counted using a Coulter counter (Beckman Coulter, Fullerton, CA). B cells were purified 
by magnetic separation using CD19-microbeads and AutoMACS (Miltenyi Biotech, 
Auburn, CA). To produce blood thin films, 10ml of blood was smeared on a glass slide, 
dried and fixed in methanol for 3 minutes and stained in 5% Giemsa.  
Western blot
Total cell lysates were obtained by addition of lysis buffer (20 mM TRIS, 137 mM 
NaCl, 10 mM EDTA, 100 mM NaF, 1% NP-40, 10% glycerol, 1mM  pefabloc, 1 mM 
Na3VO4) to cells and  incubation on ice for 20 minutes. Lysates were centrifuged (13 
000g) and supernatants were boiled with loading buffer, separated on sodium dodecyl 
sulfate-polyacrylamide gels and blotted, using standard procedures. Membranes were 
stained with biotinylated anti-SV40T antibodies (Pab108, BD Biosciences), using 
streptavidin-horseradish peroxide as a second step and developed using enhanced 
chemiluminescence. 
RNA isolation and RT-PCR
Total RNA was isolated by GenElute Mammalian RNA purification (Sigma-Alderich, St 
Louis, MO), DNAse digested and reverse transcribed with Superscript II and random 
hexamer primers. PCR Primers spanning at least one intron were designed using 
ProbeFinder software and probes were chosen from the universal probe library (Roche 
Diagnostics, Indianapolis, IN). For quantitative real-time PCR cDNA was amplified in 
universal Mastermix containing 200 nM of each primer and 100 nM probe, using the 
ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA). 
To confirm specificity of amplification products, samples were analyzed by standard 
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agarose gel electrophoresis. The obtained Ct values were normalized to those of 
hypoxanthine-guanine phosphoribosyl-transferase (HPRT) (25). 
Heteroduplex PCR and DNA sequencing
Heteroduplex analyses were performed as described(26). For DNA sequence analyses, 
cDNA samples were amplified using seven primers located in the framework 1 region: 
two high degeneracy primers MH1-2 and five low degeneracy primers MH3-7(27), in 
combination with a primer located in the 5’ cμ region(28). PCR products were directly 
sequenced using the BigDye terminator cycle sequencing kit with AmpliTaq DNA 
polymerase on an ABI PRISM 377 automated sequencer (Applied Biosystems). All H 
chain regions were sequenced in two directions from at least two independent PCR 
products and analyzed by IMGT/V-Quest (IMGT®, the international ImMunoGeneTics 
information system®, http://www.imgt.cines.fr). 
Results
Generation of IgH.T and IgH.TEμ mice 
To achieve sporadic SV40 T antigen expression, we generated two different mouse 
models by homologous recombination in ES cells. The SV40 large and small T antigen 
coding unit(10) was inserted between DQ52 and JH1 in the IgH locus, either with (IgH.
TEμ) or without (IgH.T) an extra copy of the IgH intronic enhancer Eμ (Figure 1). ES 
cell clones with homologous recombination events were identified by Southern blotting, 
using the 5’-flanking DQ52up probe and the 3’-flanking CH3 probe (Figures 1BC, left 
panel and data not shown). ES clones were injected into blastocysts to generate chimeric 
mice that transmitted the targeted IgH allele through the germline, as identified by SV40 
T gene-specific PCR (Figure 1C, right panel). Excision of the neo-cassette was achieved 
by crossing mice with transgenic mice ubiquitously expressing Cre recombinase under 
the control of the cytomegalovirus immediate early enhancer-chicken beta-actin hybrid 
promoter. Successful excision was verified by Southern blotting using neomycin, 
DQ52up and CH3 probes (Figure 1D; data not shown). Mice harboring a single targeted 
allele were further bred to C57BL/6 mice. Heterozygous offspring, referred to as IgH.
TEμ or IgH.T mice, were born at the expected Mendelian frequencies, did not manifest 
any developmental defects, appeared normal and were fertile. 
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Figure 1.  Generation of IgH.TEμ and IgH.T mouse models.
(A) Schematic representation of the targeting constructs with (IgH.TEμ + Neo) and without (IgH.T + Neo) 
an additional Eµ copy. LoxP sites are represented by black triangles and arrows indicate transcriptional 
orientation. Neo: neomycin gene; T: T antigen ; IRES: internal ribosome entry site ; SA: splice accep-
ter. (B) The targeting vectors included the SV40 T antigen gene in opposite transcriptional orientation 
without its promoter, flanking regions of 5’ (DQ52) and 3’ (JH) Ig H chain homology, the herpes simplex 
thymidine kinase gene for negative selection and the neomycin resistance gene for positive selection. 
Below the targeting vector: wild-type Ig H chain allele, the locus after homologous recombination, and 
after Cre-mediated Neo-excision. The position of the PCR primers used to genotype offspring is indi-
cated by arrowheads above the T antigen. Probes used in Southern blots are indicated by horizontal 
lines. E: EcoRI site, D: DQ52up, N: neomycin, C: CH3. (C) Southern blot of EcoRV-digested ES cell 
DNA (left panel) and PCR analysis of tail DNA from the indicated mice. The IgH.TEμ ES cell clone 
analysis showes a 16.5 kb wild-type fragment and a 11.6 kb fragment recombined fragment containing 
the Neo insertion. (D) Southern blot of EcoRV-digested tail DNA from IgH.TEμ mice before (-) and after 
(+) Cre-mediated recombination. Blots were hybridized, either with the Neo (left panel) or the DQ52up 
probe (right panel). 
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B cell development in IgH.T and IgH.TEμ mice
First, we investigated whether SV40 T antigen gene insertion in the IgH locus affected 
B cell development or H chain allele usage. Single cell suspensions from bone marrow 
(BM) and spleen from ~8-week-old IgH.T and IgH.TEμ heterozygous mice and wild-
type littermates were analyzed by flow cytometry. The presence of the targeted IgH 
alleles did not affect BM or spleen cellularity. Also the proportions of the various stages 
of B cell development in the BM or the proportions of CD19+ B cells in the spleen 
were unaffected (Figure 2A). The three groups of mice had similar IgM/IgD profiles or 
proportions of immature (CD21lowCD23low), follicular (CD21+CD23+) and marginal zone 
(CD21highCD23low) B cells in the spleen (Figure 2B).  
To determine whether SV40 T gene insertion resulted in an altered frequency 
of IgH allele usage, we took advantage of IgM allotype differences between the targeted 
IgH allele (129 strain-derived IgMa) and the wild-type C57BL/6 allele (IgMb) in F1 mice. 
By flow cytometry using allotype-specific antibodies, we found equal usage of the 
targeted and the wild-type IgH allele in mature splenic CD19+ B cells (Figure 2C).  
 Quantitative reverse-transcribed (RT) PCR analyses of purified BM CD19+ 
B-cell lineage fractions from IgH.TEμ/IgH.T mice revealed the presence of SV40 T gene 
transcripts (Figure 2D). Significantly higher levels of SV40 T transcripts were detected in 
IgH.TEμ than in IgH.T B cell fractions, consistent with the capacity of the Eμ element to 
increase transcription. Because the SV40 T gene will be excised during D-to-JH segment 
rearrangement, we reasoned that inclusion of SV40 T sequences in IgH transcripts 
is expected to be largely limited to the early pro-B cells stage in the BM, before the 
initiation of D-to-JH gene recombination. Consistent with this, we found that purified 
CD19+ B-cell lineage fractions from IgH.T and IgH.TEμ on the Rag-2-/- background had 
increased levels of SV40 T transcription, when compared with IgH.T and IgH.TEμ mice 
on the wild-type background (Figure 2D). Because B cell development is blocked at the 
pro-B cell stage in IgH.T;Rag-2-/- and IgH.TEμ;Rag-2-/- mice, this finding indicated that 
SV40 T antigen gene transcription was indeed particularly present in pro-B cells that 
have a germline IgH configuration. 
 Importantly, we detected significant SV40 T antigen transcription in mature 
splenic CD19+ B cells from IgH.T and IgH.TEμ mice (Figure 2D). Taken together, these 
findings show that SV40 T gene insertion in the IgH chain locus did not affect B cell 
development or H chain allele usage and that in a fraction of mature B cells SV40 T is 
retained and transcribed. 
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Figure 2. Normal B cell development in young IgH.T and IgH.TEμ mice. (A) Proportions of pro-B 
(CD19+/CD43+/μ-), pre-B (CD19+/μ+), immature (IgM+/IgD-) and mature (IgM+/IgD+) B cells in BM and 
total CD19+ B cells in the spleen of the indicated mice, as measured by flow cytrometric analysis. Mean 
values and SD are given for 4 mice per group. (B) Fluorescence-activated cell sorter profiles for IgM and 
IgD in total spleen cells from the indicated mouse groups (top panel). Total splenic CD19+ B cells were 
gated and analyzed for CD21 and CD23 expression. The proportions of CD21highCD23high follicular B 
cells and CD21hiCD23lo marginal zone B cells within the specified gates are given. (C) Flow cytrometric 
analysis of CD19 expression (top panel) on peripheral white blood cells of WT, IgH.T and IgH.TEμ mice 
at 2 months of age. The CD19+ fraction was gated and analyzed for the expression of the IgMa and 
IgMb allele (bottom panel). Numbers in the plots indicate the percentage of cells within the specified 
gates. (D) Quantitative PCR analysis of large T mRNA expression in CD19+ BM cells and spleen cells 
of the indicated mice. Expression was normalized with HPRT and expression in IgH.TEμ BM was set to 
1. Asterisks indicate significant differences, when compared with IgH.TEμ mice (* p<0.01, ** p<0.001, 
Mann–Whitney U test). Mean values and SD are given for three 8-10-week-old mice per group.
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Unilateral IgH allele usage in aged IgH.T and IgH.TEμ heterozygous mice
To monitor selective outgrowth of monoclonal B cell populations over time, we 
periodically determined IgMa/IgMb profiles in peripheral blood B cells from panels of 
IgH.T (n=15) and IgH.TEμ (n=31) mice (Figure 3A). Young animals consistently had 
close to equal proportions of IgMa and IgMb-expressing B cells. In contrast, we observed 
in all aging IgH.TEμ mice and in two out of fifteen IgH.T mice a gradual appearance of 
a CD19+ population with preferential expression of the non-targeted IgMb allele. These 
IgMb cells were also characterized by large forward scatter values, indicating increased 
average cell size. In mice with unilateral IgMb expression (>90% IgMb, designated UNI 
mice) significantly higher numbers of peripheral white blood cells were found, when 
compared with mice with random IgH allele usage (45-55% IgMb, RAN mice; Figure 
3B). Examination of blood smears showed the presence of enlarged cells with clumped 
chromatin and little cytoplasm (Figure 3C). Nevertheless, animals showed no outward 
signs of distress in this period.
 Collectively, these data show the accumulation over time of atypical, large B 
cells exclusively expressing the IgMb allele from the non-targeted IgH locus. 
Accumulation of monoclonal B cell populations in aged IgH.T and IgH.TEμ mice
IgH.T and IgH.TEμ mice in the UNI group had normal B-lineage cell numbers in BM, but 
spleen sizes were significantly increased, when compared with wild-type littermates or 
IgH.T/IgH.TEμ RAN mice (Figure 4A, Supplementary Table 1). A majority (~60%) of the 
IgH.T and IgH.TEμ UNI mice had enlarged lymph nodes with cell numbers up to ~15 
times those of healthy animals. As shown for three examples of UNI mice in Figure 4B, 
flow cytometric analyses of the spleen revealed the presence of a population of mature 
CD19+ B cells with increased cell size, when compared to wild-type control cells (see 
CD19/FSC profiles in Figure 2C). 
Accumulation of B cells expressing the non-targeted IgMb H chain allele could 
either reflect a selective polyclonal hyperplasia or a monoclonal expansion of IgMb-
expressing B cells. To distinguish these two possibilities, we did an initial screening for 
Ig L chain usage in the expanding B cell populations in IgH.T and IgH.TEμ UNI mice 
and found that the CD19+ B cell population was almost entirely Ig κ positive (with <0.5% 
of λ+ B cells) or in two cases largely Ig λ+ (Figure 4C). Usage of only a single L chain 
indicated monoclonality of the accumulating B cell populations in IgH.T and IgH.TEμ 
UNI mice. This was confirmed by detailed analysis of the IgH rearrangement status by 
Southern blotting of XbaI digests of genomic DNA from purified CD19+ splenic B cell 
fractions from nine heterozygous IgH.TEμ UNI mice. We used a JH region probe, which 
recognizes a 3.5 kb XbaI fragment in a germline wild-type IgH allele and a 2.0/1.7 kb 
doublet fragment in a germline knock-in IgH.TEμ allele, as present in genomic DNA 
from non-B cells (Figure 4D and 4E). All nine samples contained prominent ~2.0/1.7 
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Figure 3. Unilateral Ig H chain usage in aged IgH.TEμ heterozygous mice
(A) Flow cytrometric analysis of surface CD19, IgMa and IgMb expression on peripheral blood 
mononuclear cells from three individual IgH.TEμ mice, T1, T2 and T3, representative for mice analyzed 
that developed unilateral Ig H chain usage over time. The CD19+ fraction was gated (shown only for 
mouse T1) and the IgMa/IgMb profile was analyzed (shown for all three mice). Data are shown as dot 
plots; Numbers indicate the percentages of cells within the specified populations. Age of the animal at 
the time of analysis is indicated by the numbers above the plots. (B) Total white blood cell count in IgH.
TEμ mice showing random usage (RAN, n=17) of IgMa and IgMb alleles, or unilateral usage of IgMb 
(UNI, with <10% IgMa and >90% IgMb B cells, n=18; P <.001; Mann–Whitney U test). The RAN mouse 
group consists of IgH.TEμ (<5 months of age) as well as IgH.T mice (<9 months). The age of onset of 
UNI group is indicated in Table S1. Each symbol indicates an individual mouse. Bars show average 
with standard deviation of 17 (RAN) and 18 (UNI) animals. (C) Giemsa staining of blood smear of a UNI 
mouse, showing the presence of large cells with little chromatin. Size marker = 20 μm.
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kb fragments of the IgH.TEμ allele in the germline configuration. In addition, ~3.5 kb 
fragments of the germline wild-type IgH allele were detected (generally of low density), 
most likely reflecting non-B cells present in the spleen samples. In addition, uniquely 
rearranged wild-type IgH alleles were present (in the two cases shown in Figure 4E, 
these fragments are ~3 and ~4 kb). 
Figure 4: Accumulation of monoclonal B cell populations in aged IgH.T and IgH.TEμ mice. (A) 
Spleen size of WT (n=6), RAN (n=18) and UNI (n=33) animals. Each symbol indicates an individual 
mouse; mean values are indicated by a line. *Significant difference with WT (P <.001; Mann–Whitney U 
test) (Ages of mice are given in Table S1). (B) Flow cytometric analysis of total spleen cells in the three 
UNI mice indicated. Numbers indicate the percentage of CD19+ B cells. (C) Expression of Igκ or Igλ 
L chain in splenic IgM+ B cells of three UNI mice. Numbers indicate the percentage of cells within the 
specified quadrants. (D) Schematic representation of WT and targeted alleles, and position of restriction 
sites used for Southern analysis of Ig H chain recombination. Horizontal line indicates the position of 
the XX1.2 probe, spanning the DQ-JH region. S: SacI, X: XbaI. (E) DNA rearrangements in total spleen 
cells of UNI animals. DNA was digested with XbaI or SacI and hybridized to the XX1.2 probe. Tail DNA 
from WT and UNI animals was used as reference for the WT germline fragment (GL) and the knock-in 
germline fragment (KI). Note that digestion with XbaI results in two germline KI fragments.  
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 Similar results were obtained when we tested DNA from twelve additional 
heterozygous IgH.TEμ UNI mice using SacI digests. All twelve splenic B cell fractions 
showed a ~5 kb fragment of the IgH.TEμ allele in the germline configuration, a weak 
~4.1 kb germline wild-type IgH allele, as well as uniquely rearranged wild-type alleles in 
the range of ~7-10 kb (shown for three cases in Figure 4E). The identification of unique, 
singly rearranged JH fragments confirmed the expansion of single B cell clones in UNI 
animals. Furthermore, the presence of germline knock-in IgH.TEμ alleles indicated that 
the targeted IgH locus with the SV40 T gene was still in germline configuration. This 
was confirmed by the finding that also a SV40 large T antigen-specific probe hybridized 
to these germline knock-in IgH.TEμ restriction fragments, without revealing any other 
unique fragments (in nine out of nine samples tested; data not shown). 
 In summary, we conclude that aged IgH.T and IgH.TEμ UNI mice show 
accumulation of monoclonal B cell populations that have retained the targeted IgH 
allele in the germline configuration. We did not find evidence for the occurrence of 
Rag-mediated transposition, as no SV40 T sequences were detected on new unique 
restriction fragments. 
Monoclonal B cell populations in IgH.TEμ mice have a CLL-like phenotype
Splenic B cell fractions from aged IgH.T/IgH.TEμ UNI mice were found to express 
significantly higher levels of SV40 T antigen transcripts than B cells from RAN mice, as 
determined by quantitative RT-PCR (Figure 5A). SV40 large T protein was identified in 
all tumor samples by western blotting (Figure 5B). As expected, no SV40 T transcription 
or protein was detected in wild-type (WT) splenic B cells (not shown). 
  We characterized the phenotype of the monoclonal B cell populations in IgH.T 
and IgH.TEμ mice by flow cytometry and quantitative RT-PCR. In these analyses, we 
did not detect phenotypic differences between clonal B cell populations from IgH.T 
or IgH.TEμ mice. The clonal B cell populations expressed CD19, B220, CD2 and 
substantial levels of surface IgM, but surface IgD was generally low (Figure 5C). They 
were negative for the early differentiation markers surrogate light chain, IL-7R or AA4.1 
and the mature B cell markers CD21, CD23 and CD138 (data not shown). Importantly, 
all B cell leukemia samples expressed significant levels of CD43 and CD5 on the cell 
surface (Figure 5C), both of which are associated with B-CLL in human. In all UNI 
mice substantial populations of CD19+CD5+CD43+ cells were identified in blood, lymph 
nodes, spleen and bone marrow (supplementary Table 1). 
p53-deficiency increases CLL incidence in IgH.TEμ mice
All mice in the IgH.TEμ panel manifested leukemia formation in blood, spleen and BM 
before the age of ten months (Figure 6A), but in the IgH.T panel only two out of fifteen 
(Figure 6B). At one year of age the remaining mice in the IgH.T group were sacrificed 
and found to have no B cell abnormalities.  
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Figure 5. Monoclonal B cell populations in aged IgH.TEμ mice express T antigen and CLL 
markers. (A) Quantitative RT-PCR analysis of Large T antigen expression in RAN (n=5) and UNI (n=16) 
purified splenic CD19+ B cell fractions. Expression was normalized with HPRT and relative expression 
in RAN B cell fractions was set to 1. Each symbol indicates an individual mouse; mean values are 
indicated by a line (p<0.01; Mann–Whitney U test). (B) Western blot showing expression of Large T 
protein (LT, arrow) in purified B cell fractions from IgH.TEμ UNI mice. Numbers on the left indicate size in 
kD. Examples are representative for 20 CLL samples analysed (C) Expression of CD19, IgM, IgD, CD5 
and CD43 on BM, spleen and lymph node cells from a IgH.TEμ UNI mouse. CD19+ cells were gated 
and analysed for their IgM/IgD and CD5/CD43 profiles. Data are representative for 33 animals analyzed 
(See supplementary Table 1 for age of mice).
 In human B-CLL, loss of p53 function is associated with accelerated disease 
progression and poor prognosis(6-7). To study the effect of p53 loss in our mouse model, 
IgH.TEμ and IgH.T mice were crossed onto a p53-deficient background. Relative to 
p53-/- mice, the groups of IgH.TEμ;p53-/- and IgH.T;p53-/- mice did not show a significant 
increase in tumor formation (Figure 6). However, whereas p53-/- littermate controls all 
developed T cell tumors, five out of six animals in the IgH.TEμ;p53-/- panel developed 
B cell tumors, with the remaining animal developing a T cell tumor. Likewise, four out 
of ten mice in the IgH.T;p53-/- panel had B cell tumors. The age at which malignancies 
were evident decreased in IgH.TEμ;p53-/- mice, when compared with IgH.TEμ mice
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Figure 6. Effect of p53 on CLL development in IgH.TEμ and IgH.T mice. (A) Kaplan-Meier survival 
curve of IgH.TEμ (n=31), (IgH.TEμ/p53-/-, n=6) and p53-/- (n=9) mice. (B) Kaplan-Meier survival curve in 
IgH.T (n=15); IgH.T/p53-/- (n=10) and p53-/- (n=9) mice.  Tumor-free survival is plotted over time.
 (median survival of 138 and 161 days, respectively; p<0.01, the log-rank test). This was 
also the case for IgH.T;p53-/- mice, when compared with IgH.T mice (median survival 
of 143 days and >365 days, respectively; p<0.001). The phenotypes of B cell tumors 
in IgH.TEμ;p53-/- and IgH.T;p53-/- were similar to those present in IgH.TEμ! or IgH.T 
animals on the wild-type background, as characterized by flow cytometry and southern 
blotting analysis of IgH alleles (not shown).
 Taken together, these results demonstrate that – although SV40 large T 
antigen acts as an inhibitor of the p53 pathway – complete loss of p53 increases B-CLL 
incidence in IgH.TEμ and IgH.T mice. 
Ig VH usage in IgH.TEμ leukemias resembles unmutated human CLL 
Based on the presence or absence of Ig VH gene mutations, human CLL patients 
are categorized into two subgroups with different prognosis. We therefore decided 
to characterize the V regions from eight IgH.TEμ and one IgH.T mouse. We purified 
CD19+ splenic B cell fractions and performed Ig VH family-specific RT-PCR analyses. 
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First, we confirmed clonality of the leukaemias by heteroduplex analysis, in which 
homo- and heteroduplexes resulting from denaturation and renaturation of IgH V region 
RT-PCR products were separated in non-denaturing polyacrylamide gels based on 
their conformation(29). For most samples we observed clear single homoduplexes, 
confirming the amplification of clonally rearranged V regions, but one case showed the 
presence of oligoclonal bands. DNA sequence analysis revealed that four leukemias 
expressed VH11.2, another four expressed VH segments from the VHJ558 family, and 
one expressed both VH11.2 and VHJ558 segments, indicating biclonality.
 In the leukemias expressing VH11.2, which is the only member of the VH11 
family, the sequence was identical to the germ-line gene present in the IMTG database 
(http://www.imgt.cines.fr)(Table 1). The VH11.2 gene is preferentially expressed in B-1 
lymphocytes and is associated with autoreactivity and oligoclonal expansions of CD5+ B 
cells in old mice(30). Three of the J558 family genes expressed were (nearly) identical to 
their most homologous published germ-line genes. By contrast, two VHJ558
+ leukemias 
manifested extensive somatic hypermutation (SHM). One IgH.TEμ B-CLL expressed 
VH1-69, which is often found in human CLL (31), and contained 15 mutations (of which 
10 in CDRs) and one IgH.T B-CLL expressed VH1-74 and contained 13 mutations (5 in 
CDRs). These two CLL samples likely originated from GC-experienced B cells with high 
activity of activation-induced cytidine deaminase (AID), which induces SHM.   
Non-stochastic usage was not only observed for VH segments, but also for D 
and JH segments: e.g. DST4.2 was found twice (normally DST segment usage is <2%) 
and all VH11-2 VH segments were joined to JH1 (50%; normally JH1 usage is <16%). 
Unmutated poor outcome human B-CLL cases often express IgH chains with long 
CDR3s, containing multiple neutral tyrosine and serine residues that may confer CDR3 
flexibility and favor polyreactivity. The CDR3 length, which is on average ~12 amino 
acids in murine B cells(32), was 11-12 in six leukemias, whereas two leukemias had 
a short (6 and 9 amino acids) and two leukemias had a long CDR3 length (15 amino 
acids). Eight out of ten CDR3s were enriched for tyrosines and serines (3-6 residues), 
and all CDR3s contained multiple charged amino acids, whereby the pI values were 
relatively neutral in 7/10 cases. As a result of the biased use of certain VH, D, and 
JH gene segments, the five VH11.2
+ leukemias had identical or strikingly homologous 
IgH V regions, similar to the sterotypic antigen-binding sites observed in human B-CLL 
patients. 
Similar transcription factor expression in AIDhigh and AIDlow B-CLL cells 
Somatic hypermutation of Ig VH genes provides prognostic information for CLL patients 
(1),(2): whereas hypermutation is predictive of a more favorable prognosis, lack of mutation 
predicts a poor prognosis. However, both cases identified with somatic hypermutation 
manifested high splenic cellularity (0.4 and 1.4 x 109 cells; see supplementary Table 1). 
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We investigated AID expression in purified splenic CD19+ B cell fractions from 
leukemic mice by RT-PCR. We found that AID expression was increased in a subset of 
these CLLs, when compared to B cell populations from wild-type or non-leukemic IgH.T/
IgH.TEμ mice (Figure 7A). This AIDhigh subset included leukemic samples expressing 
unmutated VH11, while AID expression in the two samples with high levels of SHM 
was low. The AIDhigh B-CLL subset did not show late onset or slow disease progression, 
when compared to AIDlow B-CLL.  
Figure 7. Similar transcription factor expression in AIDhigh and AIDlow CLL cells 
(A) Quantitative RT-PCR analysis of AID expression in RAN (n=7) and UNI (n=16) purified CD19+ B cell 
fractions. Expression was normalized with HPRT and relative expression in wild-type B cell fractions 
was set to 1. (B) Expression of indicated transcription factors as measured by quantitative RT-PCR in 
AIDhigh (n= 5; relative expression >2, see panel (A)) and AIDlow (n=11; relative expression <2). Expression 
was normalized with HPRT and relative expression in RAN B cell fractions was set to one. Mean values 
and SEM are given. Asterisk indicates significant differences between AIDlow and AIDhigh CLL cells 
(p<0.001; t-test). 
 Finally, we used quantitative RT-PCR to analyze the AIDlow and AIDhigh subsets 
for the expression of transcription factors implicated in B cell activation and terminal 
differentiation. When compared with untransformed B cells, leukemic IgH.T/IgH.TEμ 
B cells showed markedly increased expression of the transcription factors OBF and 
E2A (consistent with the reported increased E2A expression in human CLL(33)), 
while expression of Id2, an inhibitor of E2A, was reduced. Expression of IRF-4, which 
correlates with clinical outcome in B-CLL patients(34), was ~2-3 times increased. 
Overall, AIDlow and AIDhigh leukemia samples did not manifest significant differences in 
the expression of the transcription factors analyzed. Only expression of Pax-5, a B 
cell-specific factor that is downregulated upon terminal differentiation, was significantly 
higher in AIDhigh leukemia samples. This finding does not necessarily indicate that AIDlow 
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have differentiated further towards plasma cells, as they did not show higher levels of 
Blimp-1, which is highly expressed in plasma cells. 
 Taken together, B-CLL cells with unmutated V regions express substantial 
levels of AID transcripts, which parallels findings in human B-CLL. Moreover, AIDlow 
and AIDhigh B-CLL manifest similar transcription factor expression patterns, supporting a 
common origin of the two B-CLL subsets. 
Discussion
We describe the generation of a B-CLL mouse model based on sporadic SV40 large T 
antigen expression in mature B cells. Leukemic cells present in these mice displayed 
many characteristics also found in human B-CLL, in particular in the subgroup of 
patients with germline IgH V regions associated with poor prognosis. These features 
include (i) a mature CD19+CD5+ phenotype, (ii) VH regions with predominantly germline-
encoded sequences, (iii) non-stochastic VH-family usage, and (iv) CDR3 regions with 
high serine/tyrosine content. 
 The predominant use of VH11 in our IgH.TEm leukemic cells cannot result 
from random transformation of CD5+ B-1 cells, because only ~10% of this B cell 
population use VH11(35). It rather suggests the involvement of (auto)antigen-driven 
selection. Increased VH11 usage was also found in clonal expansions of splenic CD5
+ 
B lymphocytes in aging mice(30). Moreover, the VH11- DFL16.1- JH1 H chain present 
in leukemias T4 and T20 was identical to the published CLL clone TCL1-005 from a 
Tcl1 transgenic mouse(36). Thus, the B-CLL cells express a restricted B-cell receptor 
(BCR) repertoire with several cases of (nearly) identical CDR3s. In this respect, our 
model replicates the human B-CLL BCR sequences that closely resemble those of 
known autoreactive or polyreactive antibodies. We found that VH regions were either 
unmutated, with preferential usage of the VH11 family, or manifested extensive somatic 
hypermutation and used VHJ558. The finding of high AID expression in unmutated 
VH11-expressing CLL - together with the similar transcription factor expression patterns 
in AIDlow and AIDhigh leukemia samples - would support a common post-GC origin of both 
CLL subsets. 
 In our IgH.T/IgH.TEμ models expression of SV40 large T antigen was achieved 
by insertion of a promoterless SV40 T gene in opposite transcriptional orientation 
between the D en JH segments. We detected SV40 T transcripts in mature B cells of 
IgH.T/IgH.TEμ mice, most likely from those rare targeted IgH alleles that have retained 
their germ-line configuration. The SV40 large T antigen is probably expressed as part of 
an anti-sense transcript within the D-JH region of the IgH locus, similar to the anti-sense 
transcripts described in pro-B cells(18). The apparent absence of pro-B cell leukemias 
in IgH.T/IgH.TEμ mice, indicates that transient expression of the SV40 T gene (until it 
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is lost as a result of D-to-JH recombination) did not result in malignant transformation 
of pro-B cells. Likewise, we did not detect early T-cell lineage leukemias, despite the 
presence of IgH chain anti-sense transcription in early thymocytes(18). From the finding 
of equal usage of the targeted and the wild-type IgH allele, we conclude that insertion 
of the T gene or the additional Eμ element did not affect V(D)J recombination. However, 
as IgH.TEμ mice manifested a substantially higher tumor incidence than IgH.T mice, the 
presence of an extra copy of Eμ within the D-JH region may increase the level of anti-
sense transcription. Thus, efficient transformation might be dependent on synergistic 
effects of Eμ and the IgH 3’ enhancers(37) that lead to upregulation of SV40 T expression 
in more mature B cell stages. Conversely, the absence of transformation of pre-B cells 
or immature B cells that have retained the SV40 T gene could be explained by a level 
of T expression that is below the threshold for transformation(38-39). It is also possible 
that transformation requires secondary events that only take place in mature B cells. 
 The phenotypes of the leukemias in our mouse models resemble those found in 
Eμ-TCL1 mice, which express the T-cell leukaemia/lymphoma-1 proto-oncogene under 
the control of the Eμ element and an Ig VH promoter(40). TCL1 has been functionally 
linked to enhanced PKB/Akt-mediated signaling pathways involved in cell proliferation 
and survival. In contrast, SV40 large T protein interacts with numerous cellular proteins 
and pathways, most notably the Rb and p53 pathways(10, 13, 41-42), but may also 
induce cell survival via Akt activation(43). In our mouse model, animals that lack p53 
show accelerated tumor formation, even though SV40 large T inactivation of p53 is 
thought to be necessary to generate lymphoid tumors(44). This implies that in the 
presence of p53, some of the potential transforming properties of large T are inhibited or 
diminished, as was shown in a mouse model of pancreatic islet carcinogenesis(38),(45). 
Together with the existing communication and coordination between the p53 and Akt 
pathways, it is very well possible that the mechanisms of malignant transformation 
by SV40 T antigen and TCL1 are related. When compared to the Eμ-TCL1 mice, in 
which VH regions of leukemias consistently differed only marginally (<2.0%) from the 
germ-line, our IgH.TEμ/IgH.T mouse models are unique in that – next to leukemias 
with unmutated BCR - we also observed leukemias with extensive SHM (Table 1). It 
is presently not clear whether this difference between the Eμ-TCL1 and IgH.TEμ mice 
would point to differences in the mechanism of malignant transformation or would be 
related to secondary events in leukemia formation. 
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 Although evidence accumulated that the V(D)J recombinase system is capable 
of mediating transposition of cleaved signal ends into non-specific sites in the genome, 
both in vitro and in vivo(19, 21), we did not find evidence for transposition events: all 
CLLs analyzed had retained the T gene in the IgH locus, which still had the germline 
configuration. Obviously, we cannot exclude that in some B cells transposition did 
take place, but with tranposition into transcriptionally inactive regions and therefore 
not resulting in leukemia. Even though transposition has been shown to occur in vivo 
(21, 23, 46) its frequency is very low. Therefore, our mouse model would argue for the 
existence of mechanisms that very effectively protect against transposition in vivo(47). 
 To be able to investigate the molecular mechanisms involved in CLL 
pathogenesis, next to the New Zealand Black mouse strain which is a naturally occurring 
model of late-onset CLL, several transgenic mouse models have been generated 
(Reviewed in Ref. (48)). Because in human B-CLL is a heterogeneous disease, each of 
the current models will provide invaluable knowledge about the molecular mechanisms 
of transformation in B-CLL. As a pre-clinical model to test novel treatment strategies for 
CLL, our leukemia model has the advantage that tumor progression can be monitored 
by an IgM allotype-specific flow cytometry assay. Finally, gene profiling studies have 
shown that the SV40 T antigen genetic signature, is (i) composed primarily of genes 
regulating cell replication, proliferation, DNA repair, and apoptosis, (ii) does not reflect 
a general cancer signature, (iii) is uniquely activated primarily in tumors with aberrant 
expression of p53, Rb, or BRCA1 and not in tumors initiated through Myc or ras 
overexpression(49). As human breast, lung, and prostate tumors expressing this set 
of genes represent subsets of tumors with the most aggressive phenotype(49), our 
SV40 large T-dependent CLL model should allow the identification of genes that are 
associated with treatment-resistance and poor prognosis.     
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The focus of this thesis is on the role of the pre-BCR signaling molecules Btk and Slp65 
in early B cell development and the mechanisms by which Btk/Slp65-deficient pre-B cells 
become malignant. By using genetically modified mice, signal transduction in pre-B cells 
is put into an in vivo perspective regarding the regulation of V(D)J recombination activity, 
developmental progression and cellular proliferation. Furthermore, by understanding 
the mechanisms which are responsible for malignant transformation during B cell 
development insight is given into the forces that control genomic stability in general. 
 In this thesis we describe several surprising findings. First, the restricted usage 
of VH14 gene segments in Slp65-deficient tumors which could not be explained by a 
selective proliferative advantage but was determined by aberrant Ig H chain accessibility 
(Chapter III). Second, our findings revealed striking parallels in pre-B cell tumor formation 
between Slp65-deficient and Eμ-myc transgenic mice (Chapter III). Third, although 
several lines of evidence point to the possible involvement of V(D)J recombination, we 
show that V(D)J recombination activity is not necessary for malignant transformation of 
Slp65-deficient pre-B cells (Chapter V). Last and remarkably, we found that deficiency 
of the DNA repair protein Rad54 protects Slp65/Btk-double deficient pre-B cells against 
malignant transformation and reduces the frequency of genetic aberrations (Chapter 
VII).
Btk and Slp65 and the induction of cellular maturation and Ig L chain recombination
By studying the possible involvement of Btk and Slp65 in cellular maturation and in the 
initiation of Ig L chain recombination, we found that Btk or Slp65 single deficient pre-B 
cells have a specific defect in Ig λ L chain germline transcription (Chapter II). In addition, 
Btk/Slp65-double deficient pre-B cells have an additional defect in Ig κ L chain germline 
transcription. This defect is not due to reduced cell survival, as it cannot be corrected 
by enforced expression of a Bcl2 transgene. Our experiments did not discriminate 
between a function for signals transmitted by Btk and/or Slp65 directly in the opening of 
the Ig L chain loci for recombination or an indirect role for Btk/Slp65-mediated signals 
in the induction of the pre-B cell differentiation program. Recent findings of Jumaa 
and colleagues suggest that Foxo transcription factors connect pre-BCR signaling to 
the activation of the recombination machinery (1). They found that signaling through 
PI(3)K and Akt, which induces proliferation, negatively regulates Foxo3a and Foxo1 
activation and consequently impairs Ig κ chain rearrangement in developing B cells 
(Figure 1). In addition, Foxo1 directly activates the transcription of the Rag1/Rag2 locus 
throughout early B cell development (2). The main targets of the Akt kinases are the 
Foxo proteins, which have crucial roles in a wide spectrum of biological processes, 
including lymphocyte development. Interestingly, loss or gain of Foxo function can alter 
cell fate and lead to tumorigenesis (3-4). Thus, signaling via the pre-BCR recruites and 
phosphorylates Slp65, which inhibits activation of PI(3)K and Akt and thereby promotes 
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the accumulation of Foxo proteins to activate Rag1/Rag2 transcription (5) (Figure 1). 
Activation of Ig L chain recombination is associated with germline transcription 
(6-8) and it is not clear how the Foxo proteins induce germline transcription. Germline 
transcripts originate from promoters upstream of recombining segments in a 
developmental and tissue-specific manner (6, 9). Blocking transcription from a germline 
promoter in the TCRα locus prevented rearrangements of downstream Jα segments 
(10). Therefore, it is thought that germline transcription does not simply reflect open 
chromatine structure and accessibility of the locus for recombination, but rather is 
required for recombination to occur. Since pre-BCR signaling results in the rapid onset 
of germline transcription on both Ig k alleles (11), it is conceivable that Foxo proteins 
directly bind to regulatory elements within the Ig L chain locus. Alternatively, activation 
of Ig L chain gene recombination events by Foxo proteins could be an indirect effect. 
An interesting candidate involved in the activation of the Ig L chain locus for 
recombination is Irf-4. This transcription factor binds the Ig 3’Eκ and Eλ enhancers and 
also regulates expression of the chemokine receptor Cxcr4, which induces migration of 
pre-B cells away from stromal cells expressing IL-7 (12). Another interesting candidate 
is the transcription factor E2A, since several lines of evidence implicate the E2A factors 
E47 or E12 in Ig L chain recombination. First, expression of E47 or E12 is sufficient to 
activate germline Ig κ transcription and recombinase accessibility in non-lymphoid cells 
(13-14). Second, E47 expression induces Ig κ VJ gene rearrangements (15). Third, 
The E2A proteins initiate Ig κ VJ gene rearrangements by directly binding to the E-box 
sites located within the iEκ and 3’Eκ (16). Fourth, E12 and E47 play critical roles in 
promoting Ig λ germline transcription, as well as Ig λ V-to-J gene rearrangement. Finally, 
attenuation of IL-7R signaling elevates E12 and E47 expression (17). More studies 
are necessary to determine how these different transcription factors interact with each 
other, in particular as Irf-4 has been shown to bind cooperatively with the E proteins to 
sites present in the Ig κ enhancers (12). 
Not only interactions between transcription factors regulate targeting of V(D)
J recombination activity, but also alterations in chromatin structure. The Rag1/Rag2 
complex interacts with histone H3 trimethylated at the lysine position 4 (H3K4me3) and 
gene segments poised to undergo V(D)J recombination are enriched for H3K4me3 (18-
20). The functional importance of the Rag2-H3K4me3 interaction for V(D)J recombination 
provides a new insight into the potential function of germline transcription. Trimethylating 
H3K4 requires transcription (21). Therefore, the main function of germline transcription 
might be to mark Ig loci with H3K4me3 to allow efficient V(D)J recombination. 
Furthermore, H3K4me3 plays an important role in recruiting recombination centers 
(22). Rag2 binds at thousands of sites in the genome containing H3K4me3, while Rag1 
binding is only detected at regions containing RSS. Thus, Rag protein binding occurs in 
a highly focal manner to a small region of active chromatin.
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 More studies are required to determine how Slp65 and Btk activate germline 
transcription and Ig L chain recombination, taking into account that Slp65 and Btk both 
act together  (23), but also have independent functions (24). 
Mice deficient for important pre-BCR signaling molecules, such as Syk, Slp65, 
Btk or Plcγ2 show only a partial block at the pre-B cell stage. Analyses of compound 
knock-out mice have indicated that homologous signaling proteins, which were 
previously known to be important in other cell lineages, also contribute to pre-BCR 
signaling. The partial block in early B cell development in Slp-65-deficient mice (25-
28) can be complemented by Slp76 and Lat (linker for activation of T cells), both of 
which are well-known adaptor proteins essential for signaling from the T cell receptor 
(28-31). In addition, Zap-70, the only other known Syk family kinase, can compensate 
for Syk (32). This requirement was unexpected as Zap-70 was previously reported to 
be expressed exclusively in T cells and natural killer cells but not in B cells. Likewise, 
the Btk homologue Tec has the ability to compensate for defective Btk function in pre-B 
cells in vivo (33) and Plcγ1 can compensate for loss of Plcγ2 (34). Therefore, activation 
of Plcγ1 and Plcγ2 in pre-B cells can occur via two parallel pathways: one containing 
Syk, Slp65 and Btk and the other containing Zap-70, Slp76, Lat and Tec.
Tec has a role during B cell development in the generation and/or function of the 
peripheral B cell pool and Tec and Btk have been shown to have redundant functions in 
B cell development and activation (33). The defects in early B cell development in Btk/
Tec double-deficient mice have not been studied in detail. Hence, it would be interesting 
to study the possible role of Tec in the induction of germline transcripts of the Ig k and l 
L chain loci, in the termination of pre-B cell proliferation and as a tumor suppressor. We 
have recently crossed mice deficient for Btk, Tec and Slp65.  Our first results indicate 
that Btk and Tec cooperate in the regulation of Ig light chain accessibility, because 
we observed that Btk/Tec double-deficient pre-B cells had severely reduced Ig κ and 
λ germline transcripts (V.T., unpublished results). In contrast to Btk, loss of Tec did 
not lead to an increase in the proliferative response to IL-7 in vitro. Furthermore, we 
observed that Tec did not function as a tumor suppressor and did not collaborate in this 
context with Slp65 (V.T., unpublished results).
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Figure 1. Regulation of Ig L chain recombination 
Interaction between pre-BCR signaling and IL-7R signaling in pre-B cells. The figure depicts signaling 
pathways and transcriptional regulators that are required for proliferation and Ig L chain recombination 
at the pre-B cell stage. Arrows represent positive regulation and barred lines represent repression. 
Slp65 plays a central role in inducing light chain recombination, by counteracting Akt activation and 
thereby promoting activation of Foxo proteins, and inhibition of proliferation by inhibition of Jak3 and 
PI(3)K-Akt signaling. See Appendix for full-color figure.
Btk and Slp65 and pre-BCR-mediated selection 
Pre-BCR signaling is different from BCR signaling in that BCR signaling is induced by 
antigen binding. The non-Ig-like tail of the SLC component l5 induces ligand-independent 
pre-BCR cross-linking and as a result cell-autonomous signaling, which is essential for 
pre-B cell expansion (35). Recently, Jumaa and colleagues show that functional pre-
BCR formation and autonomous signaling requires the N-linked glycosylation site in the 
CH1 domain of Ig μ H chain (N46) and that crosslinking is mediated by binding of the l5 
SLC to N46 autonomous (36). This implies an unexpected mode of pre-BCR function 
in which binding of the SLC to N46 mediates autonomous crosslinking and receptor 
formation.
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 The importance of a ligand for the pre-BCR is not clear; it is possible that a ligand 
exists on stromal cells, on other pre-B cells or on the membrane of the same cell. This 
seems likely since the pre-BCR shapes the VH repertoire at the transition from pro-B to 
large pre-B cells (37). Furthermore, several groups have identified interactions between 
the non-Ig tail of λ5 and galectin-1 (38) or stromal-cell-associated heparin sulphate (39). 
In addition, the pre-BCR is a polyreactive receptor and capable of recognizing multiple 
(self-)antigens, including DNA, LPS and insulin, via the non-Ig part of λ5 (Kohler 2008). 
It is unlikely that foreign antigens play a major role in initiation of pre-BCR signaling. 
First, pre-B cells are selected for the expression of a functional Ig μ H chain which 
can pair with the SLC (40-42). This is a selection different from BCR selection, when 
B cells are selected for appropriate antigen specificity. It would be a highly inefficient 
mechanism when selection relies on the availability of foreign antigens in the BM that 
can interact with VH regions of pre-BCRs. Secondly, the antigen specificity of the Ig μ H 
chain when paired with the SLC is different from the antigen specificity when paired with 
a conventional Ig L chain (43-44). 
 Because high-level pre-BCR expression on Slp65-deficient leukemic cells 
is thought to contribute to their strong proliferative capacity, we investigated whether 
particular pre-BCR specificities may predispose these cells to malignant transformation 
(Chapter III). We found that Slp65-deficient leukemias preferentially use a member 
of the VH14 family (55 out of 60). By contrast, the CDR3 regions of these Ig H chains 
were heterogeneous in length and sequence. This restricted usage seems to be mainly 
based on aberrant Ig H chain accessibility favouring VH14 segment recombination at the 
pro-B cell stage. Nevertheless, we currently cannot exclude the possibility that these 
particular VH14 Ig H chains have unique structural properties, which could confer an 
advantage in proliferative expansion. This is, however, not supported by the findings of 
Van Loo et al., showing that constitutive expression of pre-BCR components throughout 
B cell development did not alter tumor frequencies in Slp65-deficient mice. These results 
imply that enhanced pre-BCR may not be important in the oncogenic transformation of 
Slp65-deficient cells, in constrast to consititutive IL-7R signaling. 
Preferential usage of particular Ig H VH gene families is not unique to Slp65-
deficient pre-B cell leukemias in mice, but has been reported for several leukemias and 
lymphomas in human and mice, including chronic lymphocytic leukemia (CLL) (45-46). 
However, on the basis of the presence of stereotypic CDR3 regions and high levels of 
somatic hypermutation it has been hypothesized that preferential Ig H VH gene usage in 
CLL reflects antigenic selection rather than preferential VH gene segment recombination 
(45).
 Interestingly, recent findings show that upregulation of Bcl6 by small pre-B cells 
is critical for the development of a diverse primary B cell repertoire (47). Phosphorylated 
Stat5 activates Myc and thereby repress Bcl6 (48), which functions as a transcriptional 
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repressor in normal and malignant GC B cells (49). It is conceivable that when Slp65-
deficient leukemias acquire constitutive activation of JAK3/STAT5 signaling, mostly 
due to autocrine production of IL-7 (50), this would lead to repression of Bcl6 and the 
prevention of a diverse primary B cell repertoire. The mechanism by which Bcl6 is 
regulating B cell repertoire diversification is not known and requires additional research. 
Nevertheless, it would be interesting to investigate whether specific VH gene segments 
have selective advantage at the pre-B cell checkpoint and what the molecular basis of 
the positive or negative selection process would be. To this end, creating and comparing 
pre-B cell differentiation in panels of knock-in mice carrying various autoreactive and 
innocuous Ig H chain V regions would be informative. 
Disruption of the p19Arf–Mdm2–p53 tumor suppressor pathway in Slp65 deficient 
pre-B cell leukemia
Recent findings show that Slp65 downregulates IL-7 mediated proliferation and 
survival through direct inhibition of Jak3 (50).  The IL-7R pathway promotes cellular 
survival, proliferation and maturation, involving induction of the proto-oncogene c-Myc 
(51). B cell development can be partially restored in Jak-3-deficient mice when they are 
bred to mice co-expressing a rearranged Ig H chain transgene and a c-Myc transgene 
(52). Loss of Btk synergizes with deregulation of the c-Myc oncogene during lymphoma 
formation (53). 
In Chapter IV, we found that disruption of the p19Arf–Mdm2–p53 tumor 
suppressor pathway plays an important role in malignant transformation of Slp65-
deficient pre-B cells. Our findings reveal striking parallels in pre-B cell tumor formation 
between Slp65-deficient and Eμ-myc Tg mice. First, in both models the expression of 
a pre-rearranged Ig H chain transgene in early B cell differentiation reduces oncogenic 
transformation (Chapter IV and (54)). Second, malignant transformation of both Slp65-
deficient and Eμ-myc Tg pre-B cells involves disruption of the p19Arf–Mdm2–p53 tumor 
suppressor pathway (Chapter IV and (55)). Third, somatic hypermutation-associated, 
Aid-induced DNA damage is not required for tumor development in either of the two 
models (Chapter IV and (56)). The finding that Slp65-deficient pre-B cell tumors display 
disruptions of the p19Arf–Mdm2–p53 pathway implies that oncogenic transformation of 
Slp65-deficient pre-B cells does not exclusively result from sustained IL-7R signaling and 
endocrine IL-7 production. Slp65 regulates the activity of the forkhead-box transcription 
factors Foxo3a and Foxo1, which do not only promote Ig L chain recombination, but 
also suppress Myc-driven lymphomagenesis via direct p19Arf activation (5, 57). These 
parallels suggest that oncogenic Myc activation contributes to malignant transformation 
of Slp65-deficient pre-B cells. In addition, disruption of the p19Arf–Mdm2–p53 tumor 
suppressor pathway also plays an essential role in the pre-B cell transformation process 
mediated by Abelson murine leukemia virus (58).
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 There are also differences between the Slp65-deficient and Eμ-myc Tg tumor 
models. Many Eμ-myc lymphomas sustained either p53 or p19Arf loss of function and 
elevation of Mdm2 levels. Almost all Slp65-deficient or Btk/Slp65-double deficient 
leukemias expressed substantial levels of p19Arf, suggesting inactivation of the p53 
response, as p53 is a negative regulator of p19Arf. Arf is highly expressed in many 
human tumors that contain p53 and in up to 40% of Burkitts lymphomas (59). P19Arf 
has also p53-independent functions, e.g it promotes the progression of lymphomas by 
mediating autophagy, a process of lysosome-mediated self-digestion that occurs during 
periods of nutrient deprivation (60-61). Autophagy plays a complex role in the initiation 
and progression of tumors. It appears that autophagy suppresses tumor initiation, 
but promotes the survival of established tumors (62). Silencing of p19Arf inhibits the 
progression of Myc-driven lymphoma cells containing mutant or no p53 (61). Thus, 
Slp65-deficient leukemias may retain p19Arf to promote survival under metabolic stress. 
Autophagy inhibitors chloroquine and 3-methyladenine are effective anti-tumor drugs 
for Burkitts lymphoma and chronic myeloid leukemia (63-65). Chloroquine-induced cell 
death was dependent on p53 but not on the modulators Atm or Arf (63). Therefore, it 
would be interesting to test the effect of small molecule inhibitors of autophagy on the 
survival of Slp65-deficient tumors and to administer Chloroquine to Slp65/Btk-double 
deficient mice and follow the mice for tumor free suvival. 
 It is tempting to speculate that transformation of Slp65-deficient pre-B cells is 
dependent on early oncogenic events that induce constitutive Jak3-Stat5 signaling at 
the pro-B cell stage. Furthermore, signaling via the IL-7R represses Bcl6 and its negative 
regulation of p19Arf (47). Therefore Slp65-deficient pre-B cells which have acquired 
constitutive IL-7R signaling will be cleared via the p19Arf–Mdm2–p53 pathway which 
protects against malignant transformation. The dramatic increase in tumor incidence 
when both Slp65 and p53 are lacking supports this notion (Chapter IV). However, 
after initiation of malignant transformation, expression of p19ARF protects the cells 
against metabolic stress. Thus, p53 mediated apoptosis is an important mechanism in 
preventing transformation of Slp65 deficient pre-B cells.
 This leads us to propose the following mechanism for malignant transformation 
of Slp65-deficient pre-B cells (Figure 2). The absence of Slp65 results in sustained 
expression of the pre-BCR and the IL-7R in large cycling pre-B cells. Since IL-7R 
signaling induces c-Myc this results in constitutively high levels of c-Myc. At this stage, 
Foxo transcription factors that normally suppress c-Myc-driven lymphomagenesis via 
direct activation of p19Arf are not properly activated because of the absence of Slp65. 
Furthermore, IL-7R signaling and aberrant pre-BCR signaling represses Bcl6 and 
thereby induces p19Arf expression. Subsequently, Slp65-deficient pre-B cells acquiring 
sporadic alterations in the p19Arf–Mdm2–p53 are selected to become malignant. 
Furthermore, expression of p19Arf in Slp65-deficient leukemias possibly promotes 
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survival under metabolic stress. Malignant transformation of Slp65-deficient pre-B cells 
thus is not a one hit model, but a complex multistep process that requires different 
acquired mutations. 
 The role for Btk in suppression of malignant transformation remains unclear. It 
is conceivable that the increased frequency of malignant transformation in Slp65/Btk-
double deficient mice reflects the increased pool size of proliferating pre-B cells. Mice 
which are deficient for Btk/Plc-γ2 and Irf-4/Irf-8, however, are arrested at the large pre-B 
cell stage. Most of these mutant pre-B cells express pre-BCR on their cell surfaces, but 
so far the development of pre-B cell leukemia has not been reported (66-67). Therefore, 
a complete block at the large pre-B cell stage is not sufficient to initiate malignant 
transformation. The absence of Btk might alter the proliferative capacity of Slp65-
deficient pre-B cells. However, Btk does not cooperate with Slp65 in the suppression of 
the Jak3-Stat5 signaling pathway. Instead,  Btk seems to play a role in the accumulation 
of p27Kip1 and to induce cell cycle arrest (50). A third possibility would be that Btk 
influences the malignant transformation of pre-B cells by c-Abl.  C-Abl is a Src family 
non-receptor protein tyrosine kinase (68). Alteration of the c-Abl structure and function 
as a consequence of chromosomal translocation (Bcr-Abl) results in fusion protein. This 
translocation accounts for the majority of cases of human chronic myeloid leukemia and 
a part of the human ALL cases (69-70). In human pre-B ALL Btk contributes to multiple 
aspects of the BCR-ABL1-driven survival signaling (71). Currently, the idea is that Slp65 
and Btk may act on different levels and thereby synergistically increase the incidence of 
leukemias.
Deregulated V(D)J recombination is not essential for malignant transformation of 
Slp65-deficient pre-B cells 
One of the fundamental features of lymphoid neoplasms is the presence of chromosomal 
translocations (72-74). Involvement of the V(D)J recombinase in lymphomagenesis was 
found when translocational breakpoints in certain tumors consisted of the antigen 
receptor loci fused with an oncogene (75-76). Because leukemic Slp65-deficient pre-B 
cells express Rag1/Rag2 and manifest ongoing immunoglobulin light chain 
rearrangement (23, 77-78), we hypothesized that deregulated recombinase activity 
contributes to malignant transformation. In Chapter V and VII we investigated the 
possible involvement of V(D)J recombination in two different models. First, by inactivation 
of Rag we found that the V(D)J recombinase is not essential for malignant transformation 
of Slp65-deficient pre-B cells (Chapter V). However, we can not exclude that V(D)J 
recombination does contribute to malignant transformation as the incidence of leukemias 
in our model of Btk/Slp65-double deficient mice with the autoreactive 3-83μδ transgene 
is much lower (~11%) than in Btk/Slp65-double deficient mice without this transgene 
(40-80%) (23, 79). Thus, V(D)J recombination may contribute to malignant 
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Figure 2. Model for tumor suppression in pre-B cells.
Signaling via Slp65 inhibits IL-7R signaling and induces activation of Foxo. Acativation of Arf occurs via 
Foxo proteins as well as through sustained and increased signaling induced by overexpressed Myc. 
Once expressed, the Arf protein interferes with the activity of Mdm2, leading to p53 stabilization and the 
triggering of a complex p53-dependent transcriptional program. The activation of p53 classically occurs 
in response to many other cellular stresses that produce DNA damage. Target genes induced by p53 
can generate different biological outcomes depending on the tissue type and convergence of different 
activating signals. Arf induction primarily triggers cell-cycle arrest. See Appendix for full-color figure.
transformation but we have shown that it is not essential for leukemogenesis. 
In addition, the ability of the Rag1/2 proteins to catalyze DNA translocation 
and transposition in vitro and in vivo (74, 80-83) prompted us to investigate in a mouse 
model the possibility of in vivo transposition of D-JH circles containing the SV40 T 
oncogene and thereby leading to lymphomagenesis. In Chapter VII we did not find 
evidence for transposition events because all leukemias analyzed had retained the 
SV40 T oncogene in the Ig H chain locus in germline configuration. We obviously 
cannot exclude that transposition did not take place at all, because transposition into 
transcriptionally inactive regions probably does not lead to malignant transformation. In 
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our IgH.TEμ model all mice showed accumulation of a monoclonal population of CD5+ 
leukemic B cells at 6-9 months of age. This model represents a new mouse model to 
study CLL, next to the mouse models for CLL that have been described in the literature. 
One of these is the NZB strain, which is a model for late-onset CLL. Another model is 
represented by, double transgenic mice overexpressing Bcl2 and dominant-negative 
TNFR-associated factor 2, which develop a clonal CD5+ B-CLL resembling human 
CLL. Malignant CD5+ B-cells also accumulate in transgenic mice expressing the T-cell 
leukemia gene TCL-1, which is a proto-oncogene functionally linked to enhancement 
of Akt-mediated signaling. Analysis of IGHV genes in TCL-1 transgenic CLL suggested 
that this model represents the more aggressive U-CLL subset (46). 
Our model is unique as it gives rise to both molecular subsets, with either 
unmutated (aggressive CLL) or extensively mutated (indolent CLL) Ig H V regions. As 
CLL is a heterogeneous leukemia, the IgH.TEμ mouse model makes it possible to study 
which mechanism of transformation leads to either the aggressive or the more indolent 
form of CLL. In addition, this mouse model would be valuable to address the issue 
of how antigenic selection contributes to malignant transformation as leukemic cells 
present in these mice displayed many characteristics which were also found in human 
B-CLL (84-85).
In the IgH.Tμ model, expression of the SV40 large T antigen is probably 
expressed as part of an antisense transcript within the D-JH region of the Ig H chain 
locus (86). The absence of pro-B cell leukemias in IgH.TEμ mice indicates that transient 
expression of the SV40 gene does not result in malignant transformation of pro-B cells. 
Efficient transformation might depend on synergistic effect of the Eμ and the Ig H 3’ 
enhancers that lead to upregulation of SV40 T expression in more mature B cell stages. 
It is possible that pre-B cells or immature B cells have a level of large T antigen expression 
which is below the threshold for transformation or that transformation requires additional 
events that only take place in mature B cells after antigenic stimulation.
Rad54-mediated genomic duplications contribute to malignant transformation in 
Slp65-deficient leukemia
Faithful DNA repair by diverse repair pathways contribute to maintaining chromosomal 
stability (87-88). Deficiency of proteins involved in DNA repair pathways lead to 
increased genomic instability and malignant transformation (89) (90-92). However, in 
Chapter VI we show that repair by Rad54 and homologous recombination operates 
on a razors edge. Homologous recombination ensures high fidelity repair, but our 
findings show that Rad54-mediated repair can lead to misrecognition and thus genomic 
instability. Therefore, in our model Rad54 does not function as a tumor suppressor but 
as an oncogene. It would be interesting to investigate whether Rad54 also functions 
as an oncogene in other tumor models next to our Slp65-deficient leukemia model. 
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Interestingly, comparative genomic hybridization analysis of Slp65-deficient leukemias 
showed genetic alterations which were found in all samples investigated. Investigation 
of these lesions could lead to the identification of new oncogenes or tumor suppressors 
which are involved in the malignant transformation of Slp65-deficient pre-B cells. In 
addition, analyses of genetic aberrations which differ between Slp65/Btk-double 
deficient leukemias and Slp65/Btk/Rad54-triple deficient leukemias will give insight 
into the mechanism by which Rad54 mediates duplications. In particular, cloning of 
breakpoints of the duplications may reveal specific requirements and characteristics of 
these areas.
The role of SLP65 and BTK in human ALL
The importance of SLP65 as a tumor suppressor in human ALL has still not been 
elucidated. Deficiency of SLP65 has been found in ~50% of childhood precursor-B cell 
ALL cases (93). The loss of SLP65 protein was found to be due to defective splicing, 
leading to premature stop codons. The SLP65 gene contains alternative exons (exon 3a 
and 3b) located in intron 3. When these alternative exons are included into the SLP65 
mRNA they interrupt the open reading frame of SLP65 and prevent protein expression. 
Expression profiling studies with larger numbers of patients reported a lower frequency 
of SLP65 alterations (94-95). In the latter studies, protein expression of SLP65 was not 
analyzed in detail. Because in these cases detectable SLP65 mRNA expression could 
still be associated with defective splicing and reduced protein expression, this analysis 
does not exclude the possibility that loss of SLP65 could be a common leukemogenic 
event in pre-B ALL. 
 Cancer is caused by alterations in oncogenes, tumor suppressor genes and 
microRNA genes.  MicroRNA genes can possibly regulate every cellular process. 
Aberrant microRNA expression is associated with the development and progression 
of tumors (96-98). Examples of the role of microRNA include miR-15a and miR-16-1, 
which are deleted or down-regulated in cases of CLL (99). Regions of the genome 
that are consistently involved in chromosomal rearrangements in cancer but that 
lack oncogenes or tumor suppressor genes appear to harbor microRNA genes (98). 
Therefore, it would be interesting to investigate microRNA which may suppress Slp65 
and their expression in human ALL.
Concluding remarks
Although our understanding of the role of Slp65 and Btk as critical regulators of pre-
BCR induced proliferation, differentiation and Ig L chain recombination has greatly 
increased, the nuclear targets of Slp65 and Btk mediated signaling are still largely 
unknown. To identify downstream target genes of Slp65 and Btk signaling, DNA 
microchip array comparisons should be performed of pre-B cells lacking Btk, Slp65 
 General discussion
195
or both. As signaling networks in pre-B cells consist of many interactions, constructing 
global networks consisting of transcriptional regulators, signaling and survival factors 
are becoming more and more important. The first studies which perform genome wide 
analysis for occupancy of the transcription factors E2A, EBF1 and Foxo1 have recently 
been published (100). They described the pro-B cell stage in terms of a global network of 
transcription factors with confirmed previous connections and they identified previously 
unknown links and participants. This network is a starting point for further analyses that 
should include other key regulators (Pax5, Pu.1). This approach should also be applied 
to the large pre-B cell stage and the events unfolding after pre-BCR activation.
 CLL is a heterogeneous leukemia and the IgH.TEμ mouse model makes it 
possible to study which mechanism of transformation leads to either the aggressive or 
the more indolent form of CLL. CLL cells must interact with stroma in BM or peripheral 
lymphoid tissues to survive. It would be interesting to explore these interactions as target 
for therapy, for instance to inhibit BCR signaling by anti-CD20 therapy. Furthermore, 
comparative genomic hybridization analyses should be performed to identify genomic 
alterations which differ between the aggressive (unmutated) and indolent (mutated) 
variant. 
 This thesis has revealed an unexpected role for the DNA repair protein Rad54, 
which next to its role in homologous recombination also seems to function as an 
oncogene, thereby contributing to oncogenic transformation. This new characteristic of 
Rad54 opens new perspectives and possibilities for research. It would be interesting to 
test the function of Rad54 in other tumor models. 
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B lymphocytes are necessary for humoral immunity against a wide variety of antigens. 
A prerequisite for the generation of an effective humoral response is the diversity and 
specificity of the antibody repertoire. Diversity of the antibody repertoire is generated by 
recombination of various gene segments at the immunoglobulin (Ig) heavy (H) and light 
(L) chain loci which occurs in an ordered manner. Ig in mice have a four chain structure 
and are composed of two identical H chains and two identical L chains. Signalling by 
membrane Ig governs a number of distinct checkpoints in B cell differentiation that 
shape the antibody repertoire by a combination of cellular and molecular selection. 
A central checkpoint is the pre-B cell receptor (pre-BCR), which monitors successful 
expression of the Ig H chain and signals for proliferation, differentiation and Ig L chain 
recombination. The adapter proteins Slp65 and the cytoplasmic tyrosine kinase Btk are 
key components of the signaling pathways downstream of the pre-BCR. In humans, 
mutations in SLP65 or BTK result in defective pre-B cell proliferation and an almost 
complete arrest of early B cell development, associated with the immunodeficiency 
disorder agammaglobulinemia. Furthermore, in a substantial fraction of human pre-B 
acute lymphoblastic leukemia (ALL) SLP65 expression is defective due to aberrant 
splicing. In mice, deficiency for Slp65 or Btk results in a partial arrest of early B cell 
development. Importantly, 5-10% of Slp65-deficient mice develop pre-B cell tumours 
expressing high levels of the pre-BCR. Btk has been shown to cooperate with Slp65 as 
a tumour suppressor. 
This thesis describes studies aimed at understanding the pre-BCR checkpoint 
and the role of the signalling proteins Btk and Slp65 in pre-B cell differentiation, 
proliferation and the suppression of malignant transformation.
By studying the possible involvement of Btk and Slp65 in cellular maturation 
and in the initiation of Ig L chain recombination, we found that Btk or Slp65 single 
deficient pre-B cells have a specific defect in Ig λ L chain germline transcription (Chapter 
II). In addition, Btk/Slp65-double deficient pre-B cells have an additional defect in Ig κ 
L chain germline transcription. This defect is not due to reduced cell survival, as it 
cannot be corrected for by enforced expression of a Bcl2 transgene. Therefore, we 
analyzed transgenic mice expressing the constitutively active Btk mutant E41K. The 
expression of E41K-Btk in Ig H chain-negative pro-B cells induced 1) surface marker 
changes that signify cellular differentiation, including down-regulation of the surrogate 
L chain pre-BCR component and up-regulation of CD2, CD25, and MHC class II; and 
2) premature rearrangement and expression of κ and λ light chains. These findings 
demonstrate that Btk and Slp65 transmit signals that induce cellular maturation and Ig L 
chain rearrangement independently of their role in termination of pre-B cell expansion.
  Similar to Slp65-deficient mice Eμ-myc transgenic (Tg) mice develop rapid-
onset pre-B cell malignancies. Myc-induced lymphomagenesis often disrupts the p19Arf–
Mdm2–p53 circuitry, indicating that c-Myc activation strongly selects for spontaneous 
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inactivation of this pathway.  In Chapter III we investigated whether malignant 
transformation of Slp65-deficient pre-B cells also requires loss of the protective 
checkpoint function of the p19Arf–Mdm2–p53 pathway. We found that disruption of the 
p19Arf–Mdm2–p53 tumour suppressor pathway plays an important role in malignant 
transformation of Slp65-deficient pre-B cells. Our findings reveal striking parallels in 
pre-B cell tumour formation between Slp65-deficient and Eμ-myc Tg mice. First, in 
both models the expression of a pre-rearranged Ig H chain transgene in early B cell 
differentiation reduces oncogenic transformation. Second, malignant transformation of 
both Slp65-deficient and Eμ-myc Tg pre-B cells involves disruption of the p19Arf–Mdm2–
p53 tumor suppressor pathway. Third, somatic hypermutation-associated, Aid-induced 
DNA damage is not required for tumour development in either of the two models. These 
data indicate that malignant transformation of Slp65-/- pre-B cells involves disruption of 
the p19Arf–Mdm2–p53 tumour suppressor pathway.
Because high-level pre-BCR expression on Slp65-deficient leukemic cells 
is thought to contribute to their strong proliferative capacity, we investigated whether 
particular pre-BCR specificities may predispose these cells to malignant transformation 
(Chapter IV). DNA sequence analysis of Ig H chain V regions of Slp65-deficient 
leukemias revealed that Slp65-deficient leukemias preferentially use a member of the 
VH14 family (in 55 out of 60 leukemias analysed), despite the small size of this VH family. 
The CDR3 regions of these Ig H chains were heterogeneous in length and sequence. 
When combined with surrogate light chain or various conventional light chains, yielding 
pre-BCR and BCR, respectively, the VH14 IgH chains did not exhibit enhanced poly- 
or autoreactivity. It is therefore not likely that the VH14 IgH chains provide enhanced 
proliferative signals. Slp65-deficient leukemia cells also exhibited preferential VH14 
segment usage on non-productively rearranged IgH alleles, strongly indicating altered 
IgH chain V region accessibility. We therefore conclude that malignant transformation 
of Slp65-deficient pre-B cells occurs almost exclusively in cells with aberrant IgH chain 
accessibility favouring VH14 segment recombination at the pro-B cell stage.
Because leukemic Slp65-deficient pre-B cells express Rag1/Rag2 and manifest 
ongoing immunoglobulin L chain rearrangement we hypothesized that deregulated 
V(D)J recombinase activity contributes to malignant transformation. In Chapter V 
we investigated the possible involvement of V(D)J recombination in the malignant 
transformation of Slp65-deficient pre-B cells. We employed Btk/Slp65 double-deficient 
mice carrying an autoreactive 3-83μd BCR transgene. When developing B cells in their 
bone marrow express this BCR, the V(D)J recombination machinery will be activated, 
allowing for secondary Ig L chain gene rearrangements to occur. This phenomenon, 
called receptor editing, will rescue autoreactive B cells from apoptosis. We observed 
that 3-83μδ transgenic Btk/Slp65 double-deficient mice developed B cell leukemias 
expressing both the 3-83 μδ BCR and the pre-BCR components l5/VpreB. Such 
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leukemias were found at similar frequencies in mice concomitantly deficient for Rag1 
or the non-homologous end-joining factor DNA-PKcs. We therefore conclude that 
malignant transformation of Btk/Slp65 double-deficient pre-B cells is independent of 
deregulated VD)J recombination activity.
In Slp65-deficient mice, pre-B cell tumors arise from large, cycling pre-B cells 
which are highly proliferative. It is therefore conceivable that genomic instability in these 
cells may accompany cell division, ultimately leading to oncogenic transformation. 
Therefore, we investigated in Chapter VI whether homologous recombination (HR), the 
pathway which repairs DNA double strand breaks (DSB) in cycling cells, plays a role in 
the malignant transformation of Slp65-deficient pre-B cells. Remarkably, we found that 
deficiency of Rad54 protected Slp65/Btk-double deficient pre-B cells from malignant 
transformation, since Slp65/Btk/Rad54-triple deficient mice manifested reduced tumour 
incidence when compared with Slp65/Btk-double deficient mice. Comparative genomic 
hybridization analysis of pre-B cell leukemias from Slp65/Btk/Rad54 triple deficient 
mice showed a reduced frequency of genetic aberrations, when compared with those 
from Slp65/Btk-double deficient mice. In particular, many gene duplications abundant 
in Slp65/Btk-double deficient pre-B cell tumours, ranging in size up to 600 kb, were not 
present in the concomitant absence of Rad54. These results indicate that repair via 
Rad54 and HR operates on a razors edge: although it has been assumed that repair by 
HR ensures high fidelity repair, our findings indicate that Rad54-mediated HR results 
in misrecognition and disrepair. We therefore conclude that Rad54-mediated HR in the 
absence of Slp65 and Btk has the capacity to contribute to oncogenic transformation.
In Chapter VII we investigated in a mouse model the possibility of in vivo 
transposition of D-JH circles containing the SV40 T oncogene and thereby leading to 
lymphomagenesis. Although B-cell development was unperturbed in young mice, aging 
mice showed accumulation of a monoclonal B-cell population in which the targeted Ig H 
allele was in germline configuration and the wild-type Ig H allele had a productive V(D)
J recombination. These leukemic B cells were IgDlowCD5+ and manifested nonrandom 
usage of V, D, and J segments. VH regions were either unmutated, with preferential usage 
of the VH11 family, or manifested extensive somatic hypermutation. Our findings provide 
an animal model for B-CLL and show that pathways activated by SV40 T antigen play 
an important role in the development of a monoclonal population of CD5+ leukemic B 
cells. We did not find evidence for transposition events because all leukemias analyzed 
had retained the SV40 T oncogene in the Ig H chain locus in germline configuration. We 
cannot exclude that transposition did not take place at all, because transposition into 
transcriptionally inactive regions would probably not lead to malignant transformation.
In conclusion, we obtained important information about the role of Slp65 and 
Btk at the pre-BCR checkpoint involved in differentiation, proliferation and suppression 
of malignant transformation. This information will be helpful for the identification of new 
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markers for early diagnosis and prognosis for XLA, ALL and CLL. Clinical research has 
proved that markers for early and detailed diagnosis, stratification and prognosis are of 
high value for the development of tailormade and more effective treatments for these 
diseases. Moreover, our studies revealed a remarkable new characteristic for the DNA 
repair protein Rad54 as it contributes to malignant transformation. This finding may 
change the general idea about the tumor suppressive function of repair proteins and it 
opens new perspectives for future research.
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Leukemie wordt in Nederland bij ongeveer 1600 mensen per jaar vastgesteld. Leukemie 
is de verzamelnaam voor verschillende soorten beenmergkanker waarbij er sprake is 
van ongecontroleerde deling van witte bloedcellen. Er ontstaan grote hoeveelheden 
witte bloedcellen die vaak niet rijp zijn en hierdoor komt de productie van normale 
bloedcellen in het beenmerg in het gedrang. Er kan onderscheid worden gemaakt 
tussen twee vormen: 
•	 acute leukemieën waarbij de kwaadaardige cellen onrijp zijn; 
•	 chronische leukemieën met een opeenhoping van redelijk uitgerijpte cellen.
Leukemie ontstaat via celdelingen uit één voorlopercel en wordt als een klonale ziekte 
beschouwd. Zo kunnen alle leukemiecellen dezelfde genetische afwijkingen hebben. 
Veel voorkomende afwijkingen zijn translocaties waarbij stukken erfelijk materiaal 
(DNA) zijn verplaatst van het ene chromosoom naar een ander chromosoom. Hoe 
leukemie ontstaat, is nog grotendeels onbekend. Kwaadaardige ontsporing staat in 
verband met veranderingen in de functie van verschillende genen, zogenoemde pro-
tumorgenen en tumorsuppressorgenen die zijn betrokken bij celdeling en celrijping. 
Enkelvoudige veranderingen in het genetische materiaal leiden niet tot de ontwikkeling 
van leukemie, maar een reeks van opeenvolgende veranderingen kan zorgen voor 
kwaadaardige ontsporing. 
In dit proefschrift hebben we precursor-B (pre-B) cel leukemie in een 
muizenmodel bestudeerd en onderzocht wat het mechanisme achter kwaadaardige 
ontsporing is. Muizen die de tumorsuppressoreiwitten Slp65 en Btk missen ontwikkelen 
vanaf 2 maanden pre-B cel leukemieën. Ook zijn er aanwijzingen dat in ~50% van de 
pre-B cel leukemieën bij kinderen het tumorsuppressoreiwit Slp65 defect is. Hoewel 
er verscheidene genetische afwijkingen zijn gevonden in bepaalde leukemieën, is 
er over het algemeen nog weinig bekend over de oorzaak van dergelijke tumoren. 
Leukemieën zouden bijvoorbeeld kunnen ontstaat door storingen in de regulatie van de 
celdelingsactiviteit of door defecten in het DNA schade herstel mechanisme.
De eiwitten Slp65 en Btk zijn betrokken bij signalering op het pre-B cel stadium 
en zorgen voor het stoppen van een fase van sterke celdeling. B cellen zijn witte 
bloedcellen die onderdeel uitmaken van het immuunsysteem en uiteindelijk uitrijpen 
tot plasmacellen, die antistoffen kunnen maken die bescherming kunnen bieden tegen 
een infectie. B cellen ontwikkelen zich in het beenmerg en tijdens dit proces zijn er 
diverse fasen te onderscheiden waarin de voorlopers van de B cellen een groot aantal 
celdelingen doormaken. Tijdens andere fasen delen deze cellen zich juist niet of maken 
ze specifieke veranderingen door. Om uiteindelijk de productie van antistoffen ofwel 
immuunglobulinen mogelijk te maken, zijn herschikkingen in het DNA nodig, waarbij 
op een nauwkeurig gereguleerde manier breuken in de genen die coderen voor de 
immuunglobuline eiwitketens worden aangebracht. Dit gebeurd door een uniek 
zogenoemde V(D)J-recombinatie systeem en – nadat tussenliggende stukjes DNA 
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zijn weggenomen - worden de gevormde breuken vervolgens weer hersteld door DNA 
schadeherstel eiwitten. 
 In de verschillende hoofdstukken van dit proefschrift hebben wij onderzocht wat 
er fout gaat in cellen die het eiwit Slp65 niet hebben. Naast het signaleringseiwit Slp65 
zijn wij ook geïnteresseerd in het sigaleringseiwit Btk, omdat beide eiwitten betrokken 
zijn op hetzelfde stadium in B cel ontwikkeling en muizen die beide eiwitten niet hebben 
sneller en eerder tumoren ontwikkelen.
In hoofdstuk II hebben wij de rol van Btk en Slp65 in celrijping en het starten 
van DNA herschikkingen van genen die coderen voor de immuunglobuline eiwitketens 
beschreven. Immuunglobulines bestaan uit twee zware en twee lichte eiwitketens die 
samen een antigeen kunnen binden. Eerst worden de genen voor de zware ketens 
herschikt en vervolgende de lichte keten genen. Wij zijn tot de ontdekking gekomen dat 
Btk en Slp65-deficiënte B cellen een defect hebben in de activatie van de genen die 
coderen voor het immuunglobuline lichte keten eiwit en dat dit effect onafhankelijk is 
van celdeling en overleving. Hiermee tonen wij aan dat Btk en Slp65 betrokken zijn bij 
het toegankelijk maken van de immuunglobuline lichte keten genen en dat dit proces 
onafhankelijk gebeurt van celdeling en overleving.
Het Slp65-deficiënte tumormodel is heel vergelijkbaar met een ander 
tumormodel: het tumormodel waarin het pro-tumor eiwit c-Myc tot expressie wordt 
gebracht. Het c-Myc protumor eiwit komt in veel cellen tot expressie. Verhoogde of 
niet goed gereguleerde c-Myc expressie is aanwezig in een grote verscheidenheid aan 
humane tumoren (borstkanker, darmkanker, baarmoederhalskanker, enz.). Muizen met 
hoge expressie van het c-Myc eiwit ontwikkelen pre-B cel tumoren die vaak inactivatie 
hebben van een belangrijk tumor onderdrukkend mechanisme. In hoofdstuk III hebben 
wij onderzocht of in Slp65-deficiënte muizen tumoren ontstaan via activatie van het 
protumor eiwit c-Myc en of er ook inactivatie plaatsvindt van dit tumor onderdrukkend 
mechanisme. We vonden in Slp65-deficiënte tumoren duidelijke parallellen met het 
c-Myc muizenmodel. Ten eerste, in beide tumormodellen onderdrukt de expressie van 
een kant-en-klare immuunglobuline zware keten de tumorvorming. Ten tweede, tumoren 
in beide modellen hebben het tumor onderdrukkend mechanisme geïnactiveerd. Ten 
derde, DNA schade geassocieerd met vele mutaties in de immuunglobuline ketens 
spelen geen rol bij tumorvorming in beide modellen. Deze resultaten geven aan dat 
tumorvorming in Slp65-deficiënte pre-B cellen een vergelijkbaar tumor onderdrukkend 
mechanisme inactiveerde als tumoren die het protumor eiwit c-Myc tot expressie 
brachten. 
Slp65-deficiënte leukemie cellen brengen de pre-B cel receptor hoog tot 
expressie op hun celoppervlak en wij zijn in de veronderstelling dat deze hoge expressie 
bijdraagt aan sterke celdeling. In hoofdstuk IV hebben wij onderzocht of bepaalde zware 
ketens vaker geassocieerd worden met tumoren en een bepaald selectievoordeel met 
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zich meebrengen. Door middel van specifieke DNA amplificatietechnieken hebben we 
de herschikkingsstatus van Slp65-deficiënte en Btk/Slp65 dubbel deficiënte tumoren 
onderzocht. Deze analyse toonde aan dat de immuunglobuline zware ketens die deze 
tumoren op hun celoppervlak dragen een heel beperkt gebruik hebben van het variabele 
deel van de immuunglobuline, het zogenoemde VH gebied. Ze gebruiken voornamelijk 
genen uit de VH14 familie. Dit is uitzonderlijk omdat VH14 een relatief kleine familie 
van VH genen is met maar 4 segmenten. Normaal gesproken wordt deze familie niet 
zo veel gebruikt en worden er andere segmenten van de in totaal 150 verschillende 
genen gebruikt. We hebben onderzocht waarom deze VH14 ketens zo veel gebruikt 
worden. We hebben gekeken of deze VH14 ketens sterker zouden signaleren omdat ze 
reageren op lichaamseigen moleculen, maar dat bleek niet het geval. Bij de analyse van 
de niet-productieve immuunglobuline zware keten vonden we ook regelmatig gebruik 
van VH14. Ons onderzoek laat zien dat het specifieke VH gebruik van Slp65-deficiënte 
tumoren het best verklaard kan worden doordat in de getransformeerde cellen vooral 
dit gebied van het DNA toegankelijk was voor herschikkingen.
 Gedurende V(D)J recombinatie ontstaan DNA breuken en als deze breuken 
niet goed worden gerepareerd kan dat leiden tot chromosomale afwijkingen en 
leukemie. Slp65-deficiënte tumorcellen brengen eiwitten tot expressie die DNA breuken 
maken en lijken hun DNA herschikkingactiviteit niet stop te zetten. Daarom wilden 
we de hypothese testen dat tumorvorming kan worden veroorzaakt door niet goed 
gereguleerde V(D)J recombinatie activiteit. In hoofdstuk V hebben wij in verschillende 
modellen onderzocht of V(D)J recombinatie activiteit noodzakelijk is en of een foutief 
herstel van de DNA breuken leidt tot tumorvorming. Er was geen verschil in het 
ontstaan van tumoren tussen een muizengroep die wel DNA kon herschikken en een 
muizengroep die niet kon herschikken. Ook bij muizen die wel of niet in staat waren 
DNA breuken te repareren vonden we geen verschil in de mate van tumorontwikkeling. 
Daarom hebben wij geconcludeerd dat tumorvorming in Btk/Slp65-deficiënte muizen 
onafhankelijk is van de V(D)J recombinatie activiteit en foutief DNA herstel. 
 In hoofdstuk VI hebben wij onderzocht of verminderde DNA stabiliteit een rol 
speelt in de tumorvorming van Slp65-deficiënte voorloper-B cellen. Het DNA herstel eiwit 
Rad54 is betrokken bij de DNA schadeherstelroute dat via homologie (overeenkomst 
in structuur) repareert. Wij hebben onderzocht of DNA herstel via het eiwit Rad54 
invloed heeft op het ontstaan van pre-B cel tumoren. Verrassenderwijs vonden wij dat 
het gemis van Rad54 muizen beschermt tegen tumorvorming, omdat minder muizen 
leukemie ontwikkelden als ze - naast Btk en Slp65 - ook deficiënt waren voor Rad54. 
Analyses van het DNA van de tumoren liet zien dat Btk/Slp65 dubbel deficiënte tumoren 
specifieke genetische afwijkingen bevatten die niet terug te vinden zijn in Rad54/Btk/
Slp65 drievoudig deficiënte tumoren. Onze resultaten laten zien dat DNA herstel via 
Rad54 en homologe recombinatie op het scherpst van de snede opereert. Aan de ene 
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kant garandeert herstel op basis van homologie een hoge nauwkeurigheid, maar aan 
de andere kant kan foutieve herkenning leiden tot verkeerd herstel van DNA breuken 
en daardoor genomische instabiliteit. Dit is voor het eerst dat er wordt aangetoond dat 
een DNA hersteleiwit kan bijdragen aan tumorvorming.
 In hoofdstuk VII onderzochten wij in een muismodel de mogelijkheid van 
het verspringen van DNA stukken door V(D)J recombinatie en of dit kan leiden tot 
tumorvorming. In jonge muizen was B cel ontwikkeling niet aangedaan, maar oude 
muizen ontwikkelden chronische lymfatische leukemie (CLL). In deze tumoren waren 
geen tekenen te vinden van verspringende DNA stukken. Deze muizen hadden 
tumoren ontwikkeld omdat ze een protumor eiwit oncogen tot expressie brachten. Ons 
onderzoek heeft geleid tot het ontstaan van een nieuw muismodel voor CLL onderzoek.
 Samenvattend hebben wij belangrijke informatie verkregen over de rol van Btk 
en Slp65 op het pre-B cel stadium en hun betrokkenheid in celrijping, celdeling en tumor 
onderdrukking. Deze informatie kan behulpzaam zijn voor verdere studies betreffende 
de identificatie van nieuwe kenmerken van tumoren die gebruikt kunnen worden voor 
diagnose, prognosebepaling en de behandeling van acute lymfatische leukemie en 
chronische lymfatische leukemie. Verder hebben we een nieuwe eigenschap gevonden 
voor het DNA hersteleiwit Rad54 en deze bevinding biedt nieuwe interessante 
invalshoeken voor toekomstig onderzoek.
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List of abbreviations
Aid  activation-induced cytidine deaminase
ALL  acute lymphocytic leukemia
BCR  B cell receptor
BM  bone marrow
BrdU  bromodeoxyuridine
BSAP  B cell specific activator protein
Btk  Bruton’s tyrosine kinase
C  immunoglobulin constant region 
CDR  complementarity determining region
CLL  chronic lymphocytic leukemia
CLP  common lymphoid progenitor
CMP  common myeloid progenitor
CSR  class switch recombination
D  immunoglobulin diversity region
DAG  diacylglycerol
DSB  double strand break
Ebf1  early B cell factor 1
ELP  early lymphoid progenitor
Erk  extracellular signal-regulated kinase
Foxo  forkhead box  
GC  germinal centre
HR  homologous recombination
HSA  heat stable antigen
HSC  hematopoietic stem cell
Ig  immunoglobulin
Ig H   immunoglobulin heavy
Ig κ  immunoglobulin kappa light chain
Ig λ   immunoglobulin lambda light chain
Ig L  immunoglobulin light
IL-7  interleukin-7
IL-7R  interleukin-7 receptor
IP3  inositol triphosphate
Irf  interferon regulating factor
ITAM  immunoreceptor tyrosine-based activation motif
J  immunoglobulin joining region
LMPP  lymphoid primed multipotential progenitor
Mapk  mitogen-activated protein kinase
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MHC  major histocompatibility complex
MPP  multipotential progenitor
MZ  marginal zone
NHEJ  non-homologous end-joining
PI3K  phosphatidylinositol 3 kinase
PIP  phosphatidylinositol phosphate
PIP2  phosphatidylinositol 4,5-biphosphate
PIP3  phosphatidylinositol 1,4,5-triphosphate
PKB  protein kinase B
PKC  protein kinase C
Plcγ2  phospholipase cγ2
Pre-BCR precursor B cell receptor
PTEN  phosphatase and tensin homolog
Rag  recombination activating gene
RSS  recombination signal sequence
SCID  severe combined immune deficiency
SH2  src homology 2
SH3  src homology 3
SLC  surrogate light chain
Slp65  SH2-domain leukocyte protein of 65 kD
TCR  T cell receptor
TdT  terminal deoxynucleotidyl transferase
TI-II  thymus-independent type II response
Xid  X-linked immunodeficiency
XLA  X-linked agammaglobulinemia
V  immunoglobulin variable region
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Dankwoord
Het schrijven van een proefschrift kun je niet alleen. Ik wil daarom iedereen die heeft 
bijgedragen van harte bedanken. Voor mij is het leven van een promovendus een hele 
belevenis geweest. De afgelopen jaren zijn gekenmerkt door een aaneenschakeling 
van allerlei experimenten met interessante en leuke congressen als afwisseling. Er 
zijn mooie momenten geweest met ontzettend veel plezier en prachtige resultaten 
afgewisseld met wat dalletjes als de resultaten tegenvielen. Ik heb de afgelopen jaren uit 
vele hoeken steun mogen ontvangen, van praktische ondersteuning tot een luisterend 
oor. Een aantal mensen wil ik in het bijzonder bedanken. 
Beste Rudi, toen ik als student naar je toe kwam om te informeren naar de mogelijkheden 
voor een onderzoek werd ik met open armen ontvangen en was er veel mogelijk. Het 
was geen probleem dat ik een Geneeskunde student was zonder enige labervaring. Ik 
heb het, vanaf het eerste moment, altijd ontzettend naar mijn zin gehad op het lab en 
keek er elk weekend naar uit om maandag weer te beginnen. Het was bijzonder hoe 
goed de werksfeer op lab 853 was. Toen aan mij werd gevraagd of ik interesse had 
in een promotieonderzoek heb ik niet lang getwijfeld. Tot op de dag van vandaag ben 
ik blij met mijn beslissing. Na mijn tijd als Masters student is mijn promotie begonnen 
met een Mozaiek beurs die ik zonder jouw hulp en steun niet had kunnen behalen. 
Jouw eindeloze inzet, toewijding en onvermoeibare voorkomen vormen een bron van 
inspiratie. Het is voor mij ontzettend fijn geweest dat je altijd voor mij klaar stond. Ook 
de Sinterklaasgedichten die ik op 5 december heb gekregen heb ik zeer gewaardeerd. 
Naast al jouw energie en tijd die je in het onderzoek investeert vindt je ook de tijd om 
leuke dingen met Erica en de kinderen te doen. Ik hoop dat onze samenwerking niet 
ophoudt bij het eindigen van mijn promotietraject. 
Prof.dr. Hoogsteden. Beste Henk, bij deze wil ik u bedanken voor uw vertrouwen in 
mijn ‘bijzondere’ onderzoek op de afdeling Longziekten. U heeft mij alle mogelijkheden 
geboden om het onderzoek te verrichten en dat heb ik altijd zeer gewaardeerd. Het is 
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Chapter I: Figure 2
Figure 2. Schematic drawing of an immunoglobulin molecule.
An immunoglobulin molecule is composed of two identical heavy chains and two identical light chains 
which are held together by disulfide bonds. Each chain consists of a constant region (darker part of an 
H or L chain) and a variable region (lighter part of an H or L chain). The antigen binding sites are formed 
by a complex of the variable regions of both light and heavy chains. 
Chapter I: Figure 3
Figure 3. Framework of B cell lineage development based on ordered changes in cell surface 
molecules.
Relative expression levels are indicated by line thickness. AA4.1 is also known as CD93 and PB493; 
CD24 as HSA (heat stable antigen); CD25 as IL-2R; MHCII, major histocompatibility complex type 
II; CD79, Igα and Igβ; SLC, surrogate light chain (λ5 and VpreB). TdT and Rag1/2 (recombination 
activating gene) expression assessed by analysis of mRNA. Figure adapted from ref. (11).
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Chapter I: Figure 4
Figure 4. VDJ recombination.
Schematic representation of the Ig H chain locus and V(D)J recombination process. The V(D)J reaction 
can be divided into three steps. First, the Rag1/2 complex introduces a DNA DSB at the border between 
DH and JH segments and their respective recombination signal sequences (RSS), creating hairpin-
sealed coding ends and blunt signaling ends. Artemis, which is recruited and phosphorylated by the 
DNA-PKcs/Ku70/Ku80 complex, opens the hairpins through its endonuclease activity. The XRCC4/
Cernunnos/DNA-Ligase IV complex finally seals coding and signal joints. NHEJ, non-homologous end-
joining. Figure adapted from ref. (31).
Chapter I: Figure 5
Figure 5. Organization of Ig H chain locus on chromosome 12.
Schematic map of VH gene family distribution within the mouse Ig H chain V region according to IMGT 
(www.imgt.org). The length of boxes indicates the distance spanned by members of the gene families 
and is not related to the number of genes.
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Chapter I: Figure 6
Figure 6. Structure of the pre-BCR.
The pre-BCR complex consists of the heterodimeric Igα/Igβ signal transducer and two covalently 
associated Ig H chains which are paired with the surrogate light chain, consisting of the invariant proteins 
λ5 and VpreB. The SLC contains two oppositely charged non-Ig-like tails located at the C-terminus of 
VpreB and the N-terminus of λ5. The unique tails protrude from the pre-BCR at the position where the 
CDR3 (complementarity-determining region) of a conventional L chain is located in the BCR.
Chapter I: Figure 7
Figure 7. Signaling pathways in pre-B cells.
Pre-BCR activation results in activation of Syk which together with Src family protein kinases, such 
as Lyn, phosphorylate downstream signaling proteins resulting in pathways involved in proliferation, 
differentiation and induction of Ig L chain recombination. Activation of Slp65 recruits and activates 
Btk and Plcγ2 resulting in upregulation of Rag1/Rag2 and Irf-4, induction of Ig L chain recombination 
and induction of differentiation. An important pathway for proliferation and survival is the activation 
of the PI3K pathway. Phosphorylation of the co-receptor CD19 and the adaptor protein BCAP (B cell 
PI3K adaptor) recruit and activate PI3K resulting in the generation of the second messenger PIP3 
(Phosphatidylinositol (3,4,5)-trisphosphate) from PIP2 (Phosphatidylinositol 4,5-bisphosphate). PIP3 
recruits Akt which is the dominant mediator for controlling cellular proliferation. Ongoing signaling 
through the PI3K-Akt pathway induces proliferation, suppresses the Rag1/Rag2 genes and blocks Ig 
κ gene recombination. Proliferation in pre-B cells is also induced via the pathway involving Erk MAP 
kinase. In addition to the role of the pre-BCR, signaling via the interleuking-7 receptor (IL-7R) plays a 
central role in controlling the survival and proliferation of pre-B cells.
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Chapter I: Figure 8
Figure 8. Activation of B cells.
Productive interaction of follicular B cells with antigen results in proliferation and differentiation. The 
primary response generates pre-germinal centre plasma cells that are short-lived and usually secrete 
IgM. Some activated follicular B cells form a germinal centre. Antigen-activated lymphoblasts that enter 
a germinal centre are subjected to multiple rounds of SHM and antigen selection. Cells that express 
high-affinity antigen receptors are selected for survival with subsequent differentiation to memory B cells 
or post-germinal centre plasma cells. Post-germinal centre plasma cells that undergo Ig H chain CSR 
typically home to the bone marrow where they reside and become long-lived (122). 
Upon activation of a distinct population of B cells, B-1 cells, by cytokine and/or TLR activation antibody 
secreting cells are formed which secrete natural IgM antibodies, which often recognize bacterial 
antigens. SHM, somatic hypermutation; CSR, class switch recombination.
Chapter I: Figure 9
Figure 9. Generating antibody diversity. 
Antibodies are encoded by immunoglobulin genes; these include V, D and J regions and C regions. In 
pro-B cells an immunoglobulin gene includes the full range of V,D, J and C regions. V(D)J recombination 
generates an antibody (IgM) with a variable region that recognizes a particular antigen. When the B cell 
encounters antigen, two other processes — both catalysed by the Aid protein — are triggered. Somatic 
hypermutation generates mutations (thin white lines) in the variable regions, potentially generating an 
IgM with higher affinity for its antigen. Class switch recombination results in the excision of some of the 
constant regions, generating antibodies with distinct effector functions (IgG1 is shown here). Figure 
adapted from ref. (125).
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Chapter VI: Figure 1
Figure 1. Rad54-GFP expression in proliferating B cells.
(A) Flow cytometry profiles of GFP and forward scatter (FSC) are shown as dot plots for pro-B/large 
pre-B cells (CD19+CD2-IgM-), small pre-B cells (CD19+CD2+IgM-), immature and mature B cells 
(CD19+CD2+IgM+) from WT and Rad54GFP/GFP mice. (B) Confocal microscopy images of Rad54GFP/GFP 
pre-B cells cultured for 5 days with IL-7 (top) and for 2 additional days with or without IL-7 (bottom).
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Figure 4. Focal amplifications only present in Btk/Slp65-double deficient tumors.
Overlays of CGH analyses of chromosome 1 (upper panel) and 17 (lower panel) views of Btk/Slp65-
double deficient tumors (BS; n=6) (left) and Rad54/Btk/Slp65-triple deficient tumors (RBS; n=4) (right), 
showing different sizes of aberrations exclusively present in BS tumors and not in RBS tumors. Chr, 
chromosome. 
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Figure 5. Overview of several genetic lesions in Slp65-deficient tumors.
Overlays of CGH analyses of chromosome 4 (upper panel), 6 (middle panel) and 8 (lower panel) views 
of Btk/Slp65-double deficient tumors (BS; n=6) (left) and Rad54/Btk/Slp65-triple deficient tumors (RBS; 
n=4) (right), showing different sizes of aberrations. Chr, chromosome. 
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Figure 1. Regulation of Ig L chain recombination 
Chapter VIII: Figure 2
Figure 2. Model for tumor suppression in pre-B cells.
 

